<SUBMISSION>
<ACCESSION-NUMBER>0000950134-09-007337
<TYPE>DEF 14A
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090521
<FILING-DATE>20090410
<DATE-OF-FILING-DATE-CHANGE>20090410
<EFFECTIVENESS-DATE>20090410
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>MANNKIND CORP
<CIK>0000899460
<ASSIGNED-SIC>2834
<IRS-NUMBER>133607736
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>DEF 14A
<ACT>34
<FILE-NUMBER>000-50865
<FILM-NUMBER>09745206
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
<PHONE>6617755300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>v52006def14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>def14a</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">







<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>SCHEDULE 14A INFORMATION</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="57%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Filed by the Registrant
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Filed by a Party other than the Registrant
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Preliminary Proxy Statement</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#254;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Definitive Proxy Statement</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Definitive Additional Materials</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting Material Pursuant to &#167; 240.14a-12</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>MannKind Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>(Name of Registrant as Specified In Its Charter)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 12pt">N/A</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Payment of Filing Fee (Check the appropriate box)
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#254;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No fee required.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1) and 0-11.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Title of each class of securities to which transaction applies:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Aggregate number of securities to which transaction applies:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule&nbsp;0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined):</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Proposed maximum aggregate value of transaction:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Total fee paid:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>


</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Fee paid previously with preliminary materials.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify
the previous filing by registration statement number, or the Form or Schedule and the date of
its filing.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amount Previously Paid:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Form, Schedule or Registration Statement No.:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Filing Party:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Date Filed:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD nowrap align="left" colspan="3"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

</TABLE>
</DIV>










<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANNKIND
    CORPORATION<BR>
    <FONT style="font-size: 10pt">28903 North Avenue Paine<BR>
    Valencia, CA 91355<BR>
    <FONT style="white-space: nowrap">(661)&#160;775-5300</FONT></FONT></FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<!-- link1 "NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On Thursday, May 21, 2009" -->
<DIV align="left"><A NAME="000"></A></DIV>
<B><FONT style="font-size: 12pt">
    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">To Be Held On Thursday,
    May&#160;21, 2009</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dear Stockholder:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You are cordially invited to attend the Annual Meeting of
    Stockholders of MannKind Corporation, or &#147;MannKind,&#148; a
    Delaware corporation. The meeting will be held on Thursday,
    May&#160;21, 2009 at 10:00&#160;a.m. local time at MannKind
    Corporation, One Casper Street, Danbury, Connecticut for the
    following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    1.&#160;To elect the eight nominees named herein as directors to
    serve for the ensuing year and until their successors are
    elected;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2.&#160;To approve an amendment to increase the aggregate number
    of shares of common stock authorized for issuance under
    MannKind&#146;s 2004 Equity Incentive Plan by
    5,000,000&#160;shares;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    3.&#160;To ratify the selection by the Audit Committee of the
    Board of Directors of Deloitte&#160;&#038; Touche LLP as
    independent registered public accounting firm of MannKind for
    its fiscal year ending December&#160;31, 2009;&#160;and
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    4.&#160;To transact such other business as may properly come
    before the meeting or any adjournment or postponement thereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These items of business are more fully described in the proxy
    statement accompanying this notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The record date for the Annual Meeting is March&#160;30, 2009.
    Only stockholders of record at the close of business on that
    date may vote at the meeting or any adjournment thereof.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By Order of the Board of Directors
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="v52006v5200601.gif" alt="(-s- David Thomson)">
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    David Thomson<BR>
    <I>Vice President, General Counsel and Secretary</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Valencia, California
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>April&#160;10, 2009</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>You are cordially invited to attend the meeting in person.
    Whether or not you expect to attend the meeting, please vote by
    proxy pursuant to the instructions set forth herein as promptly
    as possible in order to ensure your representation at the
    meeting. Even if you have voted by proxy, you may still vote in
    person if you attend the meeting. Please note, however, that if
    your shares are held of record by a broker, bank or other
    nominee and you wish to vote at the meeting, you must obtain a
    proxy issued in your name from that record holder.</B>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On Thursday, May 21, 2009</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">PROXY STATEMENT FOR THE 2009 ANNUAL MEETING OF STOCKHOLDERS To be held on May 21, 2009</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">PROPOSAL 1 ELECTION OF DIRECTORS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#004">CORPORATE GOVERNANCE PRINCIPLES AND BOARD AND COMMITTEE MATTERS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#005">Proposal 2 Approval Of The Amendment To MannKind&#146;s 2004 Equity Incentive Plan</A></TD></TR>
<TR><TD colspan="9"><A HREF="#006">Proposal 3 Ratification of Selection of Deloitte &#038; Touche LLP as Independent Registered Public Accounting Firm</A></TD></TR>
<TR><TD colspan="9"><A HREF="#007">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#008">EXECUTIVE OFFICERS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">COMPENSATION OF DIRECTORS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#010">EXECUTIVE COMPENSATION</A></TD></TR>
<TR><TD colspan="9"><A HREF="#011">COMPENSATION COMMITTEE REPORT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#012">REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#013">SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></TD></TR>
<TR><TD colspan="9"><A HREF="#014">CERTAIN TRANSACTIONS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#015">HOUSEHOLDING OF PROXY MATERIALS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#016">ANNUAL REPORT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#017">OTHER MATTERS</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANNKIND
    CORPORATION<BR>
    <FONT style="font-size: 10pt">28903 North Avenue Paine<BR>
    Valencia, California 91355</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>




<!-- link1 "PROXY STATEMENT FOR THE 2009 ANNUAL MEETING OF STOCKHOLDERS To be held on May 21, 2009" -->
<DIV align="left"><A NAME="001"></A></DIV>


<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROXY
    STATEMENT<BR>
    FOR THE 2009 ANNUAL MEETING OF STOCKHOLDERS<BR>
    <BR>
    </FONT></B><FONT style="font-size: 10pt"><FONT style="font-family: 'Times New Roman', Times">To
    be held on May&#160;21, 2009</FONT>
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>




<!-- link1 "QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING" -->
<DIV align="left"><A NAME="002"></A></DIV>


<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">QUESTIONS
    AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Why did I
    receive a notice regarding the availability of proxy materials
    on the internet?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have sent you a Notice of Internet Availability of Proxy
    Materials (the &#147;Notice&#148;) because the Board of
    Directors (sometimes referred to as the &#147;Board&#148;) of
    MannKind Corporation (sometimes referred to as the
    &#147;Company&#148; or &#147;MannKind&#148;) is soliciting your
    proxy to vote at the 2009 Annual Meeting of Stockholders (the
    &#147;Annual Meeting&#148;), including any adjournments or
    postponements of the meeting. Pursuant to rules adopted by the
    Securities and Exchange Commission (the &#147;SEC&#148;), we are
    providing access to our proxy materials over the internet.
    Accordingly, we are sending the Notice to our stockholders of
    record. Our stockholders of record have also received a printed
    set of the proxy materials along with the Notice. All
    stockholders will have the ability to access the proxy materials
    on the website referred to in the Notice or request to receive a
    printed set of the proxy materials. Instructions on how to
    access the proxy materials over the internet or to request a
    printed copy may be found in the Notice.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to mail the Notice on or about April&#160;10, 2009 to
    all stockholders of record entitled to vote at the annual
    meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Who can
    vote at the annual meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Only stockholders of record at the close of business on
    March&#160;30, 2009 will be entitled to vote at the Annual
    Meeting. On this record date, there were 102,039,249&#160;shares
    of common stock outstanding and entitled to vote.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Stockholder
    of Record: Shares Registered in Your Name</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If on March&#160;30, 2009 your shares were registered directly
    in your name with MannKind&#146;s transfer agent, BNY Mellon
    Shareowner Services, LLC, then you are a stockholder of record.
    As a stockholder of record, you may vote in person at the
    meeting or vote by proxy. Whether or not you plan to attend the
    Annual Meeting, we urge you to vote by proxy pursuant to the
    instructions set forth below to ensure your vote is counted.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Beneficial
    Owner: Shares Registered in the Name of a Broker or
    Bank</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If on March&#160;30, 2009 your shares were held, not in your
    name, but rather in an account at a brokerage firm, bank,
    dealer, or other similar organization, then you are the
    beneficial owner of shares held in &#147;street name&#148; and
    the Notice is being forwarded to you by that organization. The
    organization holding your account is considered to be the
    stockholder of record for purposes of voting at the Annual
    Meeting. As a beneficial owner, you have the right to direct
    your broker or other agent on how to vote the shares in your
    account. You are also invited to attend the Annual Meeting.
    However, since you are not the stockholder of record, you may
    not vote your shares in person at the Annual Meeting unless you
    request and obtain a valid proxy from your broker or other agent.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What am I
    voting on?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Management is presenting three proposals for stockholder vote.
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Proposal&#160;1.
    Election of Eight Directors</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The first proposal to be voted on is the election as directors
    of the eight nominees named herein for a one-year term.
    MannKind&#146;s Board of Directors has nominated these eight
    people as directors. You may find information about these
    nominees, as well as information about MannKind&#146;s Board of
    Directors and its committees, director compensation and other
    related matters beginning on page&#160;7.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may vote &#147;For&#148; all the nominees,
    &#147;Withhold&#148; your votes as to all nominees or
    &#147;Withhold&#148; your votes as to specific nominees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors unanimously recommends a vote FOR each
    director nominee named herein.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Proposal&#160;2.
    Approval of Proposed 5,000,000&#160;Share Increase in the Number
    of Shares of Common Stock Authorized for Issuance under
    MannKind&#146;s 2004 Equity Incentive Plan, as Amended</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The second proposal to be voted on is to approve an amendment to
    increase the maximum number of shares of common stock authorized
    for issuance under MannKind&#146;s 2004 Equity Incentive Plan
    from 14,000,000&#160;shares to 19,000,000&#160;shares. You may
    find information about this proposal beginning on page&#160;14.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may vote &#147;For&#148; the proposal, vote
    &#147;Against&#148; the proposal or &#147;Abstain&#148; from
    voting on the proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors unanimously recommends a vote FOR this
    proposal.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Proposal&#160;3.
    Ratification of Selection by the Audit Committee of the Board of
    Directors of Deloitte&#160;&#038; Touche LLP as the
    Company&#146;s Independent Registered Public Accounting Firm for
    its Fiscal Year Ending December&#160;31, 2009</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At its February&#160;19, 2009 meeting, the Audit Committee of
    the Board approved the selection and appointment of
    Deloitte&#160;&#038; Touche LLP as the Company&#146;s
    independent registered public accounting firm to examine the
    financial statements of the Company for the fiscal year ending
    December&#160;31, 2009. The Company is seeking the
    stockholders&#146; ratification of such action.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It is expected that representatives of Deloitte&#160;&#038;
    Touche LLP will attend the Annual Meeting and be available to
    make a statement or respond to appropriate questions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may vote &#147;For&#148; the proposal, vote
    &#147;Against&#148; the proposal or &#147;Abstain&#148; from
    voting on the proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors unanimously recommends a vote FOR this
    proposal.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What if
    another matter is properly brought before the Annual
    Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors knows of no other matters that will be
    presented for consideration at the Annual Meeting. If any other
    matters are properly brought before the Annual Meeting, it is
    the intention of the persons named in the proxy to vote on those
    matters in accordance with their best judgment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How do I
    vote?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procedures for voting are fairly simple:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Stockholder
    of Record: Shares Registered in Your Name</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are a stockholder of record, you may vote in person at
    the Annual Meeting or vote by proxy using the enclosed proxy
    card, vote by proxy over the telephone or vote by proxy through
    the internet. Whether or not you plan to attend the Annual
    Meeting, we urge you to vote by proxy to ensure your vote is
    counted. You may still attend the Annual Meeting and vote in
    person if you have already voted by proxy.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To vote in person, come to the Annual Meeting and we will give
    you a ballot when you arrive.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To vote using the proxy card, simply complete, sign and date the
    enclosed proxy card and return it promptly in the envelope
    provided. Your signed proxy card must be received by 5:00 PM ET
    on May&#160;20, 2009 to be counted.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To vote over the telephone, dial toll-free
    <FONT style="white-space: nowrap">(866)&#160;437-3716</FONT>
    using a touch-tone phone and follow the recorded instructions.
    You will be asked to provide the company number and control
    number from the Notice. Your vote must be received by
    5:00&#160;PM ET on May&#160;20, 2009 to be counted.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To vote through the internet, go to
    <FONT style="white-space: nowrap">http://www.proxypush.com/mnkd</FONT>
    to complete an electronic proxy card. You will be asked to
    provide the company number and control number from the Notice.
    Your vote must be received by 5:00&#160;PM ET on May&#160;20,
    2009 to be counted.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Beneficial
    Owner: Shares Registered in the Name of Broker or Bank</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are a beneficial owner of shares registered in the name
    of your broker, bank, or other agent, you should have received a
    Notice containing voting instructions from that organization
    rather than from MannKind. Simply follow the voting instructions
    in the Notice to ensure that your vote is counted.
    Alternatively, you may be able to vote by telephone or over the
    Internet as instructed by your broker or bank. To vote in person
    at the Annual Meeting, you must obtain a valid proxy from your
    broker, bank, or other agent. Follow the instructions from your
    broker or bank included with the Notice, or contact your broker
    or bank to request a proxy form.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How many
    votes do I have?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On each matter to be voted upon, you have one vote for each
    share of common stock you owned as of March&#160;30, 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What if I
    return a proxy card or otherwise vote by proxy but do not make
    specific choices?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you voted by proxy without marking any voting selections,
    your shares will be voted &#147;For&#148; the election of the
    Board of Directors&#146; eight nominees for director listed in
    Proposal&#160;1, &#147;For&#148; the amendment of the 2004
    Equity Incentive Plan as provided in Proposal&#160;2 and
    &#147;For&#148; the selection of Deloitte&#160;&#038; Touche LLP
    as our independent registered public accounting firm for the
    fiscal year ending December&#160;31, 2009 as provided in
    Proposal&#160;3. If any other matter is properly presented at
    the Annual Meeting, your proxy (one of the individuals named on
    your proxy card) will vote your shares using his or her best
    judgment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Who is
    paying for this proxy solicitation?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will pay for the entire cost of soliciting proxies. In
    addition to these proxy materials, our directors and employees
    may also solicit proxies in person, by telephone, or by other
    means of communication. Directors and employees will not be paid
    any additional compensation for soliciting proxies. We will also
    reimburse brokerage firms, banks and other agents for the cost
    of forwarding proxy materials to beneficial owners.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What does
    it mean if I receive more than one Notice?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you receive more than one Notice, your shares are registered
    in more than one name or are registered in different accounts.
    Please follow the voting instructions with respect to <B>each
    </B>Notice to ensure that all of your shares are voted.
    Similarly, if you are a stockholder of record and you receive
    more than one set of proxy materials, your shares are registered
    in more than one name. If you intend to vote by proxy using the
    proxy cards you receive, please complete, sign and return
    <B>each </B>proxy card to ensure that all of your shares are
    voted.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Can I
    change my vote after submitting my proxy?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Yes. You can revoke your proxy at any time before the final vote
    at the Annual Meeting. If you are a stockholder of record, you
    may revoke your proxy in any one of three ways:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may send a written notice that you are revoking your proxy
    to MannKind&#146;s Secretary at 28903 North Avenue Paine,
    Valencia, CA 91355.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may grant another proxy by telephone or through the internet.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may submit another properly completed proxy card with a
    later date.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    You may attend the Annual Meeting and vote in person. Simply
    attending the Annual Meeting will not, by itself, revoke your
    proxy.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your most current proxy, whether submitted by proxy card,
    telephone or internet, is the one that is counted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If your shares are held by your broker or bank as a nominee or
    agent, you should follow the instructions provided by your
    broker or bank.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How are
    votes counted?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Votes will be counted by the inspector of election appointed for
    the meeting, who will separately count &#147;For&#148; and
    &#147;Withhold&#148; and, with respect to proposals other than
    the election of directors, &#147;Against&#148; votes,
    abstentions and broker non-votes. Abstentions will be counted
    towards the vote total for each proposal, and will have the same
    effect as &#147;Against&#148; votes. Broker non-votes have no
    effect and will not be counted towards the vote total for any
    proposal.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What are
    &#147;broker non-votes&#148;?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Broker non-votes occur when a beneficial owner of shares held in
    street name does not give instructions to the broker or nominee
    holding the shares as to how to vote on matters deemed
    &#147;non-routine.&#148; Generally, if shares are held in street
    name (shares are held by your broker as your nominee), the
    beneficial owner of the shares is entitled to give voting
    instructions to the broker or nominee holding the shares. If you
    do not give instructions to your broker, your broker can vote
    your shares with respect to matters that are considered to be
    &#147;routine,&#148;, but not with respect to
    &#147;non-routine&#148; matters. Under the rules and
    interpretations of the New York Stock Exchange,
    &#147;non-routine&#148; matters are generally those involving a
    contest or a matter that may substantially affect the rights or
    privileges of stockholders, such as mergers or stockholder
    proposals.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How many
    votes are needed to approve each proposal?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the election of directors, the eight nominees receiving the
    most &#147;For&#148; votes (among votes properly cast in person
    or by proxy) will be elected. Only votes &#147;For&#148; or
    &#147;Withheld&#148; will affect the outcome. Only the eight
    nominees named herein have been properly nominated for election
    as directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To be approved, Proposals&#160;2 and 3 regarding the amendment
    of the 2004 Equity Incentive Plan and the selection of the
    independent registered public accounting firm, respectively,
    must receive a &#147;For&#148; vote from the majority of shares
    present and entitled to vote either in person or by proxy. If
    you &#147;Abstain&#148; from voting, it will have the same
    effect as an &#147;Against&#148; vote. Broker non-votes will
    have no effect.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What is
    the quorum requirement?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A quorum of stockholders is necessary to hold a valid Annual
    Meeting. A quorum will be present if at least a majority of the
    outstanding shares entitled to vote are represented by
    stockholders present at the Annual Meeting or by proxy. On the
    record date, there were 102,039,249&#160;shares outstanding and
    entitled to vote. Thus, 51,019,625&#160;shares must be
    represented by stockholders present at the Annual Meeting or by
    proxy to have a quorum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your shares will be counted towards the quorum only if you
    submit a valid proxy (or one is submitted on your behalf by your
    broker, bank or other nominee) or if you vote in person at the
    Annual Meeting. Abstentions and
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    broker non-votes will be counted towards the quorum requirement.
    If there is no quorum, the chairman of the Annual Meeting or a
    majority of the votes present at the Annual Meeting may adjourn
    the meeting to another date.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How can I
    find out the results of the voting at the annual
    meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Preliminary voting results will be announced at the Annual
    Meeting. Final voting results will be published in the
    Company&#146;s quarterly report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the second quarter of 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">When are
    stockholder proposals due for next year&#146;s annual
    meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To be considered for inclusion in MannKind&#146;s proxy material
    for next year&#146;s annual meeting, your proposal must be
    submitted in writing by December&#160;11, 2009 to David Thomson,
    MannKind Corporation, 28903 North Avenue Paine, Valencia, CA
    91355. If you wish to submit a proposal that is not to be
    included in Mannkind&#146;s proxy materials or nominate a
    director, you must do so not later than the close of business on
    February&#160;20, 2010 nor earlier than the close of business on
    January&#160;21, 2010. You are also advised to review the
    Company&#146;s Bylaws, which contain additional requirements
    about advance notice of stockholder proposals and director
    nominations.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "PROPOSAL 1 ELECTION OF DIRECTORS" -->
<DIV align="left"><A NAME="003"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;1<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ELECTION
    OF DIRECTORS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    MannKind&#146;s Board of Directors consists of eight directors.
    There are eight nominees for director this year, all of whom
    were nominated by our Board of Directors. Each director to be
    elected will hold office until the next annual meeting of
    stockholders and until his or her successor is elected, or until
    the director&#146;s death, resignation or removal. All nominees
    listed below are currently our directors and were previously
    elected by our stockholders at the 2008 Annual Meeting of
    Stockholders. It is our policy that directors are invited and
    expected to attend annual meetings. All previous directors
    attended the 2008 Annual Meeting of Stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Directors are elected by a plurality of the votes properly cast
    in person or by proxy. The eight nominees receiving the highest
    number of affirmative votes will be elected. Shares represented
    by executed proxies will be voted, if authority to do so is not
    withheld, for the election of the eight nominees named below. If
    any nominee becomes unavailable for election as a result of an
    unexpected occurrence, your shares will be voted for the
    election of a substitute nominee proposed by our management.
    Each person nominated for election has agreed to serve if
    elected. Our management has no reason to believe that any
    nominee will be unable to serve.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Nominees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a brief biography of each nominee for director.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position Held With the Company</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    83
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chairman of the Board of Directors and Chief Executive Officer
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    59
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    President, Chief Operating Officer and Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Abraham E. Cohen(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    72
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ronald Consiglio(2)(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    65
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Friedman,&#160;M.D.(1)(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    65
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kent Kresa(1)(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    70
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David H. MacCallum(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    71
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Henry L. Nordhoff(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    66
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Member of the Compensation Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Member of the Nominating and Corporate Governance Committee.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Member of the Audit Committee.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Alfred E. Mann </I>has been one of our directors since April
    1999, our Chairman of the Board since December 2001 and our
    Chief Executive Officer since October 2003. He founded and
    formerly served as Chairman and Chief Executive Officer of
    MiniMed, Inc., a publicly traded company focused on diabetes
    therapy and microinfusion drug delivery that was acquired by
    Medtronic, Inc. in August 2001. Mr.&#160;Mann also founded and,
    from 1972 through 1992, served as Chief Executive Officer of
    Pacesetter Systems, Inc. and its successor, Siemens Pacesetter,
    Inc., a manufacturer of cardiac pacemakers, now the Cardiac
    Rhythm Management Division of St. Jude Medical Corporation.
    Mr.&#160;Mann founded and since 1993, has served as Chairman and
    until January 2008, as Co-Chief Executive Officer of Advanced
    Bionics Corporation, a medical device manufacturer focused on
    neurostimulation to restore hearing to the deaf and to treat
    chronic pain and other neural deficits, that was acquired by
    Boston Scientific Corporation in June 2004. In January 2008, the
    former stockholders of Advanced Bionics Corporation repurchased
    certain segments from Boston Scientific Corporation and formed
    Advanced Bionics LLC for cochlear implants and Infusion Systems
    LLC for infusion pumps. Mr.&#160;Mann is non-executive Chairman
    of both entities. Mr.&#160;Mann has also founded and is
    non-executive Chairman of Second Sight, which is developing a
    visual prosthesis for the blind and Quallion, which produces
    batteries for medical products and for the military and
    aerospace industries; and Stellar Microelectronics Inc., a
    supplier of electronic assemblies to the medical, military and
    aerospace industries. Mr.&#160;Mann is also non-executive
    Chairman of the Alfred Mann Foundation and Alfred Mann Institute
    at the University of Southern California, AMI Purdue and AMI
    Technion, and the Alfred Mann Foundation for
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biomedical Engineering, which is establishing additional
    institutes at other research universities. Mr.&#160;Mann is also
    non-executive Chairman of the Southern California Biomedical
    Council, and a Director of the Nevada Cancer Institute and
    United Cerebral Palsy Foundation. Mr.&#160;Mann holds a
    bachelor&#146;s and master&#146;s degree in Physics from the
    University of California at Los Angeles, honorary doctorates
    from Johns Hopkins University, the University of Southern
    California, Western University and the Technion-Israel Institute
    of Technology and is a member of the National Academy of
    Engineering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Hakan S. Edstrom </I>has been our President and Chief
    Operating Officer since April 2001 and has served as one of our
    directors since December 2001. Mr.&#160;Edstrom was with
    Bausch&#160;&#038; Lomb, Inc., a health care product company,
    from January 1998 to April 2001, advancing to the position of
    Senior Corporate Vice President and President of
    Bausch&#160;&#038; Lomb, Inc. Americas Region. From 1981 to
    1997, Mr.&#160;Edstrom was with Pharmacia Corporation, where he
    held various executive positions, including President and Chief
    Executive Officer of Pharmacia Ophthalmics Inc. Mr.&#160;Edstrom
    is currently a director of Q-Med AB, a biotechnology and medical
    device company. Mr.&#160;Edstrom was educated in Sweden and
    holds a master&#146;s degree in Business Administration from the
    Stockholm School of Economics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Abraham (Barry) E. Cohen </I>has been one of our directors
    since May 2007. Mr.&#160;Cohen served as Senior Vice President
    of Merck&#160;&#038; Co. and from 1977 to 1988 as President of
    the Merck Sharp&#160;&#038; Dohme International Division. Since
    his retirement in January 1992, Mr.&#160;Cohen has been active
    as an international business consultant. He is presently a
    director of Akzo Novel NV., Chugai Pharmaceutical Co. U.S.A.,
    Teva Pharmaceutical Industries Ltd., Neurobiological
    Technologies, Inc. and Vasomedical, Inc.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Ronald Consiglio </I>has been one of our directors since
    October 2003. Since 1999, Mr.&#160;Consiglio has been the
    managing director of Synergy Trading, a securities-trading
    partnership. From 1999 to 2001, Mr.&#160;Consiglio was Executive
    Vice President and Chief Financial Officer of Trading Edge,
    Inc., a national automated bond-trading firm. From January 1993
    to 1998 Mr.&#160;Consiglio served as Chief Executive Officer of
    Angeles Mortgage Investment Trust, a publicly traded Real Estate
    Investment Trust. His prior experience includes serving as
    Senior Vice President and Chief Financial Officer of Cantor
    Fitzgerald&#160;&#038; Co. and as a member of its board of
    directors. Mr.&#160;Consiglio is currently a member of the board
    of trustees for the Metropolitan West Funds, a series of mutual
    funds in the fixed income sector. Mr.&#160;Consiglio is a
    certified public accountant and holds a bachelor&#146;s degree
    in accounting from California State University at Northridge.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Michael Friedman,&#160;M.D.</I> has been one of our directors
    since December 2003. Currently, Dr.&#160;Friedman is the
    President and Chief Executive Officer of the City of Hope
    National Medical Center. Previously, from September 2001 until
    April 2003, Dr.&#160;Friedman held the position of Senior Vice
    President of Research and Development, Medical and Public
    Policy, for Pharmacia Corporation and, from July 1999 until
    September 2001, was a senior vice president of Searle, a
    subsidiary of Monsanto Company. From 1995 until June 1999,
    Dr.&#160;Friedman served as Deputy Commissioner for Operations
    for the Food and Drug Administration, and was Acting
    Commissioner and Lead Deputy Commissioner from 1997 to 1998.
    Dr.&#160;Friedman received a bachelor of arts degree, magna cum
    laude, from Tulane University, New Orleans, Louisiana, and a
    doctorate in medicine from the University of Texas, Southwestern
    Medical School.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Kent Kresa </I>has been one of our directors since June 2004.
    Mr.&#160;Kresa is Chairman Emeritus of Northrop Grumman
    Corporation, a defense company and from September 1990 until
    October 2003, he was its Chairman. He also served as Chief
    Executive Officer of Northrop Grumman Corporation from January
    1990 until March 2003 and as its President from 1987 until
    September 2001. Mr.&#160;Kresa is also Chairman of the Board of
    Trustees of the California Institute of Technology
    (&#147;Caltech&#148;) and has been a member of the Caltech Board
    of Trustees since 1994. Mr.&#160;Kresa serves as non-executive
    Chairman of Avery Dennison Corporation, a company focused on
    pressure-sensitive technology and self-adhesive solutions; and
    on the boards of Fluor Corporation, a provider of engineering,
    procurement, construction and maintenance services; General
    Motors Corporation, an automobile manufacturer; and several
    non-profit organizations and universities. He is also on the
    Advisory Board of Trust&#160;Company of the West, an asset
    management firm. As a graduate of M.I.T., he received a B.S. in
    1959, an M.S. in 1961, and an E.A.A. in 1966, all in aeronautics
    and astronautics.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>David H. MacCallum </I>has been one of our directors since
    June 2004. Currently, Mr.&#160;MacCallum is the Managing Partner
    of Outer Islands Capital, a hedge fund specializing in health
    care investments. From June 1999 until November 2001, he was
    Global Head of Health Care investment banking for Salomon Smith
    Barney, part of Citigroup, a financial institution. Prior to
    joining Salomon Smith Barney, he was Executive Vice President
    and Head of the Health Care group at ING Barings Furman Selz
    LLC, an investment banking firm and subsidiary of ING Group, a
    Dutch financial institution, from April 1998 to June 1999. Prior
    to that, Mr.&#160;MacCallum formed the Life Sciences group at
    UBS Securities, an investment banking firm, where he was
    Managing Director and Global Head of Life Sciences from May 1994
    to April 1998. Before joining UBS Securities, he built the
    health care practice at Hambrecht&#160;&#038; Quist, an
    investment banking firm, where he was Head of Health Care and
    Co-Head of Investment Banking. Mr.&#160;MacCallum received an A.
    B. degree from Brown University and an M.B.A. degree from New
    York University. He is a Chartered Financial Analyst.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Henry L. Nordhoff </I>has been one of our directors since
    March 2005. Mr.&#160;Nordhoff has served as Chief Executive
    Officer and President of Gen-Probe Incorporated, a clinical
    diagnostic and blood screening company, since July 1994 and
    Chairman of the Board of Gen-Probe since September 2002. Prior
    to joining Gen-Probe, he was President and Chief Executive
    Officer of TargeTech, Inc., a gene therapy company that was
    merged into Immune Response Corporation. Prior to that,
    Mr.&#160;Nordhoff was at Pfizer, Inc. in senior positions in
    Brussels, Seoul, Tokyo and New&#160;York. He received a B.A. in
    international relations and political economy from Johns Hopkins
    University and an M.B.A. from Columbia University.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The Board
    Of Directors Recommends<BR>
    A Vote For The Election Of All Named Nominees.</FONT></B>
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>


<!-- link1 "CORPORATE GOVERNANCE PRINCIPLES AND BOARD AND COMMITTEE MATTERS" -->
<DIV align="left"><A NAME="004"></A></DIV>


<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CORPORATE
    GOVERNANCE PRINCIPLES AND BOARD AND COMMITTEE MATTERS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Independence
    of the Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As required under the Nasdaq Stock Market
    <B><I>(&#147;Nasdaq&#148;</I></B>) listing standards, a majority
    of the members of a listed company&#146;s Board of Directors
    must qualify as &#147;independent,&#148; as affirmatively
    determined by the Board of Directors. The Board of Directors
    consults with the Company&#146;s counsel to ensure that the
    board&#146;s determinations are consistent with all relevant
    securities and other laws and regulations regarding the
    definition of &#147;independent,&#148; including those set forth
    in pertinent listing standards of the Nasdaq, as in effect time
    to time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Consistent with these considerations, after review of all
    relevant transactions or relationships between each director or
    any of his family members and the Company, its senior management
    and its independent auditors, the Board of Directors
    affirmatively has determined that all of the Company&#146;s
    directors other than Mr.&#160;Mann and Mr.&#160;Edstrom are
    independent within the meaning of the applicable Nasdaq listing
    standards. In making this determination, the board found that
    none of the directors has a material or other disqualifying
    relationship with the Company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Information
    Regarding the Board of Directors and its Committees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are committed to maintaining the highest standards of
    business conduct and ethics. Our Board of Directors has adopted
    Corporate Governance Guidelines to assure that the board will
    have the necessary authority and practices in place to review
    and evaluate our business operations as needed and to make
    decisions that are independent of our management. The guidelines
    are also intended to align the interests of directors and
    management with those of our stockholders. The Corporate
    Governance Guidelines set forth the practices the board will
    follow with respect to board composition and selection, board
    meetings and involvement of senior management, Chief Executive
    Officer performance evaluation and succession planning, and
    board committees and compensation. Our Board of Directors
    adopted the Corporate Governance Guidelines to, among other
    things, reflect changes to the Nasdaq listing standards and
    Securities and Exchange Commission rules adopted to implement
    provisions of the Sarbanes-Oxley Act of 2002, as amended. Our
    Corporate Governance Guidelines, as well as the charters for
    each committee of the board, may be viewed on our website at
    <I>www.mannkindcorp.com.</I>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Committees
    of the Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors has three committees: an Audit Committee,
    a Compensation Committee, and a Nominating and Corporate
    Governance Committee. All three committees operate under written
    charters adopted by our Board, all of which are available on our
    website at <I>www.mannkindcorp.com. </I>The following table
    provides membership and meeting information for fiscal year
    ended December&#160;31, 2008 for each of the Board committees:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nominating and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Audit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Compensation</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Corporate Governance</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Employee Directors:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Abraham E. Cohen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ronald Consiglio
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Friedman,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kent Kresa
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David H. MacCallum
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Henry L. Nordhoff
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    X
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Employee Directors:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total meetings in fiscal year 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Committee Chairperson</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Below is a description of each committee of the Board of
    Directors. Each of the committees has authority to engage legal
    counsel or other experts or consultants, as it deems appropriate
    to carry out its responsibilities. The Board of Directors has
    determined that each member of each committee meets the
    applicable rules and regulations regarding
    &#147;independence&#148; and that each member is free of any
    relationship that would interfere with his or her individual
    exercise of independent judgment with regard to the Company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Audit
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee consists of Mr.&#160;Consiglio (chair),
    Mr.&#160;MacCallum and Mr.&#160;Nordhoff, each of whom is an
    independent member of our Board of Directors (as determined by
    our Board based on its annual review of the definition of
    independence of Audit Committee members provided in
    Rule&#160;4350(d)(2)(A)(i) and (ii)&#160;of the Nasdaq listing
    standards). The functions of this committee include, among
    others:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    evaluating the independent registered public accounting
    firm&#146;s qualifications, independence and performance;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    determining the engagement of the independent registered public
    accounting firm;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approving the retention of the independent registered public
    accounting firm to perform any proposed permissible non-audit
    services;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    monitoring the rotation of partners of the independent
    registered public accounting firm on our engagement team as
    required by law;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing our financial statements;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing our critical accounting policies and estimates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    discussing with management and the independent registered public
    accounting firm the results of the annual audit and the review
    of our quarterly financial statements;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and evaluating, at least annually, the performance of
    the Audit Committee and its members, including compliance of the
    Audit Committee with its charter.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have appointed Mr.&#160;Consiglio as our &#147;Audit
    Committee financial expert,&#148; as that term is defined in
    applicable SEC rules. In making such determinations, the Board
    of Directors made a qualitative assessment of
    Mr.&#160;Consiglio&#146;s level of knowledge and experience
    based on a number of factors, including his formal education and
    experience. Both our independent registered public accounting
    firm and internal financial personnel regularly meet privately
    with our Audit Committee and have unrestricted access to this
    committee. The Audit Committee met nine times during 2008. The
    report of the Audit Committee is included herein on page&#160;39.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Compensation Committee consists of Mr.&#160;Kresa (chair),
    Mr.&#160;Cohen and Dr.&#160;Friedman, each of whom is an
    independent member of our Board of Directors (as independence is
    currently defined in Rule&#160;4200(a)(15) of the Nasdaq listing
    standards). The functions of this committee include, among
    others:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and recommending policy relating to compensation and
    benefits of our officers and employees, including reviewing and
    approving corporate goals and objectives relevant to
    compensation of our chief executive officer and other senior
    officers, evaluating the performance of these officers in light
    of those goals and objectives, and recommending compensation of
    these officers based on such evaluations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    administering our benefit plans and the issuance of stock
    options and other awards under our stock plans;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recommending the type and amount of compensation to be paid or
    awarded to members of our Board of Directors, including
    consulting, retainer, meeting, committee and committee chair
    fees and stock option grants or awards;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and approving the terms of any employment agreements,
    severance arrangements, change-of-control protections and any
    other compensatory arrangements for our executive
    officers;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and evaluating, at least annually, the performance of
    the Compensation Committee and its members, including compliance
    of the Compensation Committee with its charter.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Typically, the Compensation Committee meets at least quarterly
    and with greater frequency if necessary. The Compensation
    Committee met six times during 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The processes and procedures of the Compensation Committee with
    respect to executive compensation are described in greater
    detail in the &#147;Compensation Discussion and Analysis&#148;
    section of this proxy statement. Our Compensation Committee
    charter can be found on our corporate website at
    <I><FONT style="white-space: nowrap">http://www.mannkindcorp.com.</FONT>
    </I>The report of the Compensation Committee is included herein
    on page&#160;38.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Nominating
    and Corporate Governance Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Nominating and Corporate Governance Committee consisted of
    Dr.&#160;Friedman (chair), Mr.&#160;Consiglio and
    Mr.&#160;Kresa, each of whom is an independent member of our
    Board of Directors (as independence is currently defined in
    Rule&#160;4200(a)(15) of the Nasdaq listing standards). The
    functions of this committee include, among others:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    planning for succession with respect to the position of CEO and
    other senior executives;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and recommending nominees for election as directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    assessing the performance of the Board of Directors and
    monitoring committee evaluations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    suggesting, as appropriate, ad-hoc committees of the Board of
    Directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developing guidelines for board composition;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and evaluating, at least annually, the performance of
    the Nominating and Corporate Governance Committee and its
    members, including compliance of the Nominating and Corporate
    Governance Committee with its charter.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Nominating and Corporate Governance Committee charter can be
    found on our corporate website at
    <I><FONT style="white-space: nowrap">http://www.mannkindcorp.com.</FONT>
    </I>The Nominating and Corporate Governance Committee met once
    during 2008.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Consideration
    Of Director Nominees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Director
    Qualifications</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating and Corporate Governance Committee believes that
    candidates for director should have certain minimum
    qualifications, including being able to read and understand
    basic financial statements, being over 21&#160;years of age and
    having the highest personal integrity and ethics. The Nominating
    and Corporate Governance Committee also intends to consider such
    factors as possessing relevant expertise upon which to be able
    to offer advice and guidance to management, having sufficient
    time to devote to the affairs of the Company, demonstrated
    excellence in his or her field, having the ability to exercise
    sound business judgment and having the commitment to rigorously
    represent the long-term interests of the Company&#146;s
    stockholders. However, the Nominating and Corporate Governance
    Committee retains the right to modify these qualifications from
    time to time.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Evaluating
    Nominees for Director</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating and Corporate Governance Committee review
    candidates for director nominees in the context of the current
    composition of the Board of Directors, the operating
    requirements of the Company and the long-term interests of
    stockholders. In conducting this assessment, the Nominating and
    Corporate Governance Committee considers diversity, age, skills,
    and such other factors as it deems appropriate given the current
    needs of the Board of Directors and the Company, to maintain a
    balance of knowledge, experience and capability. In the case of
    incumbent directors whose terms of office are set to expire, the
    Nominating and Corporate Governance Committee reviews such
    directors&#146; overall service to the Company during their
    term, including the number of meetings attended, level of
    participation, quality of performance, and any other
    relationships and transactions that might impair such
    directors&#146; independence. In the case of new director
    candidates, the Nominating and Corporate Governance Committee
    also determines whether the nominee must be independent for
    Nasdaq purposes, which determination is based upon applicable
    Nasdaq listing standards, applicable SEC rules and regulations
    and the advice of counsel, if necessary. The Nominating and
    Corporate Governance Committee then uses its network of contacts
    to compile a list of potential candidates, but may also engage,
    if it deems appropriate, a professional search firm. The
    Nominating and Corporate Governance Committee conducts any
    appropriate and necessary inquiries into the backgrounds and
    qualifications of possible candidates after considering the
    function and needs of the board. The Nominating and Corporate
    Governance Committee meets to discuss and consider such
    candidates&#146; qualifications and then selects a nominee for
    recommendation to the board by majority vote. To date, the
    Nominating and Corporate Governance Committee has not paid a fee
    to any third party to assist in the process of identifying or
    evaluating director candidates. To date, the Nominating and
    Corporate Governance Committee has not rejected a timely
    director nominee from a stockholder or stockholders holding more
    than 5% of our voting stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Stockholder
    Nominations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating and Corporate Governance Committee will consider
    director candidates recommended by stockholders. The Nominating
    and Corporate Governance Committee does not intend to alter the
    manner in which it evaluates candidates, including the minimum
    criteria set forth above, based on whether a candidate was
    recommended by a stockholder or not. Stockholders who wish to
    recommend individuals for consideration by the Nominating and
    Corporate Governance Committee to become nominees for election
    to the Board of Directors must do so by delivering at least
    120&#160;days prior to the anniversary date of the mailing of
    MannKind&#146;s proxy statement for its last annual meeting of
    stockholders a written recommendation to the Nominating and
    Corporate Governance Committee
    <FONT style="white-space: nowrap">c/o&#160;MannKind</FONT>
    Corporation, 28903 North Avenue Paine, Valencia, California
    91355, Attn: Corporate Secretary. Each submission must set forth:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the name and address of the MannKind stockholder on whose behalf
    the submission is made;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the number of MannKind shares that are owned beneficially by
    such stockholder as of the date of the submission;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the full name of the proposed candidate;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a description of the proposed candidate&#146;s business
    experience for at least the previous five years;
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    complete biographical information for the proposed
    candidate;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a description of the proposed candidate&#146;s qualifications as
    a director.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each submission must be accompanied by the written consent of
    the proposed candidate to be named as a nominee and to serve as
    a director if elected.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Meetings
    Of The Board Of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors met eight times during the last fiscal
    year. Each board member attended 75% or more of the aggregate of
    the meetings of the Board and of the committees on which he or
    she served, held during the period for which he or she were a
    director or committee member, respectively, except
    Ms.&#160;Heather Murren, a director who resigned in December
    2008, who attended 57% of the meetings of the Board.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Executive
    Sessions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As required under applicable Nasdaq listing standards, our
    independent directors meet in regularly scheduled executive
    sessions at which only independent directors are present.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Stockholder
    Communications With The Board Of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s Board of Directors has adopted a formal
    process by which stockholders may communicate with the Board or
    any of its directors. Stockholders who wish to communicate with
    the board or an individual director may send a written
    communication to the Board or such director
    <FONT style="white-space: nowrap">c/o&#160;MannKind</FONT>
    Corporation, 28903 North Avenue Paine, Valencia, California
    91355, Attn: Corporate Secretary. Communications also may be
    sent by
    <FONT style="white-space: nowrap">e-mail</FONT> to
    the following address board@mannkindcorp.com. Each communication
    must set forth the name and address of the MannKind stockholder
    on whose behalf the communication is sent. Each communication
    will be screened by MannKind&#146;s Corporate Secretary to
    determine whether it is appropriate for presentation to the
    Board of Directors or such director. Examples of inappropriate
    communications include junk mail, mass mailings, product
    complaints, product inquiries, new product suggestions, resumes,
    job inquiries, surveys, business solicitations and
    advertisements, as well as unduly hostile, threatening, illegal,
    unsuitable, frivolous, patently offensive or otherwise
    inappropriate material. Communications determined by the
    Corporate Secretary to be appropriate for presentation to the
    Board of Directors or such director will be submitted to the
    Board of Directors or such director on a periodic basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The screening procedures have been approved by a majority of the
    independent directors of the Board. All communications directed
    to the Audit Committee in accordance with the Company&#146;s
    Code of Ethics or Non-Retaliation Policy that relate to
    questionable accounting or auditing matters involving the
    Company will be promptly and directly forwarded to the Audit
    Committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Code
    of Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a Code of Business Conduct and Ethics Policy
    that applies to our directors and employees (including our
    principal executive officer, principal financial officer,
    principal accounting officer and controller), and have posted
    the text of the policy on our website
    (<I>www.mannkindcorp.com</I>) in connection with
    &#147;Investor&#148; materials. In addition, we intend to
    promptly disclose on our website (i)&#160;the nature of any
    amendment to the policy that applies to our principal executive
    officer, principal financial officer, principal accounting
    officer or controller, or persons performing similar functions
    and (ii)&#160;the nature of any waiver, including an implicit
    waiver, from a provision of the policy that is granted to one of
    these specified individuals, the name of such person who is
    granted the waiver and the date of the waiver.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the fiscal year ended December&#160;31, 2008,
    Messrs.&#160;Cohen and Kresa and Dr.&#160;Friedman served on our
    Compensation Committee. None of Messrs.&#160;Cohen or Kresa or
    Dr.&#160;Friedman has ever been one of our officers or
    employees. During 2008, none of our executive officers served as
    a member of the Board of Directors or Compensation Committee of
    any other entity that had one or more executive officers who
    served on our Board of Directors or Compensation Committee.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "Proposal 2 Approval Of The Amendment To MannKind&#146;s 2004 Equity Incentive Plan" -->
<DIV align="left"><A NAME="005"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Proposal&#160;2<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Approval
    Of The Amendment To MannKind&#146;s 2004 Equity Incentive
    Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2004, our Board of Directors and our stockholders
    approved the amendment and restatement of our 2001 Stock Awards
    Plan, now known as our 2004 Equity Incentive Plan (the
    <B><I>&#147;Plan&#148;</I></B>). Initially, there were
    5,000,000&#160;shares of common stock reserved for issuance
    under the Plan. In 2006 and 2007, our Board of Directors and
    stockholders approved an amendment to the Plan that increased
    the number of shares of common stock authorized for issuance
    under the Plan to 9,000,000 and 14,000,000&#160;shares each
    year, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During 2008, our Board of Directors granted options to purchase
    3,903,370&#160;shares at a weighted average exercise price of
    $3.43 and 5,135,000 restricted stock units. As of
    December&#160;31, 2008, options to purchase
    5,591,101&#160;shares with a weighted average exercise price of
    $6.97 and a weighted average remaining term of 5.2&#160;years
    and 5,947,408 restricted stock units were outstanding under the
    Plan and only 1,931,782&#160;shares of common stock remained
    available for issuance under the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2009, our Board of Directors amended the Plan,
    subject to stockholder approval, to increase the number of
    shares of our common stock authorized for issuance under the
    Plan to 19,000,000&#160;shares. The Board adopted this amendment
    in order to ensure that we can continue to grant stock options
    and restricted stock unit awards at levels determined
    appropriate by the Board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You are being asked to approve an increase in the number of
    shares reserved for issuance under the Plan from 14,000,000 to
    19,000,000. The affirmative vote of the holders of a majority of
    the shares present in person or represented by proxy and
    entitled to vote at the meeting will be required to approve the
    amendment to the Plan. Abstentions will be counted toward the
    tabulation of votes cast on proposals presented to the
    stockholders and will have the same effect as negative votes.
    Broker non-votes are counted towards a quorum, but are not
    counted for any purpose in determining whether this matter has
    been approved.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company believes it is in the best interests of the
    Company&#146;s stockholders and employees to increase the number
    of shares of common stock available to the Plan by
    5,000,000&#160;shares, as this will allow the Company to
    continue to attract and retain quality personnel and to promote
    employee participation in equity ownership of the Company.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">The
    Board Of Directors Unanimously Recommends<BR>
    A Vote For This Proposal.</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Features
    of 2004 Equity Incentive Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The essential features of the Plan are outlined below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>General.</I>&#160;&#160;The Plan provides for the grant of
    incentive stock options, nonstatutory stock options, stock
    appreciation rights, stock bonuses, restricted stock unit awards
    and other stock awards (collectively
    <B><I>&#147;awards&#148;</I></B>). Incentive stock options, or
    ISOs, granted under the Plan are intended to qualify as
    &#147;incentive stock options&#148; within the meaning of
    Section&#160;422 of the Internal Revenue Code of 1986, as
    amended (the <B><I>&#147;Code&#148;</I></B>). Nonstatutory stock
    options, or NSOs, granted under the Plan are not intended to
    qualify as incentive stock options under the Code. Stock
    appreciation rights granted under the Plan may be tandem rights,
    concurrent rights or independent rights. To date, the Company
    has granted only stock options and restricted stock awards under
    the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Purpose.</I>&#160;&#160;The Board adopted the Plan to provide
    a means by which employees, directors and consultants of the
    Company and its affiliates may be given an opportunity to
    acquire stock in the Company, to assist in retaining the
    services of such persons, to secure and retain the services of
    persons capable of filling such positions and to provide
    incentives for such persons to exert maximum efforts for the
    success of the Company and its affiliates. All of the
    approximately 580&#160;employees, directors and consultants of
    the Company and its affiliates are eligible to participate in
    the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Share reserve.</I>&#160;&#160;An aggregate of
    14,000,000&#160;shares of our common stock are currently
    reserved for issuance under the Plan. If this proposal is
    approved by the stockholders, 19,000,000&#160;shares of our
    common stock will be
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reserved for issuance under the Plan. Shares subject to options
    and stock awards that expire, terminate, are repurchased or are
    forfeited under the Plan will again become available for the
    grant of awards under the Plan. Shares issued under the Plan may
    be previously unissued shares or reacquired shares bought on the
    market or otherwise. If any shares subject to a stock award are
    not delivered to a participant because such shares are withheld
    for the payment of taxes or the stock award is exercised through
    a &#147;net exercise,&#148; the number of shares that are not
    delivered to the participant shall remain available for the
    grant of awards under the Plan. If the exercise of any stock
    award is satisfied by tendering shares of common stock held by
    the participant, the number of shares tendered shall become
    available for the grant of awards under the Plan. The maximum
    number of shares that may be issued under the Plan subject to
    incentive stock options is 7,000,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of March&#160;31, 2009, 5,491,261 options and 5,784,936
    restricted stock units were outstanding under the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Administration.</I>&#160;&#160;Our Board of Directors
    administers the Plan, and the board has delegated authority to
    administer the Plan to the Compensation Committee of the Board
    of Directors. Subject to the terms of the Plan, the plan
    administrator will determine the stock award recipients and
    grant dates, the numbers and types of stock awards to be granted
    under the Plan and the terms and conditions of the stock awards,
    including the period of their exercisability and vesting.
    Subject to the limitations set forth below, the plan
    administrator will also determine the exercise price, purchase
    price or strike price, as applicable, for stock awards granted
    under the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Eligibility of awards.</I>&#160;&#160;The Plan provides for
    the grant of ISOs, NSOs, restricted stock awards, stock
    appreciation rights, phantom stock awards and other stock awards
    based in whole or in part by reference to our common stock. ISOs
    may be granted solely to our employees, including officers. All
    other stock awards under the Plan may generally be granted to
    our employees, directors, officers and consultants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stock options.</I>&#160;&#160;Stock options are granted under
    the Plan pursuant to a stock option agreement. Generally, the
    exercise price for an ISO cannot be less than 100% of the fair
    market value of the common stock subject to the option on the
    date of grant. The exercise price for an NSO is determined by
    our Board of Directors. Options granted under the Plan vest at
    the rate specified in the stock option agreement. In addition,
    our Plan allows for the early exercise of options, as set forth
    in an applicable stock option agreement. All shares of our
    common stock acquired through options exercised early may be
    subject to repurchase by us. Options granted under the Plan
    prior to its amendment and restatement in 2004 vest at the
    minimum rate of at least 20% per year and do not provide for
    early exercise. Stock options generally vest over four years,
    typically at the rate of 25% after one year and ratably on a
    monthly basis over a period of 36&#160;months thereafter.
    Restricted stock units generally vest over four years with
    consideration satisfied by service to the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, the term of stock options granted under the Plan may
    not exceed ten years. With respect to options granted under the
    Plan following our initial public offering in 2004, unless the
    terms of an optionee&#146;s stock option agreement provide for
    earlier termination, if an optionee&#146;s service relationship
    with us, or any affiliate of ours, terminates due to disability,
    death or retirement, the optionee, or his or her beneficiary,
    generally may exercise any vested options after the date the
    service relationship ends for up to twelve months in the event
    of disability, up to eighteen months in the event of death and
    up to twenty-four months in the event of selected retirements.
    If an optionee&#146;s relationship with us, or any affiliate of
    ours, ceases for any reason other than disability, death or
    retirement, the optionee may exercise any vested options for up
    to three months after the termination of service, unless the
    terms of the stock option agreement provide for earlier or later
    termination. However, in the event the optionee&#146;s service
    with us, or an affiliate of ours, is terminated for cause (as
    defined in the Plan), all options held by the optionee under the
    Plan will terminate in their entirety on the date of termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With respect to options granted under the Plan prior to our
    initial public offering in 2004, if an optionee&#146;s service
    with us is terminated due to disability or death, the optionee,
    or his or her beneficiary, may exercise any vested options for
    up to six months after the date of termination. If an
    optionee&#146;s service with us is terminated for any reason
    other than disability or death, the optionee may exercise any
    vested options for up to thirty days after the date of
    termination. However, in the event an optionee&#146;s service
    with us is terminated for cause under the terms of the Plan, all
    options held by the optionee under the Plan will terminate on
    the date of termination.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acceptable consideration for the purchase of our common stock
    issued under the Plan will be determined by our Board of
    Directors and may include cash or common stock previously owned
    by the optionee, or may be paid through a deferred payment
    arrangement, a broker assisted exercise, the net exercise of the
    option or other legal consideration or arrangements approved by
    our Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, options granted under the Plan may not be transferred
    other than by will or the laws of descent and distribution
    unless the optionee holds an NSO and the related option
    agreement provides otherwise. However, an optionee may designate
    a beneficiary who may exercise the options granted under the
    Plan following the optionee&#146;s death.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Tax limitations on stock option grants.</I>&#160;&#160;ISOs
    may be granted only to our employees. The aggregate fair market
    value, determined at the time of grant, of shares of our common
    stock subject to ISOs that are exercisable for the first time by
    an optionee during any calendar year under all of our stock
    plans may not exceed $100,000. The options or portions of
    options that exceed this limit are treated as NSOs. No ISO may
    be granted to a 10% stockholder unless the following conditions
    are satisfied:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the option exercise price is at least 110% of the fair market
    value of the stock subject to the option on the grant
    date;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the term of any ISO award must not exceed five years from the
    grant date.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Section&#160;162(m).</I>&#160;&#160;Section&#160;162(m) of
    the Code denies an income tax deduction to publicly held
    corporations for certain compensation paid to certain
    &#147;covered employees&#148; in a taxable year to the extent
    that the compensation exceeds $1,000,000. Currently, a
    &#147;covered employee&#148; is the company&#146;s chief
    executive officer and the next three highest paid executive
    officers, not including the chief financial officer.
    Section&#160;162(m) provides an exception to this deduction
    limitation for qualified performance-based compensation. In
    general, stock options that are granted by our Compensation
    Committee and that have an exercise price of not less than the
    fair market value of our common stock will be deemed to qualify
    as performance-based compensation if the Plan contains a limit
    on the maximum number of shares underlying those stock options
    that can be granted to any person during any period of time. To
    comply with this requirement, the Plan provides that no person
    may be granted options under the Plan covering more than
    2,000,000&#160;shares of our common stock in any calendar year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Restricted stock awards.</I>&#160;&#160;Restricted stock
    awards are purchased through a restricted stock award agreement.
    To the extent required by law, the purchase price for restricted
    stock awards must be at least the par value of the stock. The
    purchase price for a restricted stock award may be payable in
    cash or through a deferred payment or related arrangement, the
    recipient&#146;s past services performed for us, or any other
    form of legal consideration or arrangement acceptable to our
    Board of Directors. Rights to acquire shares under a restricted
    stock award may be transferred only as set forth in the
    restricted stock award agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stock appreciation rights.</I>&#160;&#160;Stock appreciation
    rights are granted under the Plan pursuant to stock appreciation
    rights agreements. The plan administrator determines the strike
    price for a stock appreciation right. Stock appreciation rights
    granted under the Plan vest at the rate specified in the stock
    appreciation rights agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The plan administrator determines the term of stock appreciation
    rights granted under the Plan. Unless the terms of an
    awardee&#146;s stock appreciation rights agreement provides
    otherwise, if an awardee&#146;s service relationship with us, or
    any affiliate of ours, terminates for any reason, the awardee,
    or his or her beneficiary, may exercise any vested stock
    appreciation rights for up to three months after the date the
    service relationship ends unless the terms of the agreement
    provide for earlier or later termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Restricted stock units or phantom
    stock.</I>&#160;&#160;Awards of restricted stock units are
    granted under the Plan pursuant to phantom stock award
    agreements. A restricted stock unit may require the payment of
    at least the par value of the option subject to the award.
    Payment of any purchase price may be made in cash or common
    stock previously owned by the recipient or other permissible
    consideration including services rendered to the Company. All
    unvested restricted stock units will be forfeited upon
    termination of the holder&#146;s service relationship with us,
    or any affiliate of ours, to the extent not vested on that date.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other stock awards.</I>&#160;&#160;The plan administrator may
    grant other awards based in whole or in part by reference to our
    common stock. The plan administrator will set the number of
    shares under the award, the purchase price, if any, the timing
    of exercise and vesting and any repurchase rights associated
    with these awards.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Corporate transactions and changes in
    control.</I>&#160;&#160;In the event of certain corporate
    transactions, all outstanding stock awards granted under the
    Plan following our initial public offering will be assumed,
    continued or substituted for by any surviving or acquiring
    entity. If the surviving or acquiring entity elects not to
    assume, continue or substitute for these awards, the vesting
    provisions of these awards will generally be accelerated and the
    awards will be terminated if not exercised prior to the
    effective date of the corporate transaction. We may assign any
    repurchase or reacquisition rights held by us with respect to
    outstanding stock awards to the surviving or acquiring entity.
    Following certain change in control transactions, the vesting
    and exercisability of certain stock awards granted under the
    Plan following our initial public offering generally will be
    accelerated only if and to the extent provided in the
    awardee&#146;s award agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a stock split, reverse stock split, stock
    dividend, combination or reclassification of the stock, or any
    other increase or decrease in the number of issued shares of
    common stock effected without receipt of consideration by the
    Company, our Board of Directors will make appropriate
    adjustments to any or all of (i)&#160;the number and kind of
    shares which may thereafter be issued in connection with awards,
    (ii)&#160;the number and kind of shares issued or issuable for
    outstanding awards, and (iii)&#160;the exercise price, grant
    price, or purchase price relating to any award.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Additional provisions.</I>&#160;&#160;Our Board of Directors
    has the authority to amend outstanding awards granted under the
    Plan, except that no amendment may adversely affect an award
    without the recipient&#146;s written consent. Our Board of
    Directors has the power to amend, suspend or terminate the Plan.
    However, some amendments also require stockholder approval.
</DIV>


<!-- link1 "Proposal 3 Ratification of Selection of Deloitte &#038; Touche LLP as Independent Registered Public Accounting Firm" -->
<DIV align="left"><A NAME="006"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Proposal&#160;3<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Ratification
    of Selection of Deloitte&#160;&#038; Touche LLP<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">as
    Independent Registered Public Accounting Firm</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee of the Board of Directors has selected
    Deloitte&#160;&#038; Touche LLP, or &#147;Deloitte,&#148; as the
    Company&#146;s independent registered public accounting firm for
    the fiscal year ending December&#160;31, 2009 and has directed
    management to submit the selection of Deloitte for ratification
    by the stockholders at the Annual Meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deloitte has audited the Company&#146;s financial statements
    since the fiscal year ended December&#160;31, 2000.
    Representatives of Deloitte are expected to be present at the
    Annual Meeting. They will have an opportunity to make a
    statement if they so desire and will be available to respond to
    appropriate questions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stockholder ratification of the selection of Deloitte as our
    independent registered public accounting firm is not required by
    our bylaws or otherwise. The Board of Directors is seeking such
    ratification as a matter of good corporate practice. If the
    stockholders fail to ratify the selection of Deloitte as our
    independent registered accounting firm, the Audit Committee of
    the Board of Directors will consider whether to retain that firm
    for the year ending December&#160;31, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A majority of the shares present in person or by proxy and
    entitled to vote at the Annual Meeting is required for approval
    of this proposal.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-variant: SMALL-CAPS">The Board Of Directors
    Recommends<BR>
    A Vote For This Proposal.</FONT></B>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Principal
    Accounting Fees And Services</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table represents aggregate fees billed to the
    Company for fiscal years ended December&#160;31, 2008 and 2007
    by Deloitte, the Company&#146;s principal accountant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="77%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Fiscal Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Audit Fees(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,259,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,661,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax Fees(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,924
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All Other Fees(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,639
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,390,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,810,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the aggregate fees billed for professional services
    rendered for the audit and/or reviews of our financial
    statements and in connection with our statutory and regulatory
    filings or engagements. Also includes fees for services related
    to Sarbanes-Oxley and a tender offer that took place in August
    2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents tax preparation and compliance with various
    provisions of the Code.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents tax consultation regarding the application of various
    provisions of the Code.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All fees described above were pre-approved by the Audit
    Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the fiscal year ended December&#160;31, 2008, none of the
    total hours expended on the Company&#146;s financial audit by
    Deloitte were provided by persons other than Deloitte&#146;s
    full-time permanent employees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Pre-Approval
    Policies And Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee has adopted a policy and procedures for the
    pre-approval of audit and non-audit services rendered by our
    independent auditor, Deloitte. The policy generally pre-approves
    specified services in the defined categories of audit services,
    audit-related services, tax services and other services up to
    specified amounts. Pre-approval may also be given on an
    individual explicit
    <FONT style="white-space: nowrap">case-by-case</FONT>
    basis before the independent auditor is engaged to provide each
    service. The pre-approval of services may be delegated to one or
    more of the Audit Committee&#146;s members, but the decision
    must be reported to the full Audit Committee at its next
    scheduled meeting. The delegation of pre-approval of services is
    limited to non-audit services, as set forth in the Audit
    Committee Charter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee has determined that the rendering of the
    services other than audit services by Deloitte is compatible
    with maintaining Deloitte&#146;s independence.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT" -->
<DIV align="left"><A NAME="007"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth certain information regarding the
    ownership of the Company&#146;s common stock as of
    January&#160;31, 2009 by: (i)&#160;each director and nominee for
    director; (ii)&#160;each of the executive officers named in the
    Summary Compensation Table; (iii)&#160;all executive officers
    and directors of the Company as a group; and (iv)&#160;all those
    known by the Company to be beneficial owners of more than five
    percent of its common stock. The table is based upon information
    supplied by our officers, directors and principal stockholders
    and a review of Schedules 13D and 13G, if any, filed with the
    SEC. Unless otherwise indicated in the footnotes to the table
    and subject to community property laws where applicable, we
    believe that each of the stockholders named in the table has
    sole voting and investment power with respect to the shares
    indicated as beneficially owned.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Applicable percentages are based on 102,013,623&#160;shares
    outstanding on January&#160;31, 2009, adjusted as required by
    rules promulgated by the SEC. These rules generally attribute
    beneficial ownership of securities to persons who possess sole
    or shared voting power or investment power with respect to those
    securities. In addition, the rules include shares of common
    stock issuable pursuant to the exercise of stock options or
    warrants that are either immediately exercisable or exercisable
    on April&#160;1, 2009, which is 60&#160;days after
    January&#160;31, 2009. These shares are deemed to be outstanding
    and beneficially owned by the person holding those options or
    warrants for the purpose of computing the percentage ownership
    of that person, but they are not treated as outstanding for the
    purpose of computing the percentage ownership of any other
    person. Certain of the options in this table are exercisable at
    any time but, if exercised, are subject to a lapsing right of
    repurchase until the options are fully vested. Except as
    otherwise noted in the table, the address for each person or
    entity listed in the table is
    <FONT style="white-space: nowrap">c/o&#160;MannKind</FONT>
    Corporation, 28903 North Avenue Paine, Valencia, CA 91355.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="70%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Beneficial Ownership</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Identity of Owner or Group</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percent of Total</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Named Executive Officers and Directors:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred E. Mann(1)(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,487,184
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47.5
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Matthew J. Pfeffer(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,431
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,735
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dr.&#160;Peter Richardson(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,157
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Juergen A. Martens,&#160;Ph.D.(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,065
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Abraham E. Cohen(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ronald Consiglio(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael Friedman(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kent Kresa(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David H. MacCallum(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Henry L. Nordhoff(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All current executive officers and directors as a group
    (14&#160;persons)(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,339,186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Five Percent Stockholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    LMM LLC(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,911,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    FMR LLC(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,468,321
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.2
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    Less than one percent.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes (i)&#160;39,677,899&#160;shares held by the Alfred E.
    Mann Living Trust; (ii)&#160;10,968&#160;shares held by Mannco
    LLC, (iii)&#160;4,025,979&#160;shares held by Biomed Partners,
    LLC, and (v)&#160;2,406,027&#160;shares held by Biomed Partners
    II, LLC. The Alfred E. Mann Living Trust and MiniMed Infusion,
    Inc. are each 0.1% managing members of each of Biomed Partners,
    LLC and Biomed Partners II, LLC. Alfred Mann has voting and
    dispositive power over the shares owned by each of these
    entities.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes shares described in the note above. Includes shares
    which certain executive officers, directors and principal
    stockholders of the Company have the right to acquire within
    60&#160;days after the date of this table pursuant to
    outstanding options and warrants, as follows: Alfred E. Mann
    Living Trust, 1,388,993&#160;shares; Alfred E. Mann,
    272,756&#160;shares; Biomed Partners, LLC, 321,098; Juergen A.
    Martens,&#160;Ph.D., 2,100&#160;shares; Abraham E. Cohen,
    17,054&#160;shares; Ronald Consiglio, 72,609&#160;shares;
    Michael Friedman, 72,609&#160;shares; </TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Kent&#160;Kresa, 2,100&#160;shares issuable pursuant to warrants
    and 60,109 pursuant to options; David H. MacCallum,
    60,109&#160;shares; and Henry L. Nordhoff, 55,109&#160;shares.
    Also includes 14,986&#160;shares owned by Diane Palumbo, our
    Corporate Vice President of Human Resources and
    11,320&#160;shares owned by David Thomson, our Corporate Vice
    President, General Counsel. Includes 261,676&#160;shares
    beneficially owned by Richard Anderson, our Corporate Vice
    President, Office of the Chairman, including 229,875&#160;shares
    issuable upon his retirement on March&#160;31, 2009, at which
    time all of his unvested stock options and restricted stock unit
    awards that were subject to time-based vesting become vested.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address of LMM LLC is 100 Light Street, Baltimore, Maryland
    21202. Legg Mason Opportunity Trust and LMM LLC, the manager of
    such fund, share voting and dispositive power with respect to
    these shares, and therefore may be deemed beneficial owners of
    the shares.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address of FMR LLC is 82 Devonshire Street, Boston,
    Massachusetts 02109. Fidelity Management&#160;&#038; Research
    Company (<B><I>&#147;Fidelity&#148;</I></B>), a wholly-owned
    subsidiary of FMR LLC, beneficially owns the shares, including
    334,219&#160;shares issuable upon the exercise of outstanding
    warrants, as a result of acting as investment advisor to various
    investment companies, including Fidelity Contrafund, which owns
    7,981,107&#160;shares. Edward C. Johnson 3d and FMR LLC, through
    its control of Fidelity and the various Fidelity funds, each has
    sole power to dispose of such shares. The sole power to vote or
    direct the voting of these shares resides with the Boards of
    Trustees of the various funds.</TD>
</TR>

</TABLE>


<!-- link1 "EXECUTIVE OFFICERS" -->
<DIV align="left"><A NAME="008"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXECUTIVE
    OFFICERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our current executive officers
    and their ages as of December&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="45%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Age</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Position(s)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    83
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Chairman of the Board of Directors and Chief Executive Officer
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    58
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    President, Chief Operating Officer and Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Matthew J. Pfeffer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    51
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Corporate Vice President and Chief Financial Officer
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Juergen A. Martens,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Corporate Vice President, Technical Operations and Chief
    Technical Officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Diane M. Palumbo
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    55
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Corporate Vice President, Human Resources
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dr.&#160;Peter C. Richardson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    49
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Corporate Vice President and Chief Scientific Officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Thomson,&#160;Ph.D.,&#160;J.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    42
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Corporate Vice President, General Counsel and Secretary
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Alfred E. Mann </I>has been one of our directors since April
    1999, our Chairman of the Board since December 2001 and our
    Chief Executive Officer since October 2003. He founded and
    formerly served as Chairman and Chief Executive Officer of
    MiniMed, Inc., a publicly traded company focused on diabetes
    therapy and microinfusion drug delivery that was acquired by
    Medtronic, Inc. in August 2001. Mr.&#160;Mann also founded and,
    from 1972 through 1992, served as Chief Executive Officer of
    Pacesetter Systems, Inc. and its successor, Siemens Pacesetter,
    Inc., a manufacturer of cardiac pacemakers, now the Cardiac
    Rhythm Management Division of St. Jude Medical Corporation.
    Mr.&#160;Mann founded and since 1993, has served as Chairman and
    until January 2008, as Co-Chief Executive Officer of Advanced
    Bionics Corporation, a medical device manufacturer focused on
    neurostimulation to restore hearing to the deaf and to treat
    chronic pain and other neural deficits, that was acquired by
    Boston Scientific Corporation in June 2004. In January 2008, the
    former stockholders of Advanced Bionics Corporation repurchased
    certain segments from Boston Scientific Corporation and formed
    Advanced Bionics LLC for cochlear implants and Infusion Systems
    LLC for infusion pumps. Mr.&#160;Mann is non-executive Chairman
    of both entities. Mr.&#160;Mann has also founded and is
    non-executive Chairman of Second Sight, which is developing a
    visual prosthesis for the blind and Quallion, which produces
    batteries for medical products and for the military and
    aerospace industries; and Stellar Microelectronics Inc., a
    supplier of electronic assemblies to the medical, military and
    aerospace industries. Mr.&#160;Mann is also non-executive
    Chairman of the Alfred Mann Foundation and Alfred Mann Institute
    at the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    University of Southern California, AMI Purdue and AMI Technion,
    and the Alfred Mann Foundation for Biomedical Engineering, which
    is establishing additional institutes at other research
    universities. Mr.&#160;Mann is also non-executive Chairman of
    the Southern California Biomedical Council, and a Director of
    the Nevada Cancer Institute and United Cerebral Palsy
    Foundation. Mr.&#160;Mann holds a bachelor&#146;s and
    master&#146;s degree in Physics from the University of
    California at Los Angeles, honorary doctorates from Johns
    Hopkins University, the University of Southern California,
    Western University and the Technion-Israel Institute of
    Technology and is a member of the National Academy of
    Engineering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Hakan S. Edstrom </I>has been our President and Chief
    Operating Officer since April 2001 and has served as one of our
    directors since December 2001. Mr.&#160;Edstrom was with
    Bausch&#160;&#038; Lomb, Inc., a health care product company,
    from January 1998 to April 2001, advancing to the position of
    Senior Corporate Vice President and President of
    Bausch&#160;&#038; Lomb, Inc. Americas Region. From 1981 to
    1997, Mr.&#160;Edstrom was with Pharmacia Corporation, where he
    held various executive positions, including President and Chief
    Executive Officer of Pharmacia Ophthalmics Inc. Mr.&#160;Edstrom
    is currently a director of Q-Med AB, a biotechnology and medical
    device company. Mr.&#160;Edstrom was educated in Sweden and
    holds a master&#146;s degree in Business Administration from the
    Stockholm School of Economics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Matthew J. Pfeffer </I>has been our Corporate Vice President
    and Chief Financial Officer since April 2008. Previously,
    Mr.&#160;Pfeffer served as Chief Financial Officer and Senior
    Vice President of Finance and Administration of VaxGen, Inc.
    from March 2006 until April 2008, with responsibility for
    finance, tax, treasury, human resources, IT, purchasing and
    facilities functions. Prior to VaxGen, Mr.&#160;Pfeffer served
    as CFO of Cell Genesys, Inc. During his nine year tenure at Cell
    Genesys, Mr.&#160;Pfeffer served as Director of Finance before
    being named CFO in 1998. Prior to that, Mr.&#160;Pfeffer served
    in a variety of financial management positions at other
    companies, including roles as Corporate Controller, Manager of
    Internal Audit and Manager of Financial Reporting.
    Mr.&#160;Pfeffer began his career at Price Waterhouse.
    Mr.&#160;Pfeffer serves on boards and advisory committees of the
    Biotechnology Industry Organization and the American Institute
    of Certified Public Accountants. Mr.&#160;Pfeffer has a
    bachelor&#146;s degree in Accounting from the University of
    California, Berkeley and is a Certified Public Accountant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Juergen A. Martens,&#160;Ph.D.</I> has been our Corporate
    Vice President of Operations and Chief Technology Officer since
    September 2005. From 2000 to August 2005, he was employed by
    Nektar Therapeutics, Inc., most recently as Vice President of
    Pharmaceutical Technology Development. Previously, he held
    technical management positions at Aerojet Fine Chemicals from
    1998 to 2000 and at FMC Corporation from 1996 to 1998. From 1987
    to 1996, Dr.&#160;Martens held a variety of management positions
    with increased responsibility in R&#038;D, plant management, and
    business process development at Lonza, in Switzerland and in the
    United States. Dr.&#160;Martens holds a bachelor&#146;s degree
    in chemical engineering from the Technical College
    Mannheim/Germany, a bachelor&#146;s and master&#146;s degree in
    Chemistry and a doctorate in Physical Chemistry from the
    University of Marburg/Germany.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Diane M. Palumbo </I>has been our Corporate Vice President of
    Human Resources since November 2004. From July 2003 to November
    2004, she was President of her own human resources consulting
    company. From June 1991 to July 2003, Ms.&#160;Palumbo held
    various positions with Amgen, Inc., a California-based
    biopharmaceutical company, including Senior Director, Human
    Resources. In addition, Ms.&#160;Palumbo has held Human
    Resources positions with Unisys and Mitsui Bank Ltd. of Tokyo.
    She holds a master&#146;s degree in Business Administration from
    St. John&#146;s University, New York and a bachelor&#146;s
    degree, magna cum laude, also from St. John&#146;s University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Peter C. Richardson </I>has been our Corporate Vice
    President and Chief Scientific Officer since October 2005. From
    1991 to October 2005, he was employed by Novartis
    Pharmaceuticals Corporation, which is the U.S.&#160;affiliate of
    Novartis AG, a world leader in healthcare, most recently as
    Senior Vice President, Global Head of Development Alliances.
    From 2003 until 2005, he was Senior Vice President and Head of
    Development of Novartis Pharmaceuticals KK Japan. He earlier
    practiced as an endocrinologist. Dr.&#160;Richardson holds a
    B.Med.Sci (Hons.) and a BM.BS (Hons.) from University of
    Nottingham Medical School; a MRCP (UK) from the Royal College of
    Physicians, UK; a Certificate in Pharmaceutical Medicine from
    Universities of Freibourg, Strasbourg and Basle; and a Diploma
    in Pharmaceutical Medicine from the Royal College of Physicians
    Faculty of Pharmaceutical Medicine.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>David Thomson,&#160;Ph.D.,&#160;J.D.</I> has been our
    Corporate Vice President, General Counsel and Corporate
    Secretary since January 2002. Prior to joining us, he practiced
    corporate/commercial and securities law at the Toronto law
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    firm of Davies Ward Phillips&#160;&#038; Vineberg LLP from May
    1999 through December 2001, except for a period from May to
    December 2000, when he served as Vice President, Business
    Development for CTL ImmunoTherapies Corp. From March 1994 to
    August 1996, Dr.&#160;Thomson held a post-doctoral position at
    the Rockefeller University, where he conducted medical research
    in the Laboratory of Neurophysiology. Dr.&#160;Thomson obtained
    his bachelor&#146;s degree, master&#146;s degree and Ph.D.
    degree from Queens University and obtained his J.D. degree from
    the University of Toronto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Executive officers serve at the discretion of our Board of
    Directors. There are no family relationships between any of our
    directors and executive officers.
</DIV>


<!-- link1 "COMPENSATION OF DIRECTORS" -->
<DIV align="left"><A NAME="009"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPENSATION
    OF DIRECTORS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of our non-employee directors receives an annual retainer
    of $25,000 for service on the Board of Directors. Each of our
    non-employee directors who serve as a committee chairman
    receives, in addition to the annual retainer, an additional
    retainer of $3,000 per year for his or her service as committee
    chairman and committee members receive an additional retainer of
    $2,000 per year; provided, however, the Audit Committee
    chairman&#146;s additional retainer is $8,000 per year and each
    Audit Committee members&#146; additional retainer is $4,000 per
    year. Each of our non-employee directors also receives $2,000
    for each meeting of the Board of Directors attended, and $750
    for attending each meeting of any committee of the Board of
    Directors on which he or she serves. In the fiscal year ended
    December&#160;31, 2008, the total compensation paid to
    non-employee directors was $336,050. The members of the Board of
    Directors are also eligible for reimbursement for their expenses
    incurred in attending Board of Directors meetings in accordance
    with Company policy.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Options</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each non-employee director of the Company also receives stock
    option grants under the 2004 Non-Employee Directors&#146; Stock
    Option Plan, or the Directors&#146; Plan. Only non-employee
    directors of the Company or an affiliate of such directors (as
    defined in the Code) are eligible to receive options under the
    Directors&#146; Plan. Options granted under the Directors&#146;
    Plan are intended by the Company not to qualify as incentive
    stock options under the Code.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Option grants under the Directors&#146; Plan are
    non-discretionary. Pursuant to the terms of the Directors&#146;
    Plan, each of our non-employee directors automatically receives,
    and each person who is elected or appointed for the first time
    to be a non-employee director will automatically receive, on the
    date of his or her initial election or appointment to our Board
    of Directors, an option to purchase 30,000&#160;shares of our
    common stock as an initial grant, or the Initial Option. On the
    date of each of our annual stockholder meetings, each
    non-employee director is automatically granted an option to
    purchase 10,000&#160;shares of our common stock as an annual
    grant under the Directors&#146; Plan, or the Annual Option.
    However, if a non-employee director has not been serving as a
    non-employee director for the entire period beginning from the
    preceding annual stockholders meeting, then the number of shares
    subject to such Annual Option shall be reduced proportionately
    for each full quarter prior to the date of the Annual Option
    during which such person did not serve as a non-employee
    director. No other options may be granted at any time under the
    Directors&#146; Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of options granted under the Directors&#146;
    Plan cannot be less than 100% of the fair market value of the
    common stock subject to the option on the date of the option
    grant. Acceptable consideration for the purchase of our common
    stock issued under the Directors&#146; Plan will be determined
    by our Board of Directors and may include cash or common stock
    previously owned by the optionee or may be paid through a broker
    assisted exercise or net exercise feature. All Initial Options
    vest in equal annual installments over three years. All Annual
    Options vest monthly over a period of three years. An optionee
    whose service relationship with us or any of our affiliates,
    whether as a non-employee director or subsequently as an
    employee, director or consultant to either us or one of our
    affiliates, ceases for any reason may exercise options for the
    term provided in the option agreement to the extent the options
    were exercisable on the date of termination. The term of options
    granted under the Directors&#146; Plan is ten years.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors will administer the Directors&#146; Plan,
    but the Board of Directors may delegate authority to administer
    the Directors&#146; Plan to a committee of one or more members
    of the board. The Board of Directors has broad discretion to
    interpret and administer the Directors&#146; Plan. Our Board of
    Directors may amend or terminate the Directors&#146; Plan at any
    time. However, some amendments will require stockholder approval
    and no amendment or termination may adversely affect a
    non-employee directors&#146; outstanding options without the
    non-employee directors&#146; written consent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a merger of us with or into another corporation
    or a consolidation, acquisition of assets or other
    <FONT style="white-space: nowrap">change-in-control</FONT>
    transaction involving us, the option will terminate if not
    exercised prior to the consummation of the transaction, unless
    the surviving entity or acquiring corporation chooses to assume
    any stock options outstanding under the Directors&#146; Plan or
    substitute similar stock options for those outstanding under the
    plan. Our Board of Directors will make appropriate adjustments
    for a stock split, reverse stock split, stock dividend,
    combination or reclassification of the stock, or any other
    increase or decrease in the number of issued shares of common
    stock effected without our receipt of consideration.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Director
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earned or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Restricted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Cash<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(2)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Abraham E. Cohen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    44,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    159,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ronald Consiglio
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Michael A. Friedman
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    157,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Kent Kresa
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    166,234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David MacCallum
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Heather Hay Murren(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    157,234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Henry L. Nordhoff
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    These amounts reflect expense recognized by us in 2008.
    Reference Note&#160;10 &#147;Stock Award Plans&#148; our
    financial statements for the period ended December&#160;31,
    2008, included in Part&#160;IV of our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2008, filed with the SEC on
    February&#160;27, 2009, which identifies the assumptions made in
    the valuation of option awards in accordance with FAS&#160;123R.
    All non-employee directors received a stock option to purchase
    10,000&#160;shares of our common stock upon re-election to the
    Board of Directors on May&#160;22, 2008 and an additional grant
    of 22,000 options on August&#160;13, 2008. Options granted to
    non-employee directors vest monthly over a period of three
    years. The exercise price per share represents the fair market
    value of such common stock on the date of each respective grant
    (based on the closing sales price reported on the Nasdaq Global
    Market on the date of grant). We have no consulting agreements
    with any of our directors pursuant to which stock awards were
    issued. As of December&#160;31, 2008, our non-employee directors
    had option grants outstanding to purchase 529,500&#160;shares of
    our common stock.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    These amounts reflect expense recognized by us in 2008.
    Reference Note&#160;10 &#147;Stock Award Plans&#148; our
    financial statements for the period ended December&#160;31,
    2008, included in Part&#160;IV of our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2009, as filed with the SEC
    on February&#160;27, 2009, which identifies the assumptions made
    in the valuation of option awards in accordance with
    FAS&#160;123R. All non-employee directors received restricted
    stock award grant of 10,000&#160;shares on August&#160;13, 2008.
    Restricted stock awards granted to non-employee directors vest
    annually over a period of three years. As of December&#160;31,
    2008, our non-employee directors had restricted stock grants
    outstanding to receive 60,000&#160;shares of our common stock.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    On December&#160;1, 2008, Heather Hay Murren, resigned from the
    Board of Directors effective immediately given that, having
    re-assumed the role of Chief Executive Officer of the Nevada
    Cancer Institute, she anticipated that her increased duties
    would prevent her from continuing as a director.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "EXECUTIVE COMPENSATION" -->
<DIV align="left"><A NAME="010"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXECUTIVE
    COMPENSATION</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Compensation
    Discussion And Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are pleased to present our report on executive compensation.
    The report&#146;s objective is to assist our stockholders in
    understanding the objectives and procedures used by the
    Compensation Committee of our Board of Directors in establishing
    its recommendation to the Board of Directors regarding the
    compensation of our executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    MannKind Corporation is a biopharmaceutical company focused on
    the discovery, development and commercialization of therapeutic
    products for diseases such as diabetes and cancer. Our
    compensation program is designed to attract and retain the
    individuals needed to support our business strategy and to allow
    us to compete effectively with pharmaceutical and biotechnology
    companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee is responsible for establishing and
    administering our policies governing the compensation for our
    executive officers. The Compensation Committee is composed
    entirely of independent directors within the meaning of the
    applicable SEC and Nasdaq Stock Market rules. Hakan Edstrom, our
    President and Chief Operating Officer, is not a member of the
    Compensation Committee, but he regularly attends Compensation
    Committee meetings in order to provide valuable insight and
    guidance to the Compensation Committee. Similarly, Alfred Mann,
    our Chief Executive Officer and largest shareholder, is not a
    member of the Compensation Committee, but he periodically
    attends Compensation Committee meetings for the same purpose.
    The Compensation Committee responsibilities and duties are
    outlined in detail in the Compensation Committee charter, which
    is available on our website at <I>www.mannkindcorp.com </I>. A
    primary responsibility of the Compensation Committee is to make
    recommendations regarding the compensation for our executive
    officers, including the determination and confirmation of annual
    corporate goal achievement for purposes of awarding bonuses, to
    the full Board of Directors for its approval. The Compensation
    Committee engages outside consulting firms to assist in
    developing compensation levels and practices and to provide
    external market data. For certain compensation decisions made in
    2008 and more recently, the Compensation Committee received
    support from Mercer Consulting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee meets outside the presence of all of
    our executive officers, including the named executive officers,
    in order to consider the appropriate compensation for our chief
    executive officer. For all other named executive officers, the
    Compensation Committee meets outside the presence of all
    executive officers except our chief executive officer. The
    annual performance reviews of our executive officers are
    considered by the Compensation Committee when making decisions
    regarding base salary, targets for and payments under our bonus
    plan and grants of equity incentive awards. When making
    recommendations regarding individual executive officers, the
    Compensation Committee considers the importance of the position
    to us, the past salary history of the executive officer and the
    contributions we expect the executive officer to make to the
    success of our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Philosophy and Objectives</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee oversees our executive compensation
    within the context of a compensation philosophy. This philosophy
    is to provide compensation and benefits programs designed to
    attract, motivate, and retain a high caliber workforce that
    enables us to compete with companies in the pharmaceutical and
    biotechnology industries and to reward individual and corporate
    performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that a well-designed compensation program for our
    executive officers should:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    align the goals of the executive officer with the goals of the
    stockholders;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recognize individual initiative, effort and achievement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide total compensation that enables us to compete with
    companies in the pharmaceutical and biotechnology
    industries;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    align compensation with our short-term and long-term corporate
    objectives and strategy, focusing executive officer behavior on
    the fulfillment of those objectives.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In keeping with this philosophy, our executive compensation
    program is designed to achieve the following objectives:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    attract and retain talented and experienced executives;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    motivate and reward executives whose knowledge, skills and
    performance are critical to our success;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    retain executives and employees who are instrumental in
    accomplishing our corporate objectives;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    align the interests of our executives and stockholders by
    motivating executives to increase stockholder value and
    rewarding executives when stockholder value increases;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide a competitive compensation package which is weighted
    towards
    <FONT style="white-space: nowrap">pay-for-performance,</FONT>
    and in which total compensation is primarily determined by the
    company&#146;s and the individual&#146;s achievement of results;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ensure fairness among the executive management team by
    recognizing the contributions each executive makes to our
    success;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    foster a shared commitment among executives by aligning the
    company&#146;s and their individual goals;&#160;and
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compensate our executives to manage our business to meet our
    long-term objectives.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We utilize the following principles to guide compensation
    decisions:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competitive
    Market Assessment:</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee regularly reviews competitive market
    data to determine if our compensation levels remain at targeted
    levels and our pay practices are appropriate. These assessments
    include a review of base salary, annual incentives, and
    long-term incentives. These components are evaluated against a
    group of peer companies as well as industry specific and general
    published survey compensation data. Specifically, we utilized
    the Radford Global Life Sciences Executive Survey, the SIRS
    Executive Compensation Survey and the Salary.com CompAnalyst
    Executive Survey. Since 2007, the Compensation Committee has
    engaged Mercer Consulting to benchmark the compensation levels
    of eight executive positions relative to a group of peer
    companies.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the elements described above, the Compensation
    Committee also considered the broader economic conditions
    currently affecting the United States and other major countries.
    In light of these circumstances, the Compensation Committee
    determined that it was appropriate to accept a recommendation
    from management that all 2009 salaries and wages, including
    those of named executive officers, be held at 2008 levels.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Peer
    Group:</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have developed a peer group for benchmarking
    purposes, by considering companies in a similar industry and of
    a similar size in terms of revenue and number of employees.
    Typically, our peer group was selected to consist equally of
    (i)&#160;companies with zero revenue, (ii)&#160;companies with
    revenue between $0 and $1B and (iii)&#160;companies with revenue
    between $1 and $3B. All companies are either biotechnology or
    pharmaceutical companies. Companies were selected with various
    revenue sizes because we are recruiting from and competing for
    executive with companies that are generating revenue. For 2008,
    the primary peer group of companies for pay comparison purposes
    included:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Atherogenics, Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Favrille Inc.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Barr Pharmaceuticals, Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Genitope Corp.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biogen Idec, Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Genzyme Corp.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biomarin Pharmaceutical, Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Nektar Therapeutics
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cephalon, Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Tercica, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CV Therapeutics, Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Theravance, Inc.
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we monitored the executive compensation for three
    additional companies with which we compete for executives.
    However, since these three companies have significantly larger
    revenue than us, they are not included in the peer group: Amgen
    Inc., Genentech Inc., and Schering-Plough Corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In light of our decision to hold salaries and wages at 2008
    levels, we have not updated the peer group for 2009.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Market
    Positioning:</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee reviews executive compensation at
    least annually, establishes competitive compensation levels
    using competitive market data and designs the compensation
    program to provide pay commensurate with individual and
    corporate performance. We normally position total compensation
    levels for executives at the 60th&#160;percentile of our peer
    group; however, compensation may fall above or below this level
    under a range of circumstances, such as individual performance,
    tenure with the company or retention concerns. We supplement the
    peer group data with the survey data described above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe our executive compensation packages are reasonable
    when considering our business strategy, the revenue potential of
    our business, our compensation philosophy and the competitive
    market pay data.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the factors listed above, we also consider, among
    other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our business need for the executive officer&#146;s skills;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the contributions that the executive officer has made or we
    believe will make to our success;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the transferability of the executive officer&#146;s managerial
    skills to other potential employers;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the relevance of the executive officer&#146;s experience to
    other potential employers, particularly in the pharmaceutical
    and biotechnology industries
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Pay-for-Performance:</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive compensation program emphasizes
    <FONT style="white-space: nowrap">pay-for-performance.</FONT>
    The compensation package for our executive officers includes
    both cash and equity incentive plans that align an
    executive&#146;s compensation with our short-term and long-term
    performance goals and objectives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The annual cash incentive awards under our bonus plan are
    intended to compensate our executive officers for achieving our
    annual goals at the corporate level and for achieving individual
    annual performance objectives. The goals for our company and
    individual measures are established so that target attainment is
    not assured. The attainment of payment for performance at or
    above target levels requires significant effort on the part of
    our executives. Long-term equity incentives are intended to
    reward executives for growth in shareholder value. Additional
    details of the plan are described below under &#147;Bonus
    Plan&#148; and &#147;Long-Term Incentives&#148;.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Compensation
    Components</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to provide a total compensation package that is tied to
    shareholder value creation and the achievement of strategic
    corporate goals, our executive compensation package is comprised
    of several components. These components are designed to work
    together to create a balanced approach to compensation,
    rewarding both short-term and long-term performance and
    fostering sufficient retentive effect to secure the services of
    our executive officer while we execute on our plans. Currently,
    our compensation structure for executive officers includes a
    combination of base salary, bonus, stock options and restricted
    stock awards, 401(k), medical and other benefits, severance and
    change in control and other post termination provisions. Each
    component is described in further detail below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Base
    Salary</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Base salaries are designed to provide compensation for
    <FONT style="white-space: nowrap">day-to-day</FONT>
    management of the Company assuming acceptable levels of
    performance. This component is designed to provide consistent
    and steady cash flow for the executive and represents only a
    portion of total compensation. Salary levels are based primarily
    upon the competitive market for the executive officers&#146;
    services as determined through comparisons with peer companies
    and survey data. Base salaries for our executives are intended
    to fall at the median of the competitive market. Individual
    performance, responsibility, and the importance of each role in
    our organization can also impact base salary levels.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Bonus
    Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The annual cash incentive awards under our bonus plan are
    intended to compensate our executive officers for achieving our
    annual goals at the corporate level and for achieving individual
    annual performance objectives. For 2008, the corporate goals
    were based on achievement of certain operational goals. Because
    we are still in the process of developing our proprietary
    products and have not yet brought any such products to market,
    the use of traditional performance standards, such as profit
    levels and return on equity, are not appropriate in our
    evaluation of executive officer performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each eligible position, including the executive officers, is
    assigned a target bonus opportunity expressed as a percentage of
    base salary, which reflects market competitive levels. Target
    bonus opportunities are generally positioned at the
    50th&#160;percentile of the market. For Mr.&#160;Mann, the
    target bonus opportunity for 2008 was 50% of base salary. The
    target bonuses for the other named executive officers for 2008
    were as follows: Mr.&#160;Edstrom, 50%; Mr.&#160;Pfeffer, 35%;
    Dr.&#160;Richardson, 40%; and Dr.&#160;Martens, 35%. Payments of
    target bonuses are not guaranteed and are subject to funding and
    corporate and individual performance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our bonus plan was funded based on the achievement of overall
    corporate goals, based on a careful review by the Compensation
    Committee of the accomplishments of the Company during the
    previous year. For 2008, the annual incentive awards of our
    named executive officers were determined solely by performance
    against corporate objectives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The corporate objectives for 2008, their relative weight and the
    achievement levels for each were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="86%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Objective</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Weight</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Score</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prepare a high quality NDA for AFRESA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Determine the commercialization strategy for AFRESA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Complete the Danbury manufacturing facility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expand the Company&#146;s pipeline of product opportunities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    125
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result, the Compensation Committee determined that the
    Company achieved 110% of the corporate goals for 2008.
    Accordingly, for 2008, each of the named executive officers will
    receive a bonus payment that represents 110% of his target award.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Long-Term
    Incentives</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to provide a significant retention incentive and to
    ensure a strong link to the long-term interests of shareholders,
    we provide a portion of our total compensation in the form of
    equity compensation&#160;&#151; specifically, stock options and
    restricted stock units. Executive officers, as well as all
    full-time employees, are eligible to receive awards at the
    discretion of the Compensation Committee. Equity awards are
    granted under the 2004 Equity Incentive Plan, or the Plan, which
    is administered by the Compensation Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007, we adopted annual and new hire equity grant guidelines
    that formed the baseline for the number of awards granted to
    each executive. In developing these guidelines, the Compensation
    Committee utilized published surveys and peer compensation
    information to determine an appropriate and competitive annual
    award value. This value also took into consideration historical
    grant practices, internal pay equity, and share dilution. The
    intended award value was then split between stock options and
    restricted stock units. The guidelines for executive officers
    seek to deliver approximately 75% of the award value in stock
    options and 25% of the award value in restricted stock units. We
    believe this mix of equity aligns with the interests of
    stockholders and encourages both stock price growth and
    retention. The majority of equity compensation is delivered in
    stock options, which have no intrinsic value unless the stock
    price appreciates. Awards of restricted stock units foster
    equity ownership and encourage retention. Restricted stock units
    also require fewer shares than an equivalent grant value in
    stock options. We target equity compensation at the median of
    the competitive market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our policy with regard to the timing of grants of equity
    compensation is to issue equity awards in the form of options
    and restricted stock units in connection with an employee&#146;s
    hire date, or promotion date as well as in connection with an
    annual grant of equity awards that generally occurs in August of
    each year. All employee grants are approved by the Compensation
    Committee at its regularly scheduled quarterly meeting with the
    grant date on or
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    after the approval date. The timing of grant dates is not based
    on any favorable or unfavorable non-public information
    anticipated to be disclosed at a later date. All stock option
    awards are granted with an exercise price equal to the closing
    sale price of our common stock on the Nasdaq Global Market on
    the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Stock options typically vest over a four-year period, with a
    one-year cliff for 25% of the award and
    <FONT style="vertical-align: text-top; font-size: 70%;">1</FONT>/<FONT style="font-size: 70%;">48</FONT>
    of the award vesting monthly thereafter. Options expire ten
    years from the date of grant. Awards of restricted stock units
    vest 25% per year over four years. The vesting of all awards
    ceases when an employee leaves our employ.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The named executive officers received awards in August 2008 that
    vest on a time basis as part of the annual grants of equity
    awards. These awards were made in accordance with the guidelines
    adopted by the Compensation Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, the Compensation Committee recommended to the
    Board of Directors and the Board of Directors authorized the
    Compensation Committee to grant a specified number of restricted
    stock units to the majority of our employees, including
    executives. This proposal was designed to encourage employee
    retention during a busy and critical period for us. A total of
    1,678,674 restricted stock units were granted. All units remain
    unvested until June&#160;30, 2009, at which point they will
    fully vest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;9, 2008, we announced an Offer to Exchange
    Outstanding Options to Purchase Common Stock, or the Offer,
    under which we offered eligible employees, including our named
    executive officers, the opportunity to exchange up to an
    aggregate of 5,417,840&#160;shares underlying of their
    <FONT style="white-space: nowrap">out-of-the</FONT>
    money stock options, on a grant by grant basis, for a reduced
    number of restricted stock units that vest according to the
    following vesting schedule: 50% on August&#160;1, 2009, 25% on
    February&#160;1, 2010, and 25% on August&#160;1, 2010. Eligible
    options consisted of outstanding stock options under the Plan
    that had an exercise price equal to or greater than $7.00 per
    share. Eligible employees included all persons employed by us as
    of the Offer date and excluded members of the Board of Directors
    who were not our employees. Additionally, the Offer permitted
    eligible options that were subject to performance-based vesting
    to be exchanged for restricted stock units that vest in three
    installments as follows: 20% upon the acceptance by the FDA of a
    filing of an NDA for AFRESA, 30% upon approval from the FDA to
    market AFRESA and 50% upon the first commercial sale of AFRESA.
    The Offer expired on August&#160;6, 2008. Pursuant to the Offer,
    we accepted for exchange options to purchase an aggregate of
    4,493,509&#160;shares of our common stock from 322 eligible
    participants, representing 83% of the shares subject to options
    that were eligible to be exchanged in the Offer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Benefits</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We provide a competitive benefits package to all full-time
    employees, which includes health and welfare benefits, such as
    medical, dental, vision care, life insurance benefits, and a
    401(k) savings plan. Executives, including the named executive
    officers, receive additional benefits, including additional life
    insurance, as well as short-term and long-term disability
    insurance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In November 2008, the Compensation Committee approved a benefit
    that would make our medical plans available to executives who
    retire from employment with us after reaching age&#160;65 or
    early (age&#160;55&#160;&#151; 64). Early retiring executives
    would be able to access all of the Aetna plans currently offered
    to active employees and the Aetna Premium PPO plan would be
    available to retirees age&#160;65 and over as a supplement to
    Medicare coverage. The premiums for these plans will be paid
    100% by the retiring executive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, our executive officers also received an automobile
    allowance of $1,000 per month. Mr.&#160;Edstrom received an
    automobile allowance of $1,300 per month. Mr.&#160;Mann received
    no automobile allowance in 2008. We have no other structured
    perquisite benefits (e.g. club memberships or financial planning
    services) for any executive officer, including the named
    executive officers, and we currently do not provide any deferred
    compensation programs or supplemental pensions to any executive
    officer, including the named executive officers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Stock Purchase Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to encourage stock ownership and provide greater
    incentives to contribute to our success at all levels, we
    provide all employees, including executive officers, the ability
    to purchase our common stock at a discount. The plan is designed
    to comply with section&#160;423 of the Internal Revenue Code and
    provides all employees with the opportunity to purchase up to
    $25,000 of common stock annually at a purchase price that is the
    lower of 85% of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    fair market value of the common stock on either the date of
    purchase or the commencement of the offering period. The
    executive&#146;s rights under the employee stock purchase plan
    are identical to those of all other employees.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Severance
    Provisions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into severance agreements with our executives,
    including each of the named executive officers other than
    Mr.&#160;Mann, in order to ensure that we have the continued
    dedication of such executives and in order to provide such
    executives with reasonable compensation and benefit arrangements
    in the event of termination of their employment. We believe that
    it is imperative to diminish any distraction of our executives
    arising from the personal uncertainty and insecurity that arises
    in the absence of any assurance of job security, thereby
    allowing executives to focus on corporate objectives and
    strategy. The terms of these agreements and amounts that may be
    realized are detailed under the heading &#147;Potential Payments
    Upon Termination Or Change Of Control.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Change in
    Control Provisions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into change of control agreements with our
    executives, including each of the named executive officers other
    than Mr.&#160;Mann, in order to ensure that we have the
    continued dedication of such executives and in order to provide
    such executives with reasonable compensation and benefit
    arrangements in the event of termination of their employment
    following a change of control. We believe that it is imperative
    to diminish any distraction of our executives arising from the
    personal uncertainty and insecurity that arises in the absence
    of any assurance of job security, thereby allowing executives to
    focus on corporate objectives and strategy. The terms of these
    agreements and amounts that may be realized are detailed under
    the heading &#147;Potential Payments Upon Termination Or Change
    of Control.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table includes information concerning compensation
    received for the fiscal years ended December&#160;31, 2008, 2007
    and 2006, by our named executive officers:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Restricted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Name and Principal<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(2)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(3)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(4)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
    <I>Chief Executive Officer<BR>
    and Chairman of the Board&#160;of Directors</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    743,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,980,495
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    212,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    408,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,594
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(5)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,351,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    449,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    707,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    863,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    240,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,265,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    409,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    746,863
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,248,740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    184,327
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,240
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,591,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Matthew J.
    Pfeffer<SUP style="font-size: 85%; vertical-align: top">(6)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
    <I>Corporate Vice President<BR>
    and Chief Financial Officer</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    235,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,827
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    48,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    90,697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    184,468
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(7)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    574,226
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
    <I>President, Chief Operating Officer and Director</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    583,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,822,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    83,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    296,048
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    24,753
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(8)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,809,373
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    449,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    412,347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,002,956
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    240,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    30,639
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,135,512
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    409,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    418,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    905,098
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    184,327
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,508
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,943,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Dr.&#160;Peter Richardson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
    <I>Corporate Vice President, Chief Scientific Officer</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    377,585
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    728,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    166,137
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,239
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(9)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,312,396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    359,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    205,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    179,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    161,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    917,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Juergen A. Martens,&#160;Ph.D.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
    <I>Corporate Vice President, Chief Technical Officer</I>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    323,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    661,601
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    124,577
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,849
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(10)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,156,842
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes amounts earned but deferred at the election of the
    named executive officer, such as salary deferrals under our
    401(k) Plan established under Section&#160;401(k) of the Code.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Reference Note&#160;10 &#147;Stock Award Plans&#148; in
    Part&#160;IV, Item&#160;15 of our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;31, 2008, filed with the SEC on
    February&#160;27, 2009, which identifies the assumptions made in
    the valuation of option awards in accordance with FAS&#160;123R.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Non-Equity Incentive Plan compensation is based on individual
    performance in the achievement of corporate objectives.
    Performance is compared to these objectives annually. For 2008,
    the amounts represent what was earned by each of the named
    executive officers scheduled to be paid in March 2009.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Amounts include employer contributions credited under our 401(k)
    Plan and the incremental cost of perquisites received by the
    named executive officers. Under the 401(k) Plan, which is open
    to substantially all of our employees, we make matching
    contributions based on each participant&#146;s voluntary salary
    deferrals, subject to plan and limits of the Code.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes $6,594 in medical benefits.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Effective April&#160;21, 2008, Matthew J. Pfeffer was appointed
    to the position of Corporate Vice President and Chief Financial
    Officer. Mr.&#160;Pfeffer&#146;s 2008 annual salary was $350,000.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes $7,269 in auto allowance, $174,765 in reimbursed
    relocation expenses and $2,434 in contributions under the 401(k)
    Plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes $15,600 in auto allowance, $2,841 in medical benefits,
    $250 in airline club and $6,062 in contributions under the
    401(k) Plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes $11,972 in auto allowance, $497 in medical benefits,
    $350 in airline club and $2,420 in contributions under the
    401(k) Plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (10) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes $11,972 in auto allowance, $3,800 in medical benefits,
    $300 in airline club and $5,777 in contributions under the
    401(k) Plan.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Grants
    of Plan-Based Awards</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We grant options and restricted stock units to our employees,
    including the named executive officers, under the Plan. All
    options granted to our named executive officers are nonstatutory
    stock options that do not qualify as incentive stock options
    within the meaning of Section&#160;422 of the Code. As of
    December&#160;31, 2008, 5,591,101 options and 5,947,408
    restricted stock units were outstanding under the Plan and an
    additional 2,048,783&#160;shares of common stock were available
    for issuance under the Plan. Options expire ten years from date
    of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price per share of each option granted to our named
    executive officers was equal to the fair market value on the
    date of the grant. The exercise price is payable in cash, shares
    of our common stock previously owned by the optionee or pursuant
    to the net exercise of the option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes option grants to the named
    executive officers during the fiscal year ended
    December&#160;31, 2008, and the value of the underlying
    securities held by each of these individuals at
    December&#160;31, 2008. No stock appreciation rights covering
    our common stock were granted to any named executive officer in
    2008.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Grants of
    Plan-Based Awards in Fiscal 2008</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="38%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>or Base<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plan Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Market<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Price on<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock or Units (1)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock or Units (2)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options (3)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/Sh)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    166,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Matthew J. Pfeffer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/28/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/28/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    120,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/28/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/28/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    249,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    330,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Dr.&#160;Peter Richardson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Juergen A. Martens,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,675
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/6/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Performance-based awards vest upon achieving three
    pre-determined performance milestones which are expected to
    occur over periods ranging from 27&#160;months to 42&#160;months.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Restricted stock awards vest annually over a four-year period,
    with the exception of awards issued as a result of the stock
    option exchange on August&#160;6, 2008, which will vest 50% on
    August&#160;1, 2009, 25% on February&#160;1, 2010 and 25% on
    August&#160;1, 2010.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    The options have exercise prices equal to the fair market value
    of our common stock on the date of grant, vest over a four-year
    period with a one-year cliff vesting monthly thereafter and
    expire ten years from the date of grant. Vesting ceases should
    the executive officer leave our employ.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth summary information regarding the
    outstanding equity awards at December&#160;31, 2008 granted to
    each of our named executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="30%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Equity Incentive<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Equity Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Equity Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plan Awards:<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plan Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plan Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Market or<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Payout Value of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unearned Shares,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unearned Shares,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Market Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Units or Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Units or Other<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Shares or Units<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>of Shares or Units<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Rights That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Rights That<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>of Stock That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>of Stock That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>(#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Have Not Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Have not Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Vested<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 5pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/26/2012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25.23
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/30/2012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/15/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,331,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Matthew J. Pfeffer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/28/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    120,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.86
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4/28/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    330,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    415,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,425,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Dr.&#160;Peter Richardson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    419,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    308,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Juergen A. Martens,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    386,647
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    308,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Option
    Exercises and Stock Vested</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table contains information relating to the
    exercise of options by the named executive officers during the
    fiscal year ended December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Options
    Exercises and Stock Vested in Fiscal 2008</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards(2)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares Acquired<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Realized on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares Acquired<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Realized on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>on Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>on Vesting<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Vesting<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred E. Mann
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153,712
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Matthew J. Pfeffer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    99,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dr.&#160;Peter Richardson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Juergen A. Martens,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    All options were granted under our 2004 Equity Incentive Plan.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Stock awards acquired on vesting represent restricted stock
    awards that vest annually over a four-year period.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Potential
    Payments Upon Termination or Change of Control</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Estimated
    Potential Payments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below sets forth the estimated current value of
    payments and benefits to each of the named executive officers
    upon termination or change of control. The amounts shown assume
    that the triggering event occurred on December&#160;31, 2008 and
    do not include other benefits earned during the term of the
    named executive officer&#146;s employment that are available to
    all salaried employees, such as accrued vacation and benefits
    paid by insurance providers under life and disability policies.
</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="50%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Triggering Event</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Change in<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Termination<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Control<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred E.
    Mann<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Lump sum cash severance payment
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Continuing health and welfare
    benefits<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Value of extending  exercisability term of stock
    options<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Intrinsic value of accelerated unvested stock
    options<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt; color: #000000; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;Total
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Matthew J. Pfeffer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Lump sum cash severance payment
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    647,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    708,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Continuing health and welfare
    benefits<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Value of extending exercisability term of stock
    options<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Intrinsic value of accelerated unvested stock
    options<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,971
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,971
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;Total
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    753,863
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    815,113
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Lump sum cash severance payment
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,041,556
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,157,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Continuing health and welfare
    benefits<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,911
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Value of extending exercisability term of stock
    options<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Intrinsic value of accelerated unvested stock
    options<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt; color: #000000; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;Total
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,059,467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,175,244
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt; color: #000000; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dr.&#160;Peter Richardson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Lump sum cash severance payment
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    723,216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    801,324
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Continuing health and welfare
    benefits<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Value of extending exercisability term of stock
    options<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Intrinsic value of accelerated unvested stock
    options<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;Total
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    756,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    834,134
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Juergen A. Martens,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Lump sum cash severance payment
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658,805
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    718,208
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Continuing health and welfare
    benefits<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Value of extending exercisability term of stock
    options<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Intrinsic value of accelerated unvested stock
    options<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt; color: #000000; background: #CCEEFF">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;Total
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    691,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    751,018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    We have entered into severance and change of control agreements
    with our executives, including each of the named executive
    officers other than Mr.&#160;Mann. Accordingly, there are no
    potential payments to Mr.&#160;Mann upon termination or change
    of control.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the estimated cost of providing or paying for
    continuing medical and dental coverage for 18&#160;months. The
    amounts for medical and dental insurance coverage are based on
    rates charged to our employees for
    <FONT style="white-space: nowrap">post-employment</FONT>
    coverage provided in accordance with the Consolidated Omnibus
    Reconciliation Act of 1985, or COBRA.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the fair value of the stock options held by the named
    executive officer that would be exercisable for a period ending
    on the earlier of 18&#160;months following the triggering event
    or the end of the original term of the option.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Per SEC rules, the intrinsic value of accelerated unvested stock
    options shown in the table above was calculated using the
    closing price of our common stock on December&#160;31, 2008
    ($3.43). The intrinsic value is the aggregate spread between
    $3.43 and the exercise price of the accelerated options, if less
    than $3.43.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Executive
    Severance Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into executive severance agreements with
    Messrs.&#160;Edstrom and Pfeffer, Drs.&#160;Richardson, Martens,
    and Thomson, and Ms.&#160;Palumbo. Each agreement is for a
    period of two years and will be automatically renewed for
    additional one-year periods unless either party gives notice to
    terminate the agreement at least 90&#160;days prior to the end
    of its initial term or any subsequent term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The agreements provide that each executive is an &#147;at
    will&#148; employee and that his employment with us may be
    terminated at any time by the employee or us. Under the
    agreements, in the event we terminate an executive&#146;s
    employment without cause (as defined below) or the employee
    terminates his employment with us for good reason (as defined
    below), the employee is generally entitled to receive the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the portion of the employee&#146;s annual base salary earned
    through the termination date that was not paid prior to his
    termination, if any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on the condition the employee executes a general release and
    settlement agreement, or release, in favor of us, the
    employee&#146;s annual base salary on the date of termination
    for a period of 18&#160;months following his termination,
    subject to certain limitations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on the condition the employee executes a release, an amount
    equal to the average annual bonus received by the employee for
    the three years prior to his termination (or the prior period up
    to three years during which the employee was one of our
    executive officers and received a bonus);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the event the employee met the performance criteria for
    earning an annual bonus prior to his termination, a portion of
    the annual bonus earned for the year based on the number of days
    worked during the year;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any compensation previously deferred by the employee and any
    accrued paid time-off that the employee is entitled to under our
    policy;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on the condition the employee executes a release, health
    insurance and, under certain circumstances, life, disability and
    other insurance benefits for a period expiring on the earlier of
    18&#160;months following his termination or until he qualifies
    for related benefits from another employer.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the executive severance agreements provide that, on
    the condition the employee executes a release, each vested stock
    option held by the employee on the date of termination will be
    exercisable for a period ending on the earlier of 18&#160;months
    following that date or the end of the original term of the
    option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreements, an employee may be terminated for cause if
    he, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    refuses to carry out or satisfactorily perform any of his lawful
    duties or any lawful instruction of our Board of Directors or
    senior management;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    violates any local, state or federal law involving the
    commission of a crime other than a minor traffic offense;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    is grossly negligent, engages in willful misconduct or breaches
    a fiduciary obligation to us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    engages in any act that materially compromises his reputation or
    ability to represent us with investors, customers or the
    public;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reaches a mandatory retirement age established by us.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreements, good reason includes, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a reduction of the executive&#146;s annual base salary to a
    level below his salary as of October&#160;10, 2007
    (April&#160;21, 2008 in the case of Mr.&#160;Pfeffer);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material diminution in the executive&#146;s position,
    authority, duties or responsibilities with us, subject to
    certain limitations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an order by us to relocate the executive to an office located
    more than 50&#160;miles from the executive&#146;s current
    residence and worksite;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any non-renewal of the executive severance agreement by us, on
    the condition that the executive may terminate the agreement for
    good reason only during the
    <FONT style="white-space: nowrap">30-day</FONT>
    period after he receives notice from us that we intend to
    terminate the agreement;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any material violation of the executive severance agreement by
    us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreements, an employee must inform us if he intends
    to terminate his agreement for good reason. We have 30&#160;days
    from the date we receive notice of the employee&#146;s intent to
    terminate the agreement for good reason to cure the default.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Transition
    Agreement with Mr.&#160;Anderson</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;20, 2007, we entered into an agreement with
    Mr.&#160;Anderson setting forth the terms of
    Mr.&#160;Anderson&#146;s transition to the position of Corporate
    Vice President&#160;&#151; Office of the Chairman, which
    commenced on April&#160;1, 2008 and terminated upon his death on
    March&#160;22, 2009. In this new position, Mr.&#160;Anderson
    reported to Hakan Edstrom, our President and Chief Operating
    Officer, and worked not less than 75% of a full-time schedule,
    for which Mr.&#160;Anderson was paid a salary equal to 75% of
    his salary in effect immediately prior to his transition to the
    new position. Mr.&#160;Anderson was eligible for a
    2008&#160;year-end bonus that was proportionately adjusted to
    reflect the total salary paid to him during the year (as a
    percentage of the total salary that would have been paid to him
    if he had not transitioned to the new position).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreement, upon Mr. Anderson&#146;s death, we are
    required to pay Mr.&#160;Anderson&#146;s family (i)&#160;an
    amount equal to the salary that he would have been paid had he
    worked until March&#160;31, 2009, (ii)&#160;an amount equal to
    the average bonus paid or payable to Mr.&#160;Anderson for the
    three years preceding the year of his death, and (iii)&#160;the
    premiums on the health insurance and additional health coverage
    for his family members until March&#160;31, 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Change
    of Control Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into change of control agreements with
    Messrs.&#160;Edstrom and Pfeffer, Drs.&#160;Richardson, Martens,
    and Thomson, and Ms.&#160;Palumbo. Each agreement is for a
    period of two years and will be automatically renewed for
    additional one-year periods unless either party gives notice to
    terminate the agreement at least 90&#160;days prior to the end
    of its initial term or any subsequent term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreements, a change of control will be deemed to
    occur upon:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any transaction that results in a person or group acquiring
    beneficial ownership of 50% or more of our voting stock, other
    than us, one of our employee benefit plans, Mr.&#160;Mann or any
    other entity in which Mr.&#160;Mann holds a majority of the
    beneficial interests;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any merger, consolidation or reorganization of us in which our
    stockholders immediately prior to the transaction hold less than
    50% of the voting power of the surviving entity following the
    transaction, subject to certain limitations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any transaction in which we sell all or substantially all of our
    assets, subject to certain limitations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our liquidation;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any reorganization of our Board of Directors in which our
    incumbent directors (as defined in the agreements) cease for any
    reason to constitute a majority of the members of our board.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The agreements provide that in the event of a change of control,
    the employee is generally entitled to maintain the same
    position, authority and responsibilities held before the change
    of control, as well as the following compensation and benefits
    during the period ending on the earlier of 24&#160;months
    following the change of control or the termination of his
    employment with us:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    his annual base salary in an amount equal or greater to his
    annual salary as of the date the change of control occurs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an annual bonus in an amount equal to the average annual bonus
    received by him for the three years prior to his termination (or
    the prior period up to three years during which he was one of
    our executive officers and received a bonus);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    medical, dental and other insurance, and any other benefits we
    may offer to our executives;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    prompt reimbursement for all reasonable employment expenses
    incurred by him in accordance with our policies and procedures.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the change of control agreements, we may terminate an
    executive with or without cause (as defined below) and the
    executive may terminate his employment with us for good reason
    (as defined below) or any reason at any time during the
    <FONT style="white-space: nowrap">2-year</FONT>
    period following a change of control. In the event we terminate
    an executive without cause or an executive terminates his
    employment with us for good reason, he is generally entitled to
    receive the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the portion of his annual base salary earned through the
    termination date that was not paid prior to his termination, if
    any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on the condition the employee executes a release, the
    employee&#146;s annual base salary on the date of termination
    for a period of 18&#160;months following his termination,
    subject to certain limitations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on the condition the employee executes a release, an amount
    equal to 150% of his average annual bonus received by the
    employee for the three years prior to his termination (or the
    prior period up to three years during which the employee was one
    of our executive officers and received a bonus);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the event the employee met the performance criteria for
    earning an annual bonus prior to his termination, a portion of
    the annual bonus earned for the year based on the number of days
    worked during the year;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any compensation previously deferred by the employee and any
    accrued paid time-off that the employee is entitled to under our
    policy;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on the condition the employee executes a release, health
    insurance and, under certain circumstances, life, disability and
    other insurance benefits for a period expiring on the earlier of
    18&#160;months following his termination or until he qualifies
    for related benefits from another employer.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the agreements provide that, on the condition the
    employee executes a release, each option to purchase shares of
    our common stock held by him as of the termination date will
    become fully vested and exercisable at any point during the term
    of the option, subject to certain limitations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreements, in the event we terminate an employee with
    cause or an employee terminates his employment with us without
    good reason, his agreement will terminate without any further
    obligation to either party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The change of control agreements provide that an employee may be
    terminated for cause if he, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    refuses to carry out or satisfactorily perform any of his lawful
    duties or any lawful instruction of our Board of Directors or
    senior management;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    violates any local, state or federal law involving the
    commission of a crime other than a minor traffic offense;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    is grossly negligent, engages in willful misconduct or breaches
    a fiduciary obligation to us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    engages in any act that materially compromises his reputation or
    ability to represent us with investors, customers or the
    public;&#160;or
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reaches a mandatory retirement age established by us before a
    change of control occurs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the agreements, good reason includes, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a failure by us to make all compensation payments and provide
    all insurance and related benefits to the employee required
    under the agreement during his employment following a change of
    control, subject to certain limitations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a material diminution in the employee&#146;s position,
    authority, duties or responsibilities with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an order by us to relocate the employee to an office located
    more than 50&#160;miles from the employee&#146;s current
    residence and worksite;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any non-renewal of the change of control agreement by us, on the
    condition that the employee may terminate the agreement for good
    reason only during the
    <FONT style="white-space: nowrap">30-day</FONT>
    period after he receives notice from us that we intend to
    terminate the agreement;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any material violation of the change of control agreement by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the change of control agreements, an employee must inform
    us if he intends to terminate his agreement for good reason. We
    have 30&#160;days from the date we receive notice of the
    employee&#146;s intent to terminate the agreement for good
    reason to cure the default.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The executive and change of control agreements provide that in
    the event an executive becomes entitled to benefits under both
    agreements, compensation payments and other benefits will be
    coordinated to ensure the executive is entitled to receive the
    benefits described above without duplicating coverage.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECURITIES
    AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
    PLANS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table provides certain information with respect to
    all of our equity compensation plans in effect as of
    December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Equity
    Compensation Plan Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="38%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining Available for<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Securities to be<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issuance Under Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Issued Upon Exercise of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation Plans<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding Options,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding Options,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Excluding Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Warrants and Rights<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Warrants and Rights<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Reflected in Column (a)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Plan Category</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(a)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(b)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(c)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity compensation plans approved by security holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,270,222
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,026,271
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity compensation plans not approved by security holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    268,287
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    23.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,538,509
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,026,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes 2,048,783&#160;shares available for issuance under the
    Plan and 977,488&#160;shares available for purchase under our
    2004 Employee Stock Purchase Plan. On the first day of each
    calendar year, for a period of ten years beginning on
    January&#160;1, 2005, the share reserve under our 2004 Employee
    Stock Purchase Plan will automatically increase by the lesser of
    700,000&#160;shares or 1% of the total number of shares of our
    common stock outstanding on that date, or by an amount to be
    determined by our Board of Directors. On January&#160;1, 2009,
    the available shares for purchase under our 2004 Employee Stock
    Purchase Plan was increased by 700,000&#160;shares.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes options to purchase 27,315&#160;shares under the
    AlleCure Corp. 2000 Stock Option and Stock Plan and the CTL
    ImmunoTherapies Corp. 2000 Stock Option and Stock Plan granted
    to employees and options to purchase 240,972&#160;shares granted
    to Mr.&#160;Mann outside of our plans. Mr.&#160;Mann&#146;s
    options have the same terms as those </TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    granted under the Plan, described elsewhere in this proxy
    statement, and have an exercise price of $25.23 per share. All
    of these options were exercisable as of December&#160;31, 2008.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The equity compensation plans that were in effect as of
    December&#160;31, 2008 and that were adopted without the
    approval of our security holders are the AlleCure Corp. 2000
    Stock Option and Stock Plan and the CTL ImmunoTherapies Corp.
    2000 Stock Option and Stock Plan. The material terms of these
    plans are described below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">AlleCure
    Corp. 2000 Stock Option and Stock Plan and CTL ImmunoTherapies
    Corp. 2000 Stock Option and Stock Plan</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the acquisition by us of AlleCure Corp. and
    CTL ImmunoTherapies Corp. on December&#160;12, 2001, we assumed
    all of the outstanding options granted under the AlleCure Corp.
    2000 Stock Option and Stock Plan, or the AlleCure plan, and the
    CTL ImmunoTherapies Corp. 2000 Stock Option and Stock Plan, or
    the CTL plan. Subsequent to the acquisition, these options were
    adjusted to cover shares of our common stock at the exchange
    ratios set forth in the applicable merger agreements. As of
    December&#160;31, 2007, options to purchase an aggregate of
    34,296&#160;shares of our common stock under the AlleCure plan
    and the CTL plan were outstanding. The AlleCure plan and CTL
    plan were terminated and we will not grant additional equity
    awards under the AlleCure plan or the CTL plan, which we
    collectively refer to as the 2000 plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Share reserve.</I>&#160;&#160;Except with respect to the
    outstanding options referenced above, no shares of our common
    stock remain reserved or available for issuance under the 2000
    plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Administration.</I>&#160;&#160;Pursuant to the merger, our
    Board of Directors administers the 2000 plans, but the Board of
    Directors may delegate authority to administer the 2000 plans to
    a committee that complies with applicable law. Our Board of
    Directors has broad authority to administer the 2000 plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Eligibility of awards.</I>&#160;&#160;The 2000 plans provided
    for the grant of ISOs, NSOs and stock purchase rights to
    employees, directors and consultants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stock options.</I>&#160;&#160;Stock options were granted
    under the 2000 plans pursuant to a stock option agreement.
    Options granted under the 2000 plans have a maximum term of ten
    years and vest at the rate specified in the option agreements.
    Except in the case of options granted to officers, directors,
    and consultants, options become exercisable at a rate of no less
    than 20% per year over five years from the date the options were
    granted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acceptable consideration for the purchase of common stock issued
    pursuant to options granted under the 2000 plans includes cash,
    common stock previously owned by the optionee, a promissory note
    or consideration received through a cashless exercise program.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally, options under the 2000 plans may not be sold,
    pledged, assigned, hypothecated, transferred or disposed of in
    any manner other than by will or by laws of descent and
    distribution and may be exercised, during the lifetime of the
    optionee, only by the optionee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless an optionee&#146;s stock option agreement provides for
    earlier termination, if an optionee&#146;s service relationship
    with us terminates due to disability or death, the optionee, or
    his or her beneficiary, generally may exercise any vested
    options for up to twelve months after the date the service
    relationship ends. If an optionee&#146;s relationship with us
    ceases for any reason other than disability or death, the
    optionee may exercise his or her option within the time
    specified in the option agreement, or if not specified, for
    three months. In no event may an option be exercised after the
    expiration of the term of the option set forth in the option
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The administrator may at any time offer to buy out for a payment
    in cash or shares, an option previously granted, based on such
    terms and conditions as the administrator may establish and
    communicate to the optionee at the time such offer is made.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Stock purchase rights.</I>&#160;&#160;Unless the
    administrator determines otherwise, a restricted stock purchase
    agreement grants us a repurchase option exercisable upon the
    voluntary or involuntary termination of the purchaser&#146;s
    service with us for any reason (including death or disability).
    The purchase price for shares repurchased pursuant to the
    restricted stock purchase agreement is the original price paid
    by the purchaser and may be paid by cancellation of any
    indebtedness of the purchaser. The repurchase option lapses at
    such rate as the administrator may determine.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except with respect to shares purchased by officers and
    directors, the repurchase option lapses at a rate of no less
    than 20% per year over five years from the date of purchase.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Corporate transactions or changes in
    control.</I>&#160;&#160;Our Board of Directors will make
    appropriate adjustments for a stock split, reverse stock split,
    stock dividend, combination or reclassification of the stock, or
    any other increase or decrease in the number of issued shares of
    common stock effected without receipt of consideration by the
    company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of the proposed dissolution or liquidation of the
    company, the administrator shall notify each optionee as soon as
    practicable prior to the effective date of such proposed
    transaction. The administrator in its discretion may provide for
    an optionee to have the right to exercise his or her option or
    stock purchase right until fifteen days prior to such
    transaction as to all of the optioned stock covered thereby,
    including shares as to which the option or stock purchase right
    would not otherwise be exercisable. In addition, the
    administrator may provide that any company repurchase option
    applicable to any shares purchased upon exercise of an option or
    stock purchase right shall lapse as to all such shares, provided
    the proposed dissolution or liquidation takes place at the time
    and in the manner contemplated. To the extent it has not been
    previously exercised, an option or stock purchase right will
    terminate immediately prior to the consummation of such proposed
    action.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, in the event we merge or sell all or substantially
    all of our assets, all outstanding stock awards under the 2000
    plans will be assumed, continued or substituted for by any
    surviving or acquiring entity. If the surviving or acquiring
    entity elects not to assume, continue or substitute for these
    awards, each participant will be given notice of the transaction
    and permitted to exercise all outstanding awards held under the
    2000 plans for a period of fifteen days after notice is
    provided. To the extent it has not been previously exercised, an
    option or stock purchase right will terminate at the end of such
    period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Additional provisions.</I>&#160;&#160;Our Board of Directors
    has the authority to amend outstanding awards granted under the
    2000 plans, except that no amendment may adversely affect an
    award without the recipient&#146;s written consent. Our Board of
    Directors has the power to amend the 2000 plans. We are required
    to provide annual financial statements to participants in the
    2000 plans.
</DIV>


<!-- link1 "COMPENSATION COMMITTEE REPORT" -->
<DIV align="left"><A NAME="011"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPENSATION
    COMMITTEE REPORT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The material in this report is not &#147;soliciting
    material,&#148; is not deemed &#147;filed&#148; with the SEC and
    shall not be incorporated by reference into any filing of
    MannKind under the Securities Act or the Exchange Act, except to
    the extent MannKind specifically incorporates this report by
    reference.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee has reviewed and discussed with
    management the Compensation Discussion and Analysis contained in
    this proxy statement. Based on this review and discussion, the
    Compensation Committee has recommended to our Board of Directors
    that the Compensation Discussion and Analysis be included in
    this proxy statement as well as our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2008, filed with the
    SEC on February&#160;27, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Compensation Committee</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Kent Kresa (Chair)<BR>
    Abraham E. Cohen<BR>
    Michael Friedman
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS" -->
<DIV align="left"><A NAME="012"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The material in this report is not &#147;soliciting
    material,&#148; is not deemed &#147;filed&#148; with the SEC and
    shall not be incorporated by reference by any general statement
    incorporating by reference this proxy statement into any filing
    of MannKind under the Securities Act or the Exchange Act, except
    to the extent MannKind specifically incorporates this report by
    reference.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In discharging its oversight responsibility as to the audit
    process, the Audit Committee obtained from Deloitte&#160;&#038;
    Touche LLP the written disclosures and the letter describing all
    relationships between MannKind and its independent auditors that
    might bear on the auditors&#146; independence consistent with
    applicable requirements of the Public Company Accounting
    Oversight Board <B><I>(&#147;PCAOB&#148;</I></B>) regarding the
    independent accountant&#146;s communications with the audit
    committee concerning independence.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee discussed and reviewed with Deloitte all
    communications required by generally accepted auditing
    standards, including those described in Statement on Auditing
    Standards No.&#160;61, as amended, &#147;Communication with
    Audit Committees&#148;, as adopted by PCAOB in Rule&#160;3200T.
    In addition, with and without management present, the Audit
    Committee discussed and reviewed MannKind&#146;s financial
    statement and the results of Deloitte&#146;s audit of
    MannKind&#146;s financial statements. Based upon the Audit
    Committee&#146;s discussion with management and Deloitte and the
    Audit Committee&#146;s review of MannKind&#146;s financial
    statements, the representations of MannKind&#146;s management
    and the independent auditors&#146; report to the Audit
    Committee, the Audit Committee recommended to the Board of
    Directors that MannKind include the audited financial statements
    in its Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2008, for filing
    with the SEC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee Charter provides that one duty of the Audit
    Committee is to determine whether to retain or to terminate
    MannKind&#146;s existing auditors or to appoint and engage new
    auditors for the ensuing year. In performing that duty, the
    Audit Committee evaluated the performance of Deloitte in
    performing the examination of MannKind&#146;s financial
    statements for the fiscal year ended December&#160;31, 2008, and
    engaged Deloitte as MannKind&#146;s independent auditors for the
    fiscal year ending December&#160;31, 2009.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Audit Committee</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ronald J. Consiglio, Audit Committee Chair<BR>
    David H. MacCallum, Audit Committee Member<BR>
    Henry L. Nordhoff, Audit Committee Member
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE" -->
<DIV align="left"><A NAME="013"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECTION&#160;16(A)
    BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;16(a) of the Exchange Act requires our directors,
    executive officers and any persons beneficially holding more
    than 10% of our common stock to report their initial ownership
    of our common stock and any subsequent changes in that ownership
    to the SEC. Our executive officers, directors and greater than
    10% stockholders are required by SEC regulation to furnish us
    with copies of all Section&#160;16(a) forms they file.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Specific due dates for these reports have been established and
    we are required to identify in this annual report those persons
    who failed to timely file these reports. To our knowledge, based
    solely on a review of the copies of such reports furnished to us
    and written representations that no other reports were required,
    during the fiscal year ended December&#160;31, 2008, all of our
    directors, officers and greater than 10% stockholders complied
    with the Section&#160;16(a) filing requirements.
</DIV>


<!-- link1 "CERTAIN TRANSACTIONS" -->
<DIV align="left"><A NAME="014"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    TRANSACTIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a description of transactions or series of
    transactions since January&#160;1, 2008 to which we have been a
    party, in which the amount involved in the transaction or series
    of transactions exceeds $120,000, and in which any of our
    directors, executive officers or persons who we know held more
    than five percent of any class of our capital stock, including
    their immediate family members, had or will have a direct or
    indirect material interest, other than compensation
    arrangements, which are described under &#147;Management.&#148;
    We believe that the terms obtained or consideration that we paid
    or received, as applicable, in connection with the transactions
    described below were comparable to terms available or the
    amounts that would be paid or received, as applicable, in
    arm&#146;s-length transactions. In accordance with its charter,
    our Audit Committee approves or ratifies any related party
    transaction as required by NASDAQ rules.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Sales
    of Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since January&#160;1, 2008, we sold shares of our common stock
    as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on June&#160;30, 2008, we sold shares of common stock through
    our Employee Stock Purchase Plan at a purchase price of $2.60
    per share to among other employees, the following former
    executive officer:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchaser</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Richard L. Anderson
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,164
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on December&#160;31, 2008, we sold shares of common stock
    through our Employee Stock Purchase Plan at a purchase price of
    $2.55 per share to among other employees, the following
    executive officers:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Purchase<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Purchaser</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Hakan S. Edstrom
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,249
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Matthew J. Pfeffer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,431
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times; font-variant: SMALL-CAPS">Other
    Transactions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;2, 2007, we entered into a new loan arrangement
    with Mr.&#160;Mann to borrow up to a total of
    $350.0&#160;million before January&#160;1, 2010. This new
    arrangement replaced the existing loan arrangement with
    Mr.&#160;Mann to borrow up to $150.0&#160;million through
    August&#160;1, 2008. On December&#160;29, 2008, we received an
    installment of $30.0&#160;million against this advance. As of
    December&#160;31, 2008, the amount outstanding under the
    arrangement was $30.0&#160;million. On February&#160;26, 2009,
    as a result of our principal stockholder being licensed as a
    finance lender under the California Finance Lenders Law, the
    promissory note underlying the loan arrangement was revised to
    reflect the lender as The Mann Group LLC, or the Lender, an
    entity controlled by Mr.&#160;Mann. This new license also
    eliminated the draw restrictions under the previous loan
    arrangement and we are now able to borrow up to a total of
    $350.0&#160;million from time to time with appropriate notice to
    the Lender.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with certain meetings of our Board of Directors
    and on other occasions when our business necessitated air travel
    for Mr.&#160;Mann and other MannKind employees, we utilized
    Mr.&#160;Mann&#146;s private aircraft and we paid the charter
    company that manages the aircraft on behalf of Mr.&#160;Mann
    approximately $130,000 in 2008 on the basis of the corresponding
    cost of commercial airfare.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The above related-party transactions were approved by a majority
    or more of the disinterested members of our Board of Directors.
    We believe that the foregoing agreements were and continue to be
    in our best interests. It is our current policy that all
    agreements between us and any of our officers, directors, 5%
    stockholders, or any of their affiliates, will be entered into
    only if such agreements are approved by a majority of our
    disinterested directors and are on terms no less favorable to us
    than could be obtained from unaffiliated parties.
</DIV>


<!-- link1 "HOUSEHOLDING OF PROXY MATERIALS" -->
<DIV align="left"><A NAME="015"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">HOUSEHOLDING
    OF PROXY MATERIALS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The SEC has adopted rules that permit companies and
    intermediaries (e.g., brokers) to satisfy the delivery
    requirements for Notices of Internet Availability of Proxy
    Materials or other Annual Meeting materials with respect to two
    or more stockholders sharing the same address by delivering a
    single Notice of Internet Availability of Proxy Materials or
    other Annual Meeting materials addressed to those stockholders.
    This process, which is commonly referred to as
    &#147;householding,&#148; potentially means extra convenience
    for stockholders and cost savings for companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This year, a number of brokers with account holders who are
    MannKind stockholders will be &#147;householding&#148; our proxy
    materials. A single Notice of Internet Availability of Proxy
    Materials will be delivered to multiple stockholders sharing an
    address unless contrary instructions have been received from the
    affected stockholders. Once you have received notice from your
    broker that they will be &#147;householding&#148; communications
    to your address, &#147;householding&#148; will continue until
    you are notified otherwise or until you revoke your consent. If,
    at any time, you no longer wish to participate in
    &#147;householding&#148; and would prefer to receive a separate
    proxy statement and annual report, please notify your broker,
    direct your written request to MannKind Corporation, Investor
    Relations, 28903 North Avenue Paine, Valencia, CA 91355 or
    contact David Thomson at
    <FONT style="white-space: nowrap">(661)&#160;775-5300.</FONT>
    Stockholders who currently receive multiple copies of the
    Notices of Internet Availability of Proxy Materials at their
    address and would like to request &#147;householding&#148; of
    their communications should contact their broker.
</DIV>


<!-- link1 "ANNUAL REPORT" -->
<DIV align="left"><A NAME="016"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ANNUAL
    REPORT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A copy of our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2008, filed with the
    SEC on February&#160;27, 2009, is available without charge upon
    written request to: MannKind Corporation, Investor Relations,
    28903 North Avenue Paine, Valencia, CA 91355.
</DIV>


<!-- link1 "OTHER MATTERS" -->
<DIV align="left"><A NAME="017"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    MATTERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors knows of no other matters that will be
    presented for consideration at the Annual Meeting. If any other
    matters are properly brought before the Annual Meeting, it is
    the intention of the persons named in the accompanying proxy to
    vote on such matters in accordance with their best judgment.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By Order of the Board of Directors
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="v52006v5200601.gif" alt="(-s- David Thomson)">
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    David Thomson
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vice President, General Counsel and Secretary</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Valencia, California 91355
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    April&#160;10, 2009
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><IMG src="v52006v5200604.gif">
</DIV>

<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">MannKind Corporation</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">ANNUAL MEETING OF STOCKHOLDERS OF</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">MANNKIND CORPORATION</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Date: Thursday, May&nbsp;21, 2009 Time: 10:00&nbsp;A.M. EDT</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Place: MannKind Corporation, One Casper Street, Danbury, Connecticut 06810 See Voting Instructions
on Reverse Side.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Please make your marks like this: Use dark black pencil or pen only</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Board of Directors Recommends a Vote FOR Items 1 through 3.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">1: Election of Directors</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Vote For Withhold Vote *Vote For All Nominees From All Nominees All Except</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">* INSTRUCTIONS: To withhold authority to vote for any nominee, mark the &#147;Exception&#148; box and write
the number(s) assigned below to such nominee(s) in the space
provided to the right.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Proposal Directors Number Recommend</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">For Against Abstain</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">2: For</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">3: For</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">PROPOSALS</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">1. Election of Directors:</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Nominees: 01 Alfred E. Mann 05 Michael Friedman, M.D.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">02 Hakan S. Edstrom 06 Kent Kresa</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">03 Abraham E. Cohen 07 David H. MacCallum</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">04 Ronald Consiglio 08 Henry L. Nordhoff Proposals:</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">2. To approve an amendment to increase the aggregate number of shares of common stock authorized
for issuance under MannKind&#146;s 2004 Equity Incentive Plan by 5,000,000 shares; 3. To ratify the
selection by the Audit Committee of the Board of Directors of Deloitte &#038; Touche LLP as independent
registered public accounting firm of MannKind for its fiscal year ending December&nbsp;31, 2009</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Authorized Signatures &#151; This section must be completed for your instructions to be executed.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Please Sign Here Please Date Above</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Please Sign Here Please Date Above</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Please separate carefully at the perforation and return just this portion in the envelope provided.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">MannKind Corporation</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Annual Meeting of Stockholders of MannKind Corporation to be held Thursday May&nbsp;21, 2009 For Holders
as of March&nbsp;30, 2009</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">The undersigned hereby appoints David Thomson, Ken Korioth and Rose Alinaya, and each of them, with
power to act without the other and with power of substitution, as proxies and attorneys-in-fact and
hereby authorizes them to represent and vote, as provided on the other side, all the shares of
MannKind Corporation Common Stock which the undersigned is entitled to vote, and, in their
discretion, to vote upon such other business as may properly come before the Annual Meeting of
Stockholders of the company to be held May&nbsp;21, 2009 or at any adjournment or postponement thereof,
with all powers which the undersigned would possess if present at the Meeting.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">STOCKHOLDER. IF NO DIRECTION IS GIVEN, THIS PROXY WILL BE VOTED FOR ITEMS 1, 2 AND 3.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">INTERNET TELEPHONE</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">Go To 866-437-3716 www.proxypush.com/mnkd</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">&#183; Cast your vote online. OR <B>&#149;</B> Use any touch-tone telephone.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">&#183; View proxy materials. <B>&#149;</B> Have this Proxy card ready.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">&#183; Follow the simple recorded instructions.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">MAIL</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">OR <B>&#149;</B> Mark, sign and date your Proxy card.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">&#183; Return your Proxy card in the postage-paid envelope provided.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">All votes must be received by 5:00 pm, Eastern Time May&nbsp;20, 2009.</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">PROXY TABULATOR FOR MANNKIND CORPORATION c/o MEDIANT COMMUNICATIONS P.O. BOX 8016 CARY, NC
27512-9903</TD>
</TR>
</TABLE>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">EVENT # CLIENT # OFFICE #</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>v52006v5200601.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v52006v5200601.gif
M1TE&.#EANP`E`.8``%5556AH:+"PL+:VML_/SYB8F$%!0;.SL[BXN"(B(L+"
MPAH:&J>GIW!P<*ZNKIR<G)J:FJ*BHG1T=&)B8FYN;H:&AFQL;*"@H,K*RGAX
M>#T]/7M[>TA(2*BHJ(R,C%)24F1D9$Q,3+JZNEQ<7+Z^OGU]?4Y.3HZ.CG)R
M<JNKJUI:6E!04']_?U]?7Y24E(2$A("`@$I*2HB(B!,3$UY>7G9V=D9&1BDI
M*2XN+HJ*BCHZ.D1$1):6EI"0D#(R,E=75VIJ:F9F9C<W-Y*2D@L+"_KZ^OGY
M^?CX^/?W]_;V]O3T]/7U]?/S\_'Q\?+R\N'AX>SL[,'!P?#P\-K:VN_O[]O;
MV^;FYL;&QNKJZN7EY<3$Q.CHZ+V]O=W=W>GIZ>/CXX*"@N[N[M/3T\W-S>3D
MY-C8V.WM[=34U-'1T>+BXNOKZ^?GY^#@X,G)R=?7U]75U=#0T,?'Q]_?W]S<
MW-;6UL#`P)^?G]G9V<S,S+R\O*2DI/O[^_S\_/W]_?[^_O___R'Y!```````
M+`````"[`"4```?_@'^"@X2%AH>(?D5'17Z(AGU&2'U[3E]:`P45,"]#9TE'
M?7V.CZ6FIZBIJJNLK:>*C*2G?4=&:G$=#Q5@,+L!`!5T2$6"LJ['R,G*RZI^
M?7RCI'Y\U'Y&1D=)HWM>*24>#B1H:TY)25!B01Y0Q'Y[U$75@\_0?O;WCO;,
M^_S]RM-%HBG:0W`/DR<"&F10\,0+GSWNH$5Z$:!+M8>BHNUI=*\/DB0!G8VZ
MV,>?R9,H"2DR8D^4N4A)JN0`\:!*$R9'[-5S5D3&!#<;IXTJY@XBOH?U*(EL
MF;*ITV7N2O)A=.U@@0DEQ#1YUS'@U#UF`E1L]"<?-8(CBQ@ILN?($B9*_T+E
M,V;LJ=V[CT8]LW=DRQ4($B@<V(*4$!^.SN[8\$`%8EF`CC>6G';DR)[)A^,^
M<;-D+][/H`F5E.2G29T,'&+DZ!(*HR!J?8@)0G)@!X++@N@]D[1D&!(H:=Q,
MF>(&#B8'$4Y,@&'%2,G0T/O=&S1WFKM:)`PLH(`'"I*V=47OF5)C`IN-OM<:
MD=(%3IT./2A\X&`@A`D.'#ZTL#!"!PT!6.S!4G0$*D/)-9<=]D=;?/AQA!)[
MY&%#`@]8Q,=:?.0V&2FT2"&``0^LL4858QSP``]@3&""$#C<L``1"XRP0P(;
M7""``FC,\00!>#SAG%(%!LG*1A(]DY$ST!"TA/\((=S0PQ-*.,.59<\4T004
M85CQ11P#?#!#"!.$8,,''ZPP0@`2W'`#!3HD,`$);4@P`@%;.!&/*%(T@40^
MC@GIYROZ*)+$=WL@81D22GAQQ00&Z.&$$0(J`446<K@A1AMYI*!)!BK0M\`,
M!M10@`!HD)$%%DXT48`//H0`1!2"I&!`#DR(TA)L^#SWYZZ/M)319>[8@X0:
M`M@00AY97(I!'%Q$4($$`8P@I@DC-"`##P*(X(,);4AAQ&$0+;$$&AK,H,,#
M6PCB!`@&P`$--;C>&AZO]!;S$%MM$639$5`4<$,"`6P`P@HVQ&""?AG($,$!
M="9!D!%+*,&`#P,\%*G_PTF480(1'XBQ1VX.V.!"$QD6(B57]:8\B&24)$%%
M%F<@<,$&'QB0`!$)_)#!"1$@<(4;7X0!TEI%Q./(87@$((,2"S;HW!Y?2#!#
M`%$\U\0=!FSPA&7P6BP04RKS,V\S2!KA\AT(%+#!!`3O@,,,1`#@@1U1R/%$
M8Y5E6!2\SWE400MM$%-/*%YX@(,)!#CQ&AP4".%`&UPXD9$H#4YGW=BE8%XO
M8F4)9&M$%K>EA!E65,'%!26T8((.&H!9@@QY1`'`!Q%X`:E>ODJ3I"A_]+%$
M%#;`T,0@#2[AQ`DQTO$<-RTLT,('/NPPAG-JL?5,+<`BP=)4GNG3^X:"?.P,
M_SXJN^.<@TZTAL02[T!L1AI3Q,$`&$%PH($!)DRP`0088`%*&&I`PA<.`(<F
MZ*H4M&B0((Z`A@_4P`T<^E88!."#`(Q!;U`#PZ>$H`<N-``-:B"```[P!BKD
MA">-*,(2U**-ASGG,8@P4F%2-HH[L2P24&##&][#@@D`P`8V4,$&'B``/*2A
M"4I(PK<F4Y8C,($/WWD%L!98A@P`@`"R^0,UE/``'`3@#A_[PQ&PX($$+*`!
M6GA"#U1@!Q9\P`8&:$$!MB"*0JT%"F3`@`!(L(237>8=6M2)(::3LH=1(QO#
MNL(#+*""#X1`!1DHP`"F@*H&'28DFN.=*111,B-T0?\"W"K9:ZC``Q](``M&
M$(01PA"!&W`@!4@4PP9L]H,Z>*$*+M#!`+ZCA#(@X`09^``.-!"!)>0E-@HL
MB]<T5R!W(($/2YC"`5XP`6-)P`4=N$(7AF$9MKB"F<ITQ![(`($@#,"8*]O#
M`7`@@2?,HP]3```-N(`$G(3A"AE(0`/(@`0SM'(#`M##!GYP'Q_$*`50B(V4
MC#`Z,LS!"E/`P!O6\AJT@#,Z43)"%?00@!A,P`,":`,;F&`TCVC#&=0)E.;`
MB5(_,.$"((A#R:1R!`2T[A.#6`(?WM``!4BA"$F`HA*F8`(<C*FH.`-3`"I0
M1"Y,8`0E@$$-&H""!E@@`#[_#$$,5K`#(0"@"DI8PA$JYZO)751LD[/5'XQ@
M!@9,0`4NF,(62#J4KX@$*6";ACQ2VBM1RJ(T#Z#``-I!#2,T(3L`N,(D+F(.
M*X!D*M/80Q*^T`$?CD`"="O#$];`A#TLP0@*\``(0O`#%4P@``W8P`LJ((,"
M/*`'7HI!`Q9VA3-,80YL((,5MH`%,U!!"DZ`RQ(&]1%#70-?!"E://AFJXQT
MS6+PPA<2I&"%A&YA`#K(P!0.03ZBL,)[)B/><_C0A`-8@`%2R(V#BB"&&J@@
M"F*M'%'P\==(*($)3(@O(1513RF$X;=-<$)PE4!@)1@!"U&P@(L6D``U^4`#
M'Q@!_P@D``,/\,"U$>B```;`!1&(@`0*N$(;,"`&.IQ!#`08PQCN4(4NR"$-
M7\C"%JR0!3*PP<5RJ$(9RE"%)Z3!;FD@``,H,+(G9*`"2E"<Y8IVUF1X#VH1
MH$$')*?%G(R5"G&@@S;.=]&TJE4E!0FSEXO0V=@XP0IS>,,81%``,&2``B!X
MJ@IF%P+\V-E8=8:C`33`@1#D&8@'4T$+4%O5!AB:J@V@P%4#8`&J2B`#)0!#
M!3R`@"0\`0PG:$Y9".((3:+$&GJ+C1I8``('8*$8`@)U)`HUC`,R@[[@-41;
M:G&$[QQF&&J11!*8(`4H>&$--N["',X`AS&TX0I1(($6KO]P!04H(`I1</:R
MM4#M98]8Q7`PL1C$\(8RT$$,:5B#&KSU#B4@(`!Y8$*GT:+,E"@BLD@X0P1&
MP``O\$4G4MI&?#G]F00>"!N,$)#VL(&A@L"K(/EXQD8*4K1KK.4=N:Z%]11.
M\(`PJ'J52X(9'B"!-D"!0Y,Y0E,HP0<J'"``(4#`&DJ&FWD`*QIL:3(S*$$Y
MM7`-5VE]+EF1TK6Z#&0G(OD:?8M1A&%43A1%L((#4!"!.60AI6%$2:&ZH(<1
M5*`,WXJU%DM"B6ZR1.O)\+*K378K@4=LA2U/1*Z&\@B+E1V0W-7'89#$AS5<
M`08L8``:J'`^71%2)=)0*5WP,4;_`K@`"!N(@O]H$52A$(/3E&/*1O@A]D'N
ME2AIG0X]X`7V8IBL&MU]#-T#KTS8C&1\>TC#`5@0`#`(X`QD,,,2%5XYKJA5
M-VSQVH(VTH0R,&!@&^""C^:^W[FH/6SU`E\1PN"%7[)@`V#@@0@PP(8F+-<9
M#U^+]X1"F8`;(0MM<$&G*%"'+B1!6'U$OOI7,;[<3+<+F7@655G0`P8<(`IH
M^$(3L!&2\"&!"I,R!5?@`'8@`P%`'Q:0`OY3))>W?@YX"$D1$,501TD0!EWP
M!EK``#U0`P$``C3P`S\P`A,0!!9``89V5?/19S\``A8@`1#@,^;W#B-A%`]8
M@X<`=Y\S;($`X194H`99P`950`!<<``"(`!V<`(NX%H/\``#D&Q<$`=B4`56
M$`9*H!9<<0]N9X-:F!N`5#:`ERN+`"D;<0U*`%R]H3U:]"T2068L400&5A#1
;,'9;N'Z1Y0[Q(#ZAMTEC$WKR-8=^.`B!```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v52006v5200604.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v52006v5200604.gif
M1TE&.#EAT0(Y`N9_`$N(P2\O+Q!KK\#`P$!`0(*$A<;(RN#@X/#P\-#0T#F"
MO*"@H'!P<&!@8)"0D+"PL%!04"`@(#`P,!`0$+^_O[:WN']_?XBDTI*2E=O;
MW`!AJF-D93\_/\_/SY^?GV]O;VUN<8^/CZ^OK^_O[Y&3EE]?7]_?WY26EW%Q
M<OCZ_$]/3X^JU::[W0\/#_#V^A\?'^GN]T")O\#8ZO'T^L32Z>#L]2!UM;S,
MYM#B[^+I])ZUVK7&X]KC\;#.Y=/=[I"ZVJW!X&"<RJ#$WX"PU>3DY9>OV%"3
MQ<G)RJ2EIG"FSS!^NLO7Z\C)R[_`P:VNKW^`@_+R\M;7V)^AHX6'BIB:G8B)
MC)67FFZ7RNWM[G9W>L'"Q/;V]R(B(Z:GJE]@8JVNL(R.D.OK[&)B9/GY^3L[
M/-W>WAEML4)"0X:ETD1%16N<RXBTUV]P<0AEK'^?SY6PUY*WV;J\OE976*NK
MK%.-Q&AI:EE9642"OL'6ZK/)Y*.^WDI+2X"`@````/_______R'Y!`$``'\`
M+`````#1`CD"``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F**3R(0IJ@
MH:*CI*6FIZBIJJN,,"F#,JRRL[2UMIHI.Z^'-4FWO\#!PL/$Q:LS-(0U0\;-
MSL_/.S"*/;[0U]C9VMO<A"RO,#F"0SW=YN?HBC0[C$KEZ?#Q\O.5"0/W^/GX
M":D^+'\\+ESX)\,&O8./]"G$=P#A)!@7I@WR`>2&N$%"!+APR+&C1VT$^H@<
M27(D@50L_@$1>.&/#`VQ/GXL27,D'YF-6+0<M(/E!1^#<&BPAK.HT:.H0M8L
M>1*5SA0T!*[X$P0F4H1+:=Z\6@ABD8D^+ZS8]4>#1JYHTZIEI#2KR*:G_W3>
MR,4"1@T-&G"LA>>6Y%:U-P0.BAKVHE`-[_8J7HRTK5NXII8(E/@GA@:#AOCP
M&2#H`9\%E0;P:>CYP8,^#Q;QZ<.9D&@^_%@QF-!06%^;>W5&%$38YT4A>)DQ
M'DZ\H^.LD$NE6'%!AZ`?>#\9$@E!4(0^R2&M'G!@P@0$#R*D5K1]4`()?200
M:)#J`?L_?"+4#G9;Y-^TNF\(\A'VPB[+&@A7W(`$IG/<4MF10A@--0AP&2)]
M3-#''PGT<=T@`\3V!W<(Q(;```@<4-MV(7'V84,<:OB'B.4)4J(AK:W(V8P-
MJ4@A`H)\V"&.]@AR`'H@'@!BCAHFP$^,J=37Q_]]:.DVUA\IZ."3?B[A%6"!
M6&8)4GT)DB+E!4K@%5,A`V#'6GPA46@2CNE1MV&;?3@`7Q\0+"E(F3?!6=T?
M#8@D86L']/'>(*M%"-IJ=?Z1GH01X/B`A'TP\&:=`T`:00*%GLD:`G5:R`\!
M$3"*8Y+U,<E58`(E`^4.1>B@:F56)J;EK+0*<V!-78X"$0!X$44F:DL2P$":
M&Q[0)V@6<MJ'/70B$.J<]MUI9[)U,LO>BV_>5V$#"$@PP9P2Y$G;`I'^,8$$
M"/3)[`2C@>B`H'\0N]V["R0P074A)?"NG*3>9NI5`4DU`R(]6*G!1K4FK#`M
MM]*4ZRAYM'$9PC"R1D#_2`\DFD"HZ.5YTG9XQCOA:@Q<A^*T'VO*68N!0E;>
M=BUB)PAV(>,9,@(AY2RR("1.N'.:(??;U[](+<<2$(>X8(.51CB2SWP^YC/+
MA_>,^@?5]U`8*FB6X+9(`IYM!O5!"TQPZ<*W-,P4*P!>0=FO`[S[[6K*@H?R
MG/?8F2;(,H<L\W;DRMEGC"'Q>\!I<M9Y0,P1J,D``G3^06_([SX`^4GRLL;`
MLLXV#K2=0KM%-%(]L=1)(4D8/.8B)"6'WDBSE"D2X2.!UNFW74>+"`)\0$K2
M>`A!NB?:#'.Y"G0:`#`0(MM56!W,B][-]TU[LR;R`WZG#")ZH%HOB+TCL8=>
M_\=XS[PH;7]LSGVV;X8ZP4GJ8\I:=V9;__GHH2B)OU$S^/3D(`6S4@P<$2B2
M6*V`L).%[+SW+I&\IT\6NH37#+&QI5CM'`=80`.&]X?KP(MXQ;O-PT#A`@<9
M(6!+.(1H4(2BT?SA`0O@W<I`L\+%<68!-UGABOC@`!O"AX8N1,`"'K`XJ(%'
M,[&)6Q)=J"@"/*"'YG$`H#;SO1XN@&LX_%`085@;'.X02:;0WV)*)Q"D":*$
MJG-:2;@FN9+$;B2<Z8Y(T)4C!S!@;)*8("'D^!8IBD92\%`*9`[```=<$(2K
M4%OK5%$5&VPD,/_SB,PZ(D;%&(TE*805TQ(B$@\.*O\DK^L#'KFS"!TM@I2N
M@:/((H3'1!C)E4/2XR#:PJ]$4*V40X(1&,F4RT2@,D>]G.5;")@A1OP2D8]0
MI$E2\9*\#$(G[/B(L"19*L9(AB4KF`'R\'(6-6+G.KB#7*14N:%.^>EQ@QA)
MNM8DS#-92D,+%,U(@+?*IA2*#^'Q$QL[X\%QZHX0%7)3(AX02D%9[9YEL]_L
M>N<G)B7`G-B!YULJ>),%%#0"_%H@23BCQ_B,A%V$4(IHWHG,1]AC(?JP$2FJ
M\@-"S(`Y);T%2A722OSX1`\.LE)+']%`"'2*'^0"UNP$T<"2#&\D!9WD*I/Z
M'6F))*CE"NDPH954[_T!JEK_R0PY#U%4DJ`/6A!4*)Q(`L@-^>YW3NV>G2`Z
M$CEI5)439.L<V\G40\;T&D%0@B'X<]>^HN*E4E&`P0:H'?LT4'`14M105]2`
MUA0U-JUCJ$ABTY8(\"&4&?WH2,8F2)Y]E`'FW!,")6":4)K*G+X<"00&D-!)
M9DJ5;2'M`OK9$`1`BK0$]1..WFHGS_!CG8E=G`<MZT*O96HSQW712"R+6;]F
M`P=!,$0.J.3<ZH;BFFHPF`!J$(E[!K0Z$JK.5K^'0TCQ:YEO$@F_E-)4VPJ4
MMTI5KFO)R5ZB;M:IH).J2!(!P<8)`JK\R!0!YL/>42%03E"MS8'3:Z%=QFUS
MDY4O_V2\YLE!0!!W!;Z:\*Q[C=4)XFT<#K$E6/"&G.)%5HZXI[DB%%#0**66
MDO6+^?+KM<Y*&+]CI:>-,T6H!'9*`H20Y1_,:5?KB*2LXNS#H>[;3LB\KCH0
M!/(@7L>>!>X3N"5IC8UG?!,$`N\T(FG(EK<LXC*;^2,S$.PF)=&IFW0*PCA2
MRE;"&@$"0&HK$ZSQ5.N)7_8,UVH[3B"T?$9F(6>*GD'^IV+MQ&/]0J:S9.YL
M/`?1+:2V1<M[7G0.MSKI,6?ZS*`.=3P"R$TTD"69T6J@A)HB9S4]5;YX_J>>
ME6KC28,YOX'>KV=U_>-$Y]<\Z#6$!Y$\ST$7@LQ4YM-<I_]\9`;'2-6076RA
MH^7E0=PZSGLFLZBWS>ULH-%*5[B`&2&AE-0@,$ZP-K8@7A=K&NO.TY.<]"I%
M>6-UJ[NHK;GUO]K"+4-TRK]7O6^CV]G4%;6UC6'V4>V<W>0<T7?97!8$I`;5
MWWKSN=L8SW@SC&"P.[#D(JCV'FW3#54IAK7=?YDU7&I-SH!.,M<^4S<")\"`
MV0B90KZ[EV8(4)T%KK:U]A2T?-,#0P^V][:EU2W#!7%A[(6R-1"F$\IWO21Y
MOCO;G]:XUK<NBV;B!0#,$4@13LT(2$$=XIUU;TVF'O&+7US>RA9):F#>8UT/
M&JF*!NA922*(J).$CO8>.DW8>&O_KR:1TUEIS5O;_H>J?M#MVL8X>L93IO=<
M3&0GDV<ZMR+.45U>JU(F7Y873Y,RY<WR3;$Y:0N!`-6W)LO6OHYEYSV[UDM(
M`JT!+@0R'_#&>N_S#I#]>EWVT4WS7:,$<)3LF72`3NV>P7:?E=*LY$C^L(2Z
MC2#G`"[&1@@WI8(.+!0@\WQU6D\5[FIO%-VI3@C)3L`S>2<$[Y(*^'SZJ=_L
MUZ\$Z(SH!#@&`A*U6/\%*>S2*<#36C[34;XS>PUG<1E70.\A.YQQ>3IC>JNQ
M>?_U:O&2((6"(Q*2)XU5-67B1S,R`!*`>WF3-_8#/Q-@<O1F81.P``.@.(H2
M@KD4*(WU_RX9,@"#`R(-$(,S2&]V5EI`9GKD4F6_=Q+D@EQ*MH'MQQKRE#<D
M^"92]"@-@(-Q8U4=A%L2T#@CB`\),P0&HQ=_0$:[@0KV4&3<D#628`\J)2-O
MB`AI5TR[PX8)L4N\U`CV4%-<APCO0C=OHAY.""H3D((7.#-;`0$7(V6?5PBK
M00#W$!)Y<A^F9PB?9WIE(HB7EU]4Y'"U1'.*8BH5P@>[-2(^`SF?^#A-2"&D
M6":;$X%)V'C#`P%`UHAS,@@1X'M(4HFR.(JE:&W+\CVHP8L)<Q<Z10A?TAQ]
M&'(CM(SH$`$`V(1E\B@/0($$<%D6&'-V$B@.\"YBQH%+PD.KD?\GQ[=(+M(4
MF(@:[W<Q%3(CFA$CQ+B)=39-%C9'I.A9TD(XD*B%#$9Y:\.)$V*+A[B!R!>(
M!-"%_!!E]XB/FY>)W%<K`*(!3>-28?<3SL@667>1\%`A#%`I/7<F\[B!MC4X
M`VDG]!(X3JA5&0,!IP&"8/B%=)B2Z2@:\]B.5R6)P`8\$B!>U_@9A9!!?;(5
MAU@A.AF-8%1YWK);<7(/@@B*??<M`AES^P>31R(H?$`I/J)!^?4NHX**E?>.
MM$)JCF0(`2,69*>1CH:6].!W??`AUG,=F*.$LT,N#1$HH%%0M0B.W2$?TT*)
M_"B34/B6,O,^PG@?T"B,R&(J!P")Z[;_)P-YF&H"&O?"=-]A>A5R$KQX>0W0
M*%>3BRG)D!4B@UK(BTNRF*VQDX/`C?8E)'^9)4N#%V1H"*AR`:^BE@!U#W%H
MF]P`F:%9B>02ET8&(MYA9XVBFFVTF._#CCUF+M\R+?-(`**I'LH)F"D8<"=Q
M&G5F(??Q*-G9%+\F3`>)&@SY0F:C,P%W@M)H/>.8F2=Q`*%"G&*6G`0@/Q=S
M+FXIG?-)FM2#'9/WA.BY:7A8(,"!%SN%"%\R%;J9H`XA0X1"1$SDDU=T)T&$
M0S'$B@H&&SBD&4RT(15U*"NCH6(#HDP4H3O$(B/"-0?@`.T"1BF*3X02H)X!
M11*Z1RI*3XLC_Z-%1%2P,:)<(T2?,2H9JAE"HJ$5NC@@:J)$-1XQBD>8`AL^
MLJ&S(H8:0%B)`%AGJ*!8FJ5:*A,#REV+0!A;&J9B.J;I<!=ZQ0C],VYDNJ9L
MVJ;#,`14J@C]`V)N6J=V>J>F$`,4DP@^`!1X^J=&,2Q<,YV?.2P\,I_^QR\U
MESZ`-"P)L`#PDWP4@J@7\Y"%`*D$4$L)T`#K$1O#<C$`.*F5VJ/#PI+_5:E.
M9![3Y'^HR@"0FB.E.AZ0JF7[U(<N$)N)0*?6YI.EP*M/VHE&&J"*X'^U>@F.
MND>?NI"2X$7M5ZR'P*RIV8FB`*G[I!EL9*V7`*TJ.H%E11[%RH/K(?^LJ0"I
MN=D8?;-88#8>(2$IZ8@^UJAL2R8R[!J8#<`'QT((FU-SDUDFU_@BH*(92?F5
MU6);EA64<Z(96)D^(A$BFH$=GW&!!&NOC)8>B`BHX!1&D"$[3=%`^Q-D)T&L
MH$`N$J`A<G0QR=)$Y!9S,].,.Y-*'2L)@1(!^Y1``<6RBD`L?6)YW9H(\=5&
M[R,ASFH*(4.NBQ&>DH,M#7"">V)GHM2NUQ*7]WJ+3,N:U3ED4E:Q+Y1\M#AE
M^(*.@?EZ/-263WF+6)N+Z(:U%\B58[L:,1B*?WH:$C(>)^(9K9&&/(0C)W(G
ML1$VD)6Q%H([$'`=6^$9%=H9/ZHF(YNW=FO_2(.`0T*B4IA2I'W"N/8U'O12
M(2/K(]TX'SZ*:7<"(A'EJR_DHLI51P[0DH9;N!GRJ%>#0XBFN5"$`.]RA4%V
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M<D/+$IH;&"A\`ZX4:";C<8$7X\9?RS/+*[]NBX]V9K+&UVR-F(WUV10_>)P`
M_)G9V$'CB*<$VT%BRZ\=(C,8,V2!B6>8PQZ7@[(8LB0899=+LBUMY`"@O"\H
MR\'B22EE4AWO`AG.HR;/HX4J3"=<,TEF@P#.\BVD'!*+J60?Q$K.,B&DG,LC
M@VY!.<KHIE[Z(IX.,&"$4,NWS#X>NT$=])OQ@LDRX\L70C)MM)_JY;'70__)
M>5,=U-QCNQ3,QQPG_,!BSVS.<H+,LZJP>7,3Y>',SZ+-?RA-F0H!A6@]$-6U
M\/$GIJ>\P.DM#4'''P/0WH.:&'BTG'*UJ/EYF_,F2**VZ3,W/G,:G'%6YR64
MP"RV%7V+E?*=;4HNDK(Y-`0ZDNPST[.R.T2+U^RW5PD!LX4G+=RPUVB5CUC*
M>J/2*L/2Y%RZ+4((#\``KR/!T+P=B:)?+_AR`:F-F-/4TM*P]9K3\39''>FR
MGA7/A8`=#D`;HB0SB^/26,QJPSPC.^TMP<C2F1.%/IW5ENC4FJS)J^%_<*U4
M"S`L""W/E9S5Y1$TQK&/^PBZ(=@G.',2[E6=.7W_>9@KM8:-T/5:)_24K[,Q
MK_VZ@O@HOQ%KL(=H>HC#E%;,T1I6L!.K7`:<I6SUD9;<LBN-LM[!`*<QUB[;
MU>\;CCC]L+5MU*:<U95S-?'5(M6SBTQTF3K-T=NGLB(3$GO"U"W;Q!.2U#1]
MVW'-@Z\#CZ"SVNDTGY'2G"?1VJ^MR;_-/B$A1"?+W+KM/?&%NGV7?,2"LDHU
M7W1]W9J\R@[0@Q.KU7C3UR)]$(L*G?YG#_/Y/9"XJ$=K)/^-,R4-2-3ZJ@*^
MS`0.JJ\+J3)M'IS:`)X*2-78(?\M?[%ZJCX"B<O<N)(*G1Q^-1M^DW<BXG8:
MLQIJ,@_\U%G=RJ\=,L(=_U\V8R%2],GPDJB@G*C#K=KSDQX\&%^MW,I!_4(?
M=!HNW!3T;-%R$MYI\B+*S<X[0\K%G..9JLG5J,;WL>30#-\6PI,R_M)`;3VY
M3<G)[>)XT\KCG"/>494G(>7M/0$)L,[H1LK*#<XA,\^-\LSX7=J`^N>8<,]]
MMY0HC>;E872#^;/G$M?L,UDA8T[H`^D-P3UE_C)SU+-1ASY%3GOR$</7B59\
M5"YI$K/>[3-;O#,J7,.2KLF59F=?U1EHY==J?<S;K>A`IMQ]WK*_;-1K'7<@
M;&T+&!NG'N<+%\/+-DGOTH77040?&,9HE>N`'NVGD(:4EB%YNR'#"RA#(KN&
M5/],-]HA,Z(BBFLBJ(0IE,N*YV[MI-0C,F)@')4=D>ON=M6D]$2'*2JC5[.M
M4SS%'Q(;["Z]^Y[O/53N=ZNWE$:X=G7OM7'MPMONV+Y#AM0C=-@C0H*WZQXC
M0A+N%*+M0-HN*M6BEB/4I/OP*RL:2%(:#?]?FY&W)U+QL*M@VWY,TC[S"X.Y
M`[`YM43SE-"S.M_SNFE1VNGSE4"/]$`UY7H)^W``:G@(1[\AHQ),AB`DJ6D(
MIF1*Q7(G2R_T6K_UQ5`I=J8BFJ$)?+`>."2NQU9V<F(OPKI]5]F9K!<N6COV
M\#$LA&2H7'_W>$\,VY<^I+A![MDXU9@:"U#&B4!%FG'_1_7RJ`E02*[[0@X`
M9#67HD054NSA`*MU\U)TNSPS@?`!<#/Z&27=?"^T`#T7M'E_^JA_"GMOK7:D
MH>;2'5=%^,RS,MCSCB8O*4IH+(V7\9]Q#_NT'GRR&2ZV.'P"4$M["#CC&?"Q
M]Z)QG7Z>^K/R[S>[L\.*XM-?""`KJJ@ZG]:?"<.RK!?3&IC:]##B4_O4W[YD
M_M;F4U_&_K"Z'K*?%JM/B@?I^F9R"89_#[:/7)(#"`T#`WQ_!'\.#7P(?`P(
M?Y"&#@F*`PE\$7\,#P^1`P2/AI&1!P0)A']\GW^$"P00A:.RL[2UMK>XN;J[
MO+V^O\#!PL/$Q;X$?;I]A[L#_WVQM\NRSK$)!`01?1+7U,:1R+]\?<^0R'T#
MOLX1$N0'#^SHM.KLA0]]$=F=]OA]#PC9!"9,".6MH$%@JR`L:,2G8:%DT(*I
M2C6H8454"PP=*&2*`:I&LDPU6#@``H)#("$=:#"*V2B3?Q`P^-,``<L%#S(N
MB'>PI\^?0(,*'4HTUX!LL19`4#AK&1\"BR`]@$#`P;0^#!A`C>3@5:<_TE@M
M=4!NE+AXSK)N_;,0$J$#&P<P6("@*X2OC*""0W3-T:5X#JQ&$K<-DK9S?Z82
M:)#@+Z3`+_L<^",AD[AQ/&5!D$PYTV8$"/I`^/,Y]-T^&0_T$5RT-3%G]Q`<
MA4HV5?^$F00R]YJHBM"#!@Q4%<IJM8&#""<7L(2<L1SEN'RZ'D@P&A*?;<R8
M-9]MZBG+!]<0O*ONNKSY\^C3J[>U8((TPO1DC5O7Y_L]=C,]C:M,CH&V?&`=
MDD`?$Y@342J(L;(?4H8D@^`@!#X#P00,;&;59OQ!I`TR$J@VFFHL#895,FF=
MHTY`$SCS87VCG`*)!!.(J%LD+E(68X'EW)C=!&<91MYZ0`8)#!^3?87+`,W=
M8J203#;IY)-0Z@).:-GU01!8R#78V2/($.0,2U2:%M,$$@2H"6)D'=BC@F!*
ML]=9SDCPR#T)I$*7-/\DTQ9ER;"#P`+]F-7/.0Y(`">19P[_X">@2T;2`%8R
MXO+H3&&!4VD?`^;VJ$M1=AKD`'CE<@!KMUSIZ:FHIJIJ0>!T\^`H89U%X#79
M\.3J,B<&E(R;#KH:J8*Q\&J=B67Y1R`$IY0%#G79C,-6/Q!D(NA1?$`0W#DV
ML8,9H]'.8A.+O]+R;8B7FJFEL>QPNNJZ[+;K[KOPKKHLI&?6&4E8_AU`YB"#
M>%G6,@,*PJ^9CS[BZ[!H_7O(F\1"<\EF$:B6'S@P+E!*,J$U0*$L9S40T$+G
M^,?')=C6M[$L[)#Z:BTI1U(9).MT!G.9,240VH'QYJSSSCSW[+.4B,'("9GR
MK?;`!)D\ZH"B`^D7["$13##T(=(`_RI(?-.ZI3!-1M?J*CX'_!-CU`^0E0S1
M`[@'R:.8<DRH>QN=\]D!\'#=MJ"&-O2K5G@[=&9@D/H'.`.9#O"HO3\38TYN
MZA:$"MT2V`MYG01(D"0"$TQFG;0>RU+@PM<\8$V!229N^NFH_])>,@DT&P'B
MAD5-8)T7$UCZK8<<-5^=8;&-]:^XL^(>F0U#DH![MO]Q/('9G'D/,D7>,\M9
M`UIVCCW'HI:8]"&-X_VO>Y7CO;,(:"MG3.8_<IGVJ0NC]P$6+[#T)']L-!E<
MOWPR'%R.',``_SDA3206DJ2G3*9S+?E&3++3O@8Z\(&V:(PM9'.E`PS`5+>H
MT2PD*`P*9O\P,QZDD6Z<H3)177`4)!1&X^0!.U;`+H00W$TA/G&4XSSE#Q%8
M0"864#I>H"([%LS.1%S"$O(TQ&(W'(4$!B&*)JXPAE",HA0;*([,$:.*FOO%
M)J9H'KW1D'&K>(:#@O%#YSAQB-]8A74,MQ-U14!O#&PB%^=(QSK"BQ`M1,C(
M[(@J+X*1<6!!A3!0`:80%7(G`E2>7NRE"N#(T8Q-K,X3^4C)2EKRDI@TAA^_
MN(K%E(F'>F1%`^YB0</=!0'6RL]$WD((0G"$+9%X(T<:T9Q)9O*6N,RE+NV(
M/P38[)>^=(M*LM@+!&A.@L94GN1X@CB;P04TDZD3X@9VBF;N\IK_V-RE!3&8
MS6YZ\YO@1`]LQN>+L&BI%N;4&L[*HZ\$*0A<V%MG+M(IBP2P(P+QL*<V\F@\
M#GU%GY$S'CL"*A/WU"2<"$VH0COE#*CXK1?F#%]3U'6P\XC#`?[2!B2,)4]<
MT',4Z^"#0!XA$)'&B!91NPYG2BH02+`T1OX!S@1"=$EK$&`FA.L)`P0SDEPL
MH$Z.R(\LA&H34PQ#)_R<WEHFZ+&DZD(KG1@`,6=AP9`LAIML<6HMJ`,38&1$
MJ+-(DC5F<H"E^/*F@XF)61=:E(K:1"`'=45[,A-1![U#&U^)%5S)H<\<*K)0
MB]"8:*;*`/?X]:V#K2?$"J'#?>JG2Y1!_P9CL[$Q:P!6$P:=DP0@!CMGH`-.
MJT&$._4S$Q*FD"P0L@IJ8W:F3"KJ*-9`1P*.&8H9[6(QZ"O$;)67S+#5214.
MR(@TPZ82ERSM),:+R73@DL4Z&;-.%RS?;!]!7&?6DR6,\:WQ"')<`6GNA!QD
MA7+MA1-1&(>YXJW?9)1SI4/(3WGW"Z8J)I-,9R*3F#6AA'+K%\SG#E.8TG6N
M<Z-)-\W5I)&RF8I,9DL51%2$K41IJ$,FLYFLB`9!`(/5YW2E/&VHE'>'L(>A
MW+.(DL(#-I;S#TZ(-D#1?%C%1Z,9),16K=5\HCY9I$:@Q$@D#UL(Q2"SUH7'
M`1SNC4(VE6$$8O\J*@NR@`P=U.@1-5CL']O6<15+S$V%(O:.#BT&)1VEQ4W%
M$YR%0*`42ME(F:,S,1R"AS0/D%83ZW07C^2&(9VH,PT;`![IJN(!?&@`FL]L
M%B@WI,QE(P\S$F!F__WF`!&8BIWL'`_EV,LX@=[(`O['`$&S-X&&:#1#%K+3
M!_QPSVS)S*)7P@=`E_D3C^ZTHVL2N4/<13@:Z9!S"#&2S_XF%`N#)(2!,D[,
M@&AMDKEH4S:LMD?=CT72</;V^,"H^M5'19"HL"4R8T$+;J8D6-GV*`#5''RL
M3)TW]>PS9&-!<:CBPC)#Q$-H)E&M75C*9:$%H.2$[X8L^1F/*O)H*0G_FX59
MP@$I.J)JG`$,`G!B$X5`Y2J$4Y&G2%(4=Y:C2RY!FH^@HSL=CP6D1:&*T0R@
M*Q0I-"LL0@@(&"X>G))X3TE.PR5&Y"DH::4A%!48!^`:U(>0>&\LLG..H,(!
M_@L)5]`!BXMPI.?54A[&.7Z*5[HD=YAXN<\)C7%A#]LG!W/56=8$JZLG(WS2
M$!:PUC>.W)2E==X#*]R1=@ZXCP.L:P('V8'%`$.Y?1'FH$?PRBZ^6JBXW[4@
MC/K^[6\HKUMCF[V;)=6X\T[?>60W"[,M0-'I5@)GXJUTI5P^CO$R9GNCIR[$
M$%.?"I3G'.LY'[<^2$*(W)PPD1[Y?&),DO,E_SX8$C^E",4I4Y&EM5OI-C&<
M1X:^>J,7`GY@Q?T0A_[#Z$CU$&$SN&[+Z!*3.\#D-Q2DK4__=6+GV]J&3/;`
MS:4E:1];&OF:=K5=Z*IJ+H`=B'O49^MNB?M+GMPP8SV900WVD&[/`"@S]`RN
M@C2/817E(B+Z8&.AA5JT(`XT=5K$HEK\MS8G=4F4EQNP@$_?]SHY%"-,Q`N'
M$!R$X``/8&?"5W$7-!K!=@@U(6<+(6DUL7RM=W(T(1.H8!)EDG.3,`DY!QHJ
MX7)GQGP)\#_`UVH0P((>81*"AARC41,N!PVM!`K#9X4GEQ./XS*^`86AUQ!#
M*!>Q%0M,D45\%AT),/^$U&=T+,A>9[8P-G$29AALJ(<L?,88>N8</!0=Y6=^
M!U)A_C$:>V<89M=AAH)_9A(G(K5N);49.U$6[J8HG(%L.>$>A*"`[)!%-&8A
MYP8LJM$/U("`=_5NL5"(,64N$C4@AI(-D_%2P$(*;7<-&2&+?R"+,>4?T4=)
M\#-`<!%<DQ%<]8,H)[@+&?$`<'%!2X,DK-!MI50DOZ@3K`!*`X11]8-1545M
M@C$JQB1;..$..[%>Z)`14E55;K%*R^A@XX91==$O0Q1\C+".D0!HTC1?,8$H
M`32/!=1J,=&,Y\@O@K$3%A,/<14)=;$=YKB,596,&<$(=9(3PH5TJ9812S/_
M8_[(")V@D0/4@($(%-;00V\U4X_@"GF$5AO%#'<E`5^!DNU!(01@CIO!(XJ4
M)`R0#2S9(@#1%9UPDWBE6/>0%$9%(S%)&J`0DB=Q#ZXP,D49$VQS4"C)-Z,0
M9S^I/#@I389"E-=@BU;I6%U)4!IS,A_I*<%7##9S$+UH#%:F.K&PEF/YEMDT
M$7`YEW19EW;9)!QWET*!2L@R0:IT)5^%"VD)?#ZE"<:@%7U)#-90$V59EG<)
M0WH9F9))%#6!2C6S79%P<5)78/8U8].A0-;%"J`1.=,E3<+$F<D%7]350O8R
M70IDF<'4FNDE0;N57J=7-L05%[Q5E^5S/I/YF\#9_Q/GM3;!E6B1\#])5V<%
MQCB_`6<=N#!IM@F,46L8%6S2N9R:(&F11@`KT8*9Z9W;"9I5&%Q$LA'4-A,Y
M!&BM=I[?0!<4L0FY89QSV9M8%9SV>9^\D"TC(PBO\')NP4.B4P@R6'2&P'%7
M1W,SAX?!-AJ4(PJ&:`T:P9TT(J!=5P[88`G\R6@_E1M!R!:.L',R1ATLJ0HY
MYW*",)<#M96#.3U')%7`@(ZUX**Z4#H]5`LU&@P]E%0+@8WZUI&#<40W2@Q5
M90FXD!J-XA;$%#8RJ@LP:IYNJ6^3(55!2@Q3&E:E`@W&!*-D]$Q+Z@U:)0O)
MY!H3\W*Q=7N:P!+<1Z`9=_^@L:=@"MIUV==U)"H*&R$8:7J@,D>D64%\I*<\
M5W.,$S.G)-HO<_DHL'!$S6`<CI$_849<4@)JN&!+O=!"3Y0;RK%5"N0)BBJI
M>H1<D4H:4Z425S)\S8"%@L!UNZ`(%/&EP<"IF9IXMO)SPA`VI,HJ/J1Y/=%J
M"E83BK"$6;2G/8@;:MJ#STES4E@*320G28-*R)J"-C%U_T-3.5BAD52'+*$W
M5B@*<2B'CG)R%N$(5^BKK*I0&C.N'/-9G4<)-$5S56$22Q@<ZHI#A`,<?[$0
M=Y:N#7"MQ]$2W_<GQB&O-L%[#N`(WX$7$"`P4-%&U,86<*0_2)=#P1$1V8%*
M@E#_L"BQKRK7KKZ4%8Q`'&Q(KS)!.(UPHBB4:6SQKQ&0"/RZD5EQ"E6A"N]Z
M$HK0>9HJL.Z:%5@X'!?4LI1`.,I!*DABB)W4K\#!@IU@')TV"T6+0RH;'7)V
MLDLS2K[D2"F[KC&+6]81D[1QIH3@L2K#"4@B$R0ZLR3+"@F;"M0&MG0QKRQQ
M&YZ`3PL1$45K$_]C0.7A<X_0AH]PD9X0#][H8`4)2SE!'M0H58R`#A+YGP^Y
M1TOSD!1)C65#$']+C80)2WK+"N@PC["$"(OKB8!XCBPXC.5(EQH3JKC`&Q5Q
MK8CS>A1A$KR6"A`:7,94<IHPAM>Z:8^4<T4D"CMQ<KDS_[`R$0K&!&BL-W[_
MLZ88%TR9"@KNT`C!VQ&/E'*Z*QZT]W1T`3_^4`F"]+;5L;MX&(`EF;T>5Q,Y
M07';&S8N6'*R@841<`ULD;VRNQ*)M%$K<;C!!K,G$;PY)6,T@EP+LX2/5$3H
M:SCL]KT]6+ZQ^D,;01I#%[V,8!$D8;XYJQ$S81(.@22JJR[&VUS)H8R_%R_`
M4:7X.4>H6WL-D46L.Z<F3"1!EPAQD7-#YU!MP2DY)TLD5PE8EP#>Z2@JZ'QR
M2D-6QPH[!6I5J(+>B;P92Q%8U\"@X,+3]\%N468X!$>/M$37^G$>M\1C2`JC
M!'I8YPD"JIM-/(5ZXS+80+SWN_^"*/%3+<B_UN%ZPQI+)]S%;)I`H@?&IY:P
M3#P+.Q48T+'%Z3BL?8QT#H6L"11[;PP5:(&K(]S(X?!9J?LG*%R[.><(@,:8
MR/I3WFHX-&&[?P+`_%NBJ<"[HM-GG$`3K-%*JE#!<B%`+.$(R)N"\RL*0H<*
M0\QYE'&N-&?)Q/M#FFRT8@O%*^>@HVS`-.@._J"#JRP>Q-O`:R2H<B$>$_QG
MR?S+ALC%]8/#[*JM+&'`SC&#,I'+F8FVGB<><'R<S"R7*Z?`,\%RKS14+'C%
M$NP)%1S.KQS//6@Q&DP3FD`0T.D/5WA+Q38^Z^?(3Q)\/\5H,D$JK@;`/^4_
MLCO$,Q'_LI_\,$C2&&NK6BI[G%FUA#UI'8LP%[$@:*.PAB4Q,B=]CSW):(9)
M;9NV)(CY"&NH"4"%"!L]0#7]4XQ@%0G]510M;Q6MR322C**S13@U"F15"'C+
MTCH-B"W8TZ10:C/QT#LE5L+5"7A+T1[M"5\Q%P`\U9?0G/);-O]#*JWVRH89
M&%:["1"=S"%MF`@)B([9G8&Y$(R&T6D]E3_%6#KLU2SM%K`0D7N4$QRWT'#=
MK6%M%LW9$+-%TIBT"O[PCSMGT'94L4&A7_+0EHR,*K7)18<K"T?:*:&M"]L+
MG*O0`!TB`=W\I)2M4U!BICYQEJWM$\IKEZY@J>9Z"X[9$[M]_YR,EI;)E!]_
M/0MJ%'#EP!/YL:(;M4%6#7S\I-PV"L`',=RS7=W6O1ZJ<!+SQ;CF2"1U\17P
M,S*+<`EQ@5&$D+=2Y0_$2(TLV(`G9S,3P8+`-2I)PIV?4!=L(1@W5!6S)543
MD22K4#YDPB4\`42K%!6)\6;KO1.M!EV*<+CDG=\%^A4X$56+4.'%>`J&G-^R
M83&L4#89WKRAH)OR<PIS@0@0Y!`/]0N,5E70O:2!69C0+9C1;4'471`R8;K&
M4Z,V'KCC=MA!T=N[<./U,[IF>:/2;:4^15ZL*N2W(*5.Y>16.N,_'A1:&F@1
MJRC7(1<<>M9]%Z6P<*C!`142@'02D/^TI1!<:^@*HO`Z,!-GX.%SF?`ZUZ'6
M"'YGE<-H2]'=;G9GL,#3GG`($B`GJ#W99O0*T4$W24L=X,'EL*8HU5$24['*
M3[&C<>:;#G<79^XQ<;9SVLRPO]$0ZD.&BWC2L0""D-;HF(#9#A2TH/(CI1)-
MO`4_-<&=H2";=?*O]>-EQ%7;R25=S(N9X?69_A43GAHV]14VRF&/+8(XR"[K
MM$-@DEN2!U4_M`--;V$\ZR5HM(X_L]4ALJF:Q+V:S6X\LEE=Q.6WL+-;VE7D
MT/"9EJ9KZ.Y+O6Z:O`5"SP0[_WI[F1M0;I&WCJJ;JRKLR/Y;+AKNHKF9-N%S
M1/KKRR4;1'K_EK*!D+46IF>Y6V&ZZ[).(P4_7AY_EI^I7OQ5)Y_VQI!L<\HA
M"`NQ6;BYSL*AM=6"+'?1'-N`2N8,"AWZS89@'!T:\VVHZWC^A#Z'2-P7AJ8P
M34NT"1>Q1-\`&@[7%4H10$N8'/FZ"I]P/M'<=%K+@J>P#O;">5'/YL'&\,S`
M@J@DE[I:**HL?C2M?5`50Q0YRJGZK()`;37X9ILPH#38C1T2GL9ADPI6:VEF
MG'Y5/[#01H\V$LR`)#GAI,ON<#05::-QR?6+7?XC:%41"I3_:=VI@ED(:.J9
M$VL^T]SI9=DY&N%9TN#1^;&DG1E19ZAT"<*Q::S/L$F(:`QQA"X]_YW-B_D8
MY??D"1?54A)@/&J.D@AX_VO^SF=0D_RY81V(]GV2L/"D)M_"OS9OIKL^)\5Z
M=F>#L.S2CX0S)OAG1OA3D68JT2%Y_PT8]?>P1FF)UOF7KV:[3Q"-J<,QN82"
MT!63``@0#']_"0N&A@P.#8<-"7P$"80+#840#0@+EW^#A(.?"WP0"(.-#Q`0
M!YZ)"*D-HW\'!)R<A@,$E9V%!+R]O9*$"000";>5D,`,R@D,#0.#A@X+A0R1
MAXJ8#9@,SX2X@\B??P\$#]>$"*^(A**CY(?PA.1\M`R&!Q&$^OO\_?[_``,*
M'#A0%I\&]`AR&I!K`!^'?V;-@O"'C["(%?\'Z),8,8&S680H6N3X$`+#6_SX
M/*1'X"%&3PX<#'CPT"%$D!A+_AG@@%NNF`X@[:/($V(L`JIJKHRX@`&"G2MM
MLL0XL>)%G/KPR5*U,>.L1W\H+I"`X"&!`1*V[FMET^$LH^R65N4)4J+'6X8.
MG8W%9X%#I:$.N,07MM!+0H0YSG*9T:')CX4^NK1V*&N^Q5('.`1KDIY+IX]O
M:>R*.33)T1A%`OOZ\2;$QPN0_@&J4O-2A;@)1D"=N[?OW\"#\\,JG+%OA,*3
M*P]>EO?`VGP>2*6:$R5FTA%/`JM^^NP`!#C!A[HY69]*E<VGX\3\]KQ#FC)E
M[6L/5W!0VS<CXX__.E6QU\/L.#"+?5V9!15&L64D@69\.4`(0]PHU1XZ!(S7
M'U1U9>>,)'P,D@DF`Q13VV;?K20@1@>`9]Z)_C$FH68J:E=>ARN>%I5Z$#TD
M6';??8B=63">]N-H;VWH&DLPVL='?$K!M=R34$8IY9145FGEE?VT4DY"!)WR
M1P0(J(>14Y60E8]QBJ63CCYD4K<2,_(%PP!--R7@P$4P#2#2?H>!2=&==WH)
M)D_F8`6HB'(>@-`#]XVBB#E^\??,56.NR1%782$@`9R5$.+G2]O\X<Q]F!##
M@**$./!`A+8!FA`S=$YU:(8$J'G,(+52]."(7):DJ:BMQ)FI!-2!-II2_Q:=
M.HNM2]I9D2ZC$)MK9A!MDR-#3R4K2RM#:BND-YRL":ZM>J:3(ZRGCFI.DUQB
MZ>Z[\,8K[[Q8+E`6+0IE,ELL)1XPS30(.*#*``M,`U:J!/]AL`-/H2/P.`7O
MI(I,"N]SYP(':/1OPL$,<,`#$J=7L3>5*:R1O@Y"/+(^?O&K#Z,(!*S9QPS/
M!G!-9?F;L$P`/_SORH8\0'/#3$DR32P,)V"TQSF/4_,?,L^<<=3Z7)PSQ2T?
M_;.=3RT`\B.89NQQQOIX''2*%JE<B-?^5GR`JER-K1'6P3"L6<I>ZW/VVT(_
M(C?2")#ML4K34`SVRQ%[/)O&%2N.<,"8'LWU,_\,D[VXTT^9(_'4?&!*[^>@
MAR[ZZ%8^P@<II*?>CRZJX^;</ZRWW@]#L@M$>^V_&8+[[KSW[OOHY!#S^_#$
M%V_\\<@GK_SRS`MTWGG-1R_]]-3S+@PN1`\4^\LI1S2,)+H+M-U`L;4D;\D!
MH<X7/^/O4PT!@PCH"">\8,)R`H$#]\#X1K>/V_8"`AGS"&82+RF'./U`WY1T
M@4`G`<06[0((KG`3/@#]PT#!B-1S7M<;D[`C'Z)"X.SH82I_&`<2M1*..`(B
M"PD<[4G7`]GVN@(0QBB0.!#\C0C=AQN<S/!`,>GA/["R+&+E3R`[-.'<NN<N
MXP2$6`ICH@4WLJ$$3.#_%!3!Q0`BT"O;_.8!"YI/1H!#G`-0I%/,>UA%7-<Y
MA;7,7S@!V0&6%I%*4&PMTBA$&R<AG9WTT2]AVHF^-#,+S;F12Y!S(VH@T92'
M<4T?D,-';#B&M>Z!37`H,20D\XC!BE1($:IXI#P8UA>&!>Q??:M9'K-BM]VP
M0S8-F,4"[,:3P#$J8]%QT+]:E@ENH*,2C#*9PH0V2ZYDC9BM3-C;;*E&3JAB
M63[#6,+\XK&:+9-FF-+5J2*P,:BU49;!.`#9:#++,*'MF2U[92-5H4FR[5(C
M</2F.,W1G(KE19'RW`E*)J%'ST$$9@@I14_*T@`R.0"$D6&`7[A)0WO89!BB
M_[('*>:T@-UX1*%_D``Q.M3%G3AH5?0(124N.@UN*B*(GXS)($#ZK"55!!(A
M*B@PRM(7\VBD`7,LZ$*G(=.-)$0H`^A#1.@A@2[&4IP%+8LBEH2)BV[G)"S;
MS4%<"K^"-0-1K!%*!!P`"ZBIXH?&,PAR%`*:+X&G%0A`J!WMM)F'W,E^+YO4
M+!CH-Y4LSB*5J,191F(GF;B52Z4R*TYL,HHS'@Q86>R(/=Z:5DS-52K"Z"MO
MI&./3A*66XYXE5-4HBI5R?6FC_"L`#.E5_/T13!(Z>R2&%6NQ^AJ%F":"%MV
M5;7-[,5/,AM)-8/)D5$XH[`T)$1@8\N,R"HTF+YMK?]Y('"T6?C5(]PB@*KJ
M5C#3J19;%(EMV7Q%C)B,)C^Q16L^TM5:R,EV`H)UIC-&@AW6;9$7;A15VU8"
MLHA!4;[4H6&35@HR1L@0(SC%"!2)]<*IPN(89E281YZ9$Y!QI!NS0/!D4!4A
MH8V&;#@!2X097,C^;J0/?6C)6X1*@`B4F&A*"1?!7$(L^EJ.';Q9C(,C\I0!
MK1?`@9M%BU$#'K`:SYRY>9MB\C,)9F#D+[>`*3_(P9#3=07)1Z81KB9S$(1,
M"%P&&JQ<DKR>_[`'IEA!2)AJ,U1M1)#)EMVRB"DTC10S^2TBUA-J\H.3AS`"
M)1[AE6LTRF$W?9=+[<F0@=S_$@SD2.1(AR&BE__#KNQ,A64,2&R@]6%B]\5$
M.LC:9WZA0AXSTW;(4^&B5&<3X+U2![9\X*)&NBSF?4!$&BYYR"/VJI'R@&O3
M+VGT5!F`II=P1&$2&.V2&%+2@^#)U]6A#GB-/9EK@0>NLQ&*/E(Q03<%U*>O
MW`F)G;%5FY)'H3/Z#O;VX<3K_+HN=`;7=8;B.>0IU!<]5)%='HVT01#E/@/*
MWBQE+:RWW*<P/"G8-*2[ZH<$CBA<4LVO.8TD>FQ'X=R)A8KT)@N'4*PEW_'<
MOA^Z743/-&,(L<W&)Y0`M$F.A(>Q,Z[,B&0<X?74A6',`5;*58\*.@'W'E!G
MJ,(9_R(#*S56Z4YC+$)"G],*X"?R6%%1P^N@#'W0\M$R>3+^:9Y?"%'X2T4D
M+L01MB:Z$,(ZD,5E>)&H7`XGL%CX2Q#^:HW13;;4R9_PQO@:B1'%C#5.]H.G
M<O?)@$76EDC5C/7AWTQ1AV[>2,A8QG$9EG2Q[KA<=4;`IRL8B[$\&6(+W]4]
MQC$Z,7DE]\U9I)6:!R`T+"!CU*E6NXA`3N(@IW@`&BN$4Y>H/D5@BHBB8C/S
MA\R2U^:1_:890A,`%Y\=PH\$9AB%":Q`0/8.V3U2>#VVUS>`3H.]_E2TCQA&
M\$JDY!`N36CB2_'3>R4L,6-/&FUJ1_AG3GL)"21HIBQ/>?_I]CKO24;EHWV?
MZTD9%9%\$9=B_4=OJP*`D7![T5$KN;(B*)%I"RAO9<-]T\<8.)<@O65Z`7AC
M<S(*$?8`Z$42LB=]7?%\:+03(B9.Y7!HS#48S(5>\M``^H<57`2`TZ$H,:%^
MTY`6LC>#4',6*31&%'8*I*`)XR"#$X1Y!S)71%@>S+4@2^)T"A,=9!%5,3B#
M)2>#W6,^L3`!$C`!4Q81NE`3F$!^-E$=4=@N3I062L@)BR`TSX=>!_@M!B%+
M_E,\'L%<V2,0*0(^AA$X_-,P*0(U&H$_*U,(@>-ZWI`_@RAQ#Q(,$B<)XA0,
M1P2)AC$^U2<)"-`^P#!'DO@4ACC_/H'$B)L8"ZKP8O@C3J58-I.HB>,S1Q*7
M/ZDX4\`0>OM0BUD1,Z%TB2F2B*&4/X!XB>&4/=^!&*#H#8TXB+@(/K#XA[N8
M%=NQC)$8BURAB<_8,8CQB8\HC.B0(J>HBX,X&G[(BKLXB;GHA]8(#"<3-\>(
M,10QCA>VBG_H'&'B.(9AC"77,#$CBM7H:B'2C4<4D-6H"D<T4[S1B.*H-Y#4
MC\KHC/?8B<=HBJ#H.;\(2=MQ1+!8B6#G:@,9"]L1CD\QB`VIC.W6B.'4D!\I
MB*4X1VNBC>@0C]'#`$)%+^WV#R]4/?Y0DSB9'#>YD[[3$W?HDT))/1`2E$09
M2T\SE$JY_Y1,V91.^910*3JV&)546956>958F95*^3Y&25:T<`B?=Q@^Q@\*
MI!#$,4-@^3H_-%<*@0@]"3NX4994DD1IB40",9:UDT2]X4"QD`KDXS<``4:B
M]R!]H`H+,)/]X)9:N9B,J1Q]A"\$T30%XS'<-'`AUS3Q%`L,E4[CX)'"A`N7
MXVIM-)FQD"#[L#$OA`NEE#D_PS:(D2#3`#.7PS9<`U,:H4RWM`^2)$SRX)&)
M!)IWU#C^\I@M<S=$DT?3H#@7QYF?B1#EI#*NR2/">3@8DYN:4T^',PFF9!S4
MM$RG%$C%&$6&Z2#+))Z%4#F%`IX-\TBX:2\M(TK/8"\J,W_7I/\YP:F:SZE)
MHC*:69,U$A-]+W$+/+4L;:0YMFF<X\`QC;F@#+IDHX&7;((JVF4CSZ`HXM45
MSR5<L\%61,<3T.4^W!)>HW!Z/&</,,9ZDG5HZ#"BBE46,J$LH,4??B,3P"5&
M&2HJ&QI8;O6AW#&C;=59@C<3F/&B^#!Q=U57G96BJ!$),L$>M'`6A259HR`P
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M1NO6J087=7K3'X'#$`/BJ@XG%12S<\0Q%RGS-O9F%0/;,$[*$P+K11+7%TZ:
M,0L7LIF68[EZ(OQV:(Z7<5DW1W'"<A81+*WJ$!O'**.U&!?!&3GA=%CE-`($
M$;.D$1:KJ>I(_T(+VU9AD1^-J+!41VI\0'K^P1X2"!4J02E^\[#HURJ2QTI]
M\#K#]K7^$+&]<5\9):028SL15*]NVR4M85<*$1VE91>+<1]TBWH(E8`]D4VI
MU[>L!R(;@1;4\7SYL*3)5A'W$7W4IW:&JWO>QWS[U'_:-W.>-15+F@"W-VT@
MD[>!VS#/!X240'^"(;)F&+HSL0C6P3VKM[B=T[CST11FQ&0F>*V]]PQ$6+M]
MV1,=Z+%#!WX(,`%$$P%>`A+<1[QG%"L8$;Q$<WW4=KG4P7TH2!.W6RW*RWP-
MLR1*<;NWEF6%^V:$^Z?>2[?5JWW;JPA8$1MARPD%AKBK`C[#QDVZ`_\?460<
M-&4(KG1K.`4/^H<>T>812'&_G)!9:?.V!LPOFL%!`)&0DJ@TA!B.W?B1+DF)
MQDB(B+@R?2B,P?A"?MB(YJ2+ILB-$6P8S1B*Z*".DPB,N_A"L$BPAGB/@?3"
MPU@K7"&2(!Q.PWC!XUC!'\R(UXB(`QDSXBB+(2Q(%JR0DG"OGRB+^<,Z`7R/
M]_C$I4C$D`DU'^=5&GR1S9C"_5B01-/#IX@I'X>.#^F-I7C%\(@8<2-.O3A/
MJ,(/Z\N94S5PM%`)%&$/[:$BT1$=8BEN``(2_.$@AD`*]+1SW*`B@T(/$'K`
MBPD)`58\.OD/D2P[DRP<[(J5)LHR`7');-+_E5FI5'OX!^N;$C(A"4"8:J.Z
M%.=*0VH'R)E1$5;&&$3&$>#A9(SLMIHS<[>\R[R\E*-,;DL*$:8L<?1!#ZM\
M:ZTL7,T1:X7H$D&[:>'7RXA:,FW;ED0SKSFYGME<P4'F.1H9.@2KFZ$<C="8
MC>+SD?[@..K<D?*2BED9S@51R>3\#SLL)>N+40'"(+*U868*$62Q460;$S@'
M(`OB)6;W"!Y17!$R&W>26.6DE])\E0LP`00@`2:VR'H#5RIA$GQI>5/4>6&)
M1'%S&_$B0B'=>6)T:Q4!0K$4$`<!?&G5#RW1&=4@&#6-10H\1,F!%#D='!!-
M$!U]0#9UT@`A&P!!_\=)I'91,IIS!CW34)Z)9`YD\S9);)C[0$^'R%E/X3'J
M?#0)TS18K37-%-%D[4T.,G_@@DM(\0CUU:%ZT11F/7E<%5,WY12\1C0T40SY
MRT@0$&NLX[]!D0EX>U-\K`QS1'TIDS);%")\'!>G0PK=HQ*G\BP8P2CW)0J2
MT-*&+<A$@F4D&F4480ZA;80X&@Q\7%!L<BJ+G2J^I(7_V#V&;3/6$&V;.`WV
MH`B_=]@R$42RRPPUD;\NJC#E%PI.EM>D<#J0`%*2D->^K3&GLG$N(;NYO=IU
M)-E)\0F=([OC8!'4G2IK9"_<L!L2$$0/H@B;MBAFK2_T<-:E$"$%7-;P[?^4
MSXUI;,)%8U88.'4,?8$KS3'?!N(3A;%CEK,FB;4K$/8`"'XTYJ"Y4LUKE"5@
MHI+`#X$KU)2:^)V]#Y`.=LT5T?$>"8X49;(B@,+3@%H1&I<0.P09KRH*,8-V
MP')?8D-O="PM.](I,5XPX/$>&+/0R!J`-C$(TD(*YC)!/C2<C1V`%FK'.H(?
M_&W'$";DB_+D9-+AY_<>'IZ>4$[@%F3'`\T1I,=/_D$(Q()3\^T(%/%\"4[E
MAQC?;"Z4Q:PWAG!CBR&WJ4;'@U8;F,%%B:4HMIQN!NYX.N715.9%I[$(<@'*
M0V)YO&!L,/87.M6K-B6#%V'HTG&"BQ!<D,0(4=;_'L+0TJUJ*(;V,D+!$7,R
M6H8>K=&JJ>R7'2W!XZE\0J::?F+F<M>:9-3G&JV>8G76%I[Z;BC8(7[.,I!"
MY)OV")?Q=7>N4'X1%#KE$@55R5/B,Q=YA^Y!.CM3<C7!QB^4KOW`)0RB.V]S
MBZ$L+QK11S.Q%M1.9DO)`%O%R?U0"00#%Q2A>3BZQYPPOK2S8K2C$W3L,<&T
M/J7UYQ$1'Z-!,0I%V(0^)JLB)C32%0AF>:^PMD-'\$A1Y:BMI1`!?)-PDPB4
MR97@-1\O'>($6":>8:[.>22A"\R`L['>,G)^+6*R=29S(1JJ[S:5#C7N[W[U
M&CG/$F`Q'G424KH^U%YK_[)ZI#`U;D$)354P%Q(2V&7ILA.Y#:=<O>3<$B\R
M^"5L#&Q;O0]AJSA3[,#MG`]]$!T<K0VW,(AG\52$,).FTX4*,U(QXT)63"\)
M4%1&J.F3.!9=KP]?3Y"NZ,G'LS^*3$'*<-^34-%*@Q3$?>^U43"8P0R;Q1,P
MU4@8X1&/_%)T'`P5PA(:SA4:GN'+,/1;Y12TEQ_D+>8KUBM7=5'>=CK/'F$'
M95-.QX"4$!;;T0N=`!(O1-$50@ZU`OR!(P%&/87T)AYE,AK/1[6!QV:E(B`.
M,5$E!P'0[QE\0NIJKF/B>/@G=%6:C_ES5"$MT69]D1\./O3G[T5A)+6V\?D@
MX?_@FH\@^Q""P[P@"[<D2+%PI4\-3@$("01_$W\(#0P'?`.'#`]_D)&2DY25
MEI(/$`D2#!`0#'P1!Q(-$I%]`XP/G!(#$X.7L;*R$YD$#`Y\?`0$K@P3![P0
M#0<1H0=]?YS&D!()$*L,$@[&Q9^SV-F0"'P."(43")V?QZ2FD*BJK*ZPVN[O
M\)4/`WQ_]?'X^?KY[99\!_L"0FJ`[9'`?`,6R*)W\-VB60P;2C38L)_$B^@<
M.$CV!Q6!!,8B#$"G*]A(`KLP8O.T(,)'7;H&#.K52Z8N>WP\XH2D2^0@F;T<
MH.2H<A8!!Q`ZHI,),M3(CB5[_4%IL:C52@Q<*KS*]6K_@E@#*':-M>#K+`1C
M+QUP,.M?VDD'T,I"`/"M.[D-S=K-!Z%/L00@91:C5Y=H`V\1%E0=NZ"/H`@X
M8\Z4F8K`@J00&A=#`.%>@C[$(B!PT*#7Y0?W]D+:J#`"8)^#W2H=B%BQ:JX(
M!M2]S;NW[]_`@PL??O$!P00-&B3@G.#!T4CMQ$%+P.!VL#\+ZBTH^[$Z`^J`
MJPME.R@3@ZU_((PTCV!!=3[0>@=#BUPY<^=L(47O](`Z\8#!\'$8/@<\A9TD
MZ&US0('Q)$@)@]A`F`UZ#A[$H`.[X4,7)1M"\E6%D<@FVR0;@OC?B2BF6%1N
MJ;3HX@!ZI?7BC#36Z&*,*N;8_YLW/.$3T1\Q6D3/C^XL%DF'$*6&33M&[D,7
MD3XJ"<F/,UW"S``B5<(0CCIVZ>678(8IYIA_#-!`6&=RR6%U!)V)$GF-!(.4
M7+LHULTA$-"9RB)OBB,4GMRH!\HB?!PBE$W>-)`G=:`,]`=!#+1WTR!\VD,-
M='Q$RFA[#"32`!\+`#KH(:!.J0L!`-G4VG?)_3&HJV=F&BNJA@Q##ZW%*#;G
M`@/J1Y"`"0W(P*PF]7E8DV0FJ^RRS#;;+#TPE3H+`S(]RM!,"SQ0(*5/#5F/
M9:GDMXBW4SGP"+@#Y'(2`@G0DRT"O7R[0+AY1E1=+P0EE0BWW4T%W1\/D(;`
M`Y<M:/\FD/.F2P"[R`%I:D37^ONK(.PJDMZXA"J(&I7^+I(O=&UZG)[%ZGU[
M[;O(.JNRL@CT41UEL`S@UVR7^/<6.Q_=Y3(Z-/>AD%0U5_?;`WT\$BU/+N6L
MC<W..M<`7M,ZD-"\WT[U4,?=9HS2IT]A?.U#6Q,ZT@"X0'O2UUS_=$_`Z=YK
M3[5\1JQ?F2D1UBEVL7)--EN\9@UQU3.5M+>J7J>&2,9S<VM,:N!RO;BJUWY]
MTLJ4KZP89#!/^8I2['4*`5(PLHH(P`0\XMPC0HGE8SN=9OL)IT=E%LGE/!/5
MAVB]L.=>[&6)7MTS]0`/<&=%E?8K3#S=P]D!FB"G*?&@:-+_P`1JCIE`/0<(
MC0VO\!8(^+L0</NPO/T9M,C&WS[P`+S9-O=0=26K;Q+YS46*&B3!9*\0I/"Z
M*I,XRH!.>QY@/P+:8SOI:9\!-:&0I-`-8O"36'NR-[+W%&Y\'.-64A@7C(UM
MD():NY;\4E:Y$G:I="+)7)D(``V_B(8TI>N4<R@C&@D\0!2NP6%+F!<0G%D-
M2Z/YE",DT#+HW'`DR;"=`QA@F1<*<14MHR$"6N&,S%2Q,<C)T$&^D8!P',T>
M2?L#-9+B&G-=\2B!(>&7%E`7*<6"@DE)@$*\@Q/_E`5_#2"8JW`B%^HXH"QS
M=)5[^'A']_1'(:#Z2"!U01=<H$=?_P"YGNDRY1^-$$0_V3%$-X#4*$H2TA'V
M^(Z'`#FESGRE.G["#BBS(T?`L)$8`T'-`6!YP.J4A3H485-[PO,(5LXR>W+<
M8R+W:,)B@@D9!)B`FZJUPE'H!"AFHTFU4/**HU3S>@20@!;AP<RI5&:%DID-
M,I6I%-LIPQ@_04FE/#)-F?&B,>]TC@TQLH!7^.R+-\&?SY2RH#Z\4RHZ<19G
M!&2B,/E1=2I18Y2LAPN$&O.A*2(-D":@0K@E@Q4SE$SF:`(?>,&G&*&`6CRZ
M*16,AI,C$NUB.4]1)E28=)T;)5LG&*6)6[0"([)#"C[5&:!P=*(7GA,$"[\C
MBI7I1F4'J/\>1(.3U*4Z544)J(MNEF,6=DW)0_2A2URH:M7EE"D2!F)$0*R*
MU;(NR*I/B>J4<O/5JP(IJW\XZU<80=6WVO6N:L6(6'.SH`7AKT4,4JM7[=H+
MLPQV6;Q(K$*?RMC&.O:QD(6L*$UXU,A:]K*8S:QF-SL<SI3.C9P-K6A'2]K2
MBC94]=">:5?+VM:JY`@5B*UL9YL!,F5@MKBMP!&2==O<RG:W2[U>H53KVN(:
M][C9P``2?%L!#%2`3,UE+A(PD*SH^G:Z3W6.)I#+W>YZ%Q(8J&TE8@O=YU8B
M`]0MKR70Z]2^??>]\&UM>"U!WC'5EQ+L5>]YT[O4M5PCO@`.<&;_YSM>\XKI
MOI/(KWT-G&#^0M2_Q!6PA"<,40)3`L%@PG`D%'Q@!DN"P\8DC4,I3.(2J\S"
MD]"PEU3\!Q!GV,,;=O!#LY-/$]OXQLE"L218K",6N_A+/I9Q,1<@M53@^,A(
M]I*.(\'C'`6YNC"&Q(]+R,8D6_G**%HR))JLHB?K%[]"-F$]$XOE,IOY-AAH
M0@;6S.8U+Q>Z2&ASFYL0YA7'6<YKIO.9]\QG"3L!`X`.M*"!*Z8C"/K0&'!"
ML@R-Z$`KVJE9^6.?)TWI2B.Y/ZE52;M@Y%6N`LDL!1H)B^3B5\"4J4`(8"O^
MYDH7P&1UTV5"RU-"'5<CE[5,1TW%7(^Z_QRV-I5%29UKJ$']%:\RHD4L6DXJ
M1,J(IAZ[K7X%:[=@%->OJ#JMNH9UN_32UZ_X-=1T-414ESVE2)KEJ&RMF+<-
M1E=J1X+6<66W(5)1EZB"&]BC!NM5=9UO77]5K+,^:E/5"MANX=JPL@92)-GE
M;EC3VT-SW4:N$\YO<EOZXO&81SU`&Q#%6$8JTNS$)7<1/BQE99:>.!/UPH$(
MI$1B%1VA,<AE\JF.$(0C)*=**:8H#87T@0\4_;G/0S'#/T0@$VS!TKA6WK)2
M$0`1\$*B(GZ.#%`IG1F1L&$H5HKSU)C<%$(O4R$NTQ37>%PQ-7]Z`XH*$[_<
MQ$S&J)9-4%(8,O\.HHM)D=F\AJ*(4_WCZ;<(T2V.#I.GMR+NHP`%W!<1]ZO?
M@R-)M'H$3A[V)-[<5S9$!A?!>";(0V4K`)T*9&B2'%$\O1X_/[K(E<('"=P$
M-.64?"@XCO':6R(KEBG*I,[6BV'0J5`>F>(-(6'ZQ,0U`MH\DD>82!EO`NUV
MR$A>T_\Q`5X=7RF@,.>Q1G(9R*P0.L;GB/7U@T2>S:9:!RA$)$#!"^>L="=3
MLB'8)4&]S#1`(=;?/?D?Q1:81.!3]R!WZ51C'9%#E/(+91(!/A$*`)A/IN%`
M.W$9T9)^S'1_8)5.4S((Z6=^292!4_09+`5]'!$[CZ`HE^1-L]&!T%'_?@20
M&-+$?\_'?[[7$9MQ"J*@@NBG?K:W@[XQ*1*03)0!+^$`1G$W`3_(3/&""@-Q
M@LWP*<DT%3](4=DT"#[3`#BG@#VQ.(_7$2V(3-7A3^$`-,8G=KF7$TAT"S46
M>BEX"\Q$%,-#"L2C@C7V=2T3>/P7AF-#*=_R@RAX$]'R?P'X$Z_P@Z&@-"R$
M")`Q#4='<Z71$P#H$H(@`105(O5@$UFX"*^@&&$EB.`""Y#'"TG$AD9(A8&7
M1+PR@J7!%LBP&P`%BEPH-*'71"]X*GP(AJF63%$T"`Q@BE;XBFW(@\#(&_HG
M30!Q4_E4+<!`/5WT#2F!$VL1"6N7?I/A?$^1_PP1T'7)`Q(@,1I)84X\DQE`
M`S3,Q(Q4."6B@!:'`1(<F(&/HAX&40R?,HERZ'4+XPQN>$.FX'*?LQ/A""/4
M$QF@\G/L*(!S:$TM4W5LB"K^I`N-@3S>)%'2-PW1DD8\D2>RAH'?IRCKR!'(
M&'VU8W0CF!`.Y(9JJ(*TH8[XPDY=)`C5F$#%*#.$4'[6B(.#H)'!>).24%DJ
M@4"B]!W?,1Z0@$"<Y#_U(4?UL%W;D4F0X'[GX2JG1!V\(`C?AQU;@4`+PQ[^
MHA^\X"]$QD3=85B\<!Y'*53EX0F&H"AF`0N))52%<B:1D!E2Z2^)=79`P@OD
ML968M!K/096N$I5,E/]'09F4C[(5_E&8Y_%.G.0?0%4FRB$>Y[$_V_%.W]$P
M0<E"?".8-!%X0A$\OQ.6;"D7:CD5?ND_9%8ES/27:2D)HA2:9':6V_4=\`*5
M@.F54DED0/D3I>$VTQ25O%`H.(F3GG4_9+(^D550OWF<R!DFJ$5,R=F<SOF<
M72)<``2=U%F=UND;VJ54)Z((V@(3"V(NVT!DW(`=\S`V(W$]NQ:4W0`0-(83
M#G(`;!03//$5V`.>IL('NP8M"R*?:T$U):$0:V$^]!F4<:$11\)*X<*>1KEQ
M`_INWGD/&Q=7?&`0V>$-^@DD^"E&NO$/A9(04X)(!4(P\-E&DJ`N=.,6&(+_
M'5$%GM#"H1B3H<D#H.#9=]-&8_[I/1+*GK[I5I*@:J82E+W4=Z$"5MLD'/5&
M%QO"","V;$BZ<,#F;=Z&I#Y::SH)%_ASI9)0%T7Z;I6PI7?AI=?Y;BT")K6P
M/C(#(T<'=8GQ"*C@11LWH52$&O=P%/4D"%+3$3*1'QDX`*U0&%18#,8A-`*R
M"KF@"_='47W*I_.P%JT@&&GZA>7H39VQ%=]09+I`/,!P%&=(,_.&"D6T4F6J
M'Z3Q*8>Z"HJZ`)QP+ZC:+:(Q`4MT*#%X"EAR/6>"%IB*)8'*J*G0IX,Z#4L1
M58^JJ*Y11\E!JXR0$P&#"DBA+<W@AI#P">=P3B>!_X>H`'3J"0S;^33>)!+=
M4!JSU`O&4#)#`@':5!K_PT+TP#6?H#UKD:)=&J'V,`D0Z@_Q^B!20GM38B#V
M`*9A.@"=08`Z(@$04!ABA$JNJCVW8S1G\BGQD0D..!+L=Z<>(1:4T:?HT`M]
ML$2&H'XWX1PP<7]4I!OQ,9!'8;!<")/>)`U/H;$PPI"]8`J:>K+.FH*IT($"
M6Q=!T1D@V[!)(0&B429\**N`QY*Q2A)$!"QHH8G38+)RQZOUX'YXF@`:^PV*
MFGQ^N'&UN@N[T`H/4'W*5PG?L`T3D"FBN0LH>U-`RZ_6D9:NH"[J03?*D`G>
ML@AS93*$,GO0XDKYBAKF,_\ON0!4Y@(J@8L:X@`+2Z0("8$JB)`];)(=I;,=
M:!$4B1"O$UJYH**MDMMW<54VF<(6>MJ</"(FA^!]R3"U8XNP9JFU*,&S#^LJ
M0E%SJ9<A-'0U'I&Q)KL3#GLJGZ!T,D$1`FBZ>$H`(6D/V*JQC0A\DP*[,C&S
MD*<+'3BZ^B&PV/0)/&MTV!JWDO!/A?""G.H1CNL6TP>\<A=W'3N2@FNP7Y<\
M.Z&U^B,,;'%#Z#&SCW(/+;%V4X&/9VL6K:>=P($OQB!'IL`0DT<M=TMMD7.W
M:P<CHR-M\)HM!..'Z_NF>X(_4H,Q;S,N#'$3!DJY\3H/]S,N3S<2$3J'U$(/
M'OS_G)FB3OCZ']FB?LD`J(N[IAU!M5=KJEIW)G+B`)DJ-45T&`.[I_V0#,(+
MPX*:1[4P@8@*(ZLP#]_GJ(&J%,)+?O,PK.E'9.J4'HY1+HP@Q$*,%YZW4BV\
M?\Y8"W%J)Y<$-)#P"]^0%#3!P^FP%)8!+'71%\#ZQ$W;LD9L$!Q!Q-4RK%=K
M#S@,KH6:"OO(,Y3Y*&B[NWZ1A&=:"OGZ.1.:(O'2&="@-G()/'_4>G"+*I.*
MB7SJKQT2+F(4E&2CN6]J*6*$GP9D#QJG<6_CP!9S$T)9#]Z@$/`R&AI*#UY%
MRY*2KR5<-<^9$"UBG"SLKO<0H!3<?V62,+B&H76["-E1_V4T9C%A$;HCFB#8
M4Y^^VPWY*<+"I1"2%%<`*J/F(Z$$JLOOE@L.1[\ED<V'7*_SJAWN6F7-7"CH
M*4;+X9OT["':P7WPV<[YI`N/8#8_&E?V"9\2:G7<'"+I_`@(?4=&%M$QP49L
M1&^1S-"2ECSWD**`!!`N2IP8JA#]D2(5W2Z(6VL'PC<\,J/<!S!)=P#:0A@0
M<E8[FE0#[7!CPPULM<&;UAPP72`+HC[_UM,>`B-Z*FJ%TA[I<E52VU;D:3"C
M',PJ#(%A"B`B56+\"YV?JQ+NYIR(^W!5'=9B/=9D7=:FI:_O@!X+4B%`+9]@
MX=3O-M*FI@TF`M5F?==X73D!`_\D28<A21<6^<PNGQLPS:'3Z?*TD=$?.@TD
MW3EORR'4#M`NWE`3^`S3,9TJU(+/`[T:4274EU%N+8(AMA'9>?T@8UK:J(TB
MOPR?WK$GA7(G&C'2:1P6B\`-K^V;>\(-WO"Y7/.?D,M(?AB?M)V3J!&?^1-O
MU((:]<,3X=*A[C*>J5TF_[K"T5W=;V'!?NC:@,PG(X(QF+9QD8)K6'LU/0(P
M"2.DIYS=1*+=]:"M_[PG$UPFYI))KBTMJ1VZ)52XMW#5UCUIXY(=L<S>[I&N
MJN;=[K%QN"Q<M:2OGQ(P&)(I]##(%:P(":,D9O+@1/:,BG`F]'`(K$,UN%8R
M6YW7'@O_L&+B`#_(?KQPC<CWC_V-#5(K((HU*'>T9VAM%=3]XE8!;C<>)@DQ
M`:#P"WTPY/YT._RMX^M'+4<NM=N%Y$Z.$8?9FLER*Y4`B@+YY).PU$L)$]DA
M5H:P6*;55^_0XW'A(0MQYG"=YEF:#3VN);&@%UF-Y;>!354NO+<CYSDI51C<
M(B<X(D#R(MU,;1)2U"XR;_X&<40:"5*[SUTM<"]RY&,Q2V$!$-'65''1:@XS
MN>RRZ>"<:K.V<%\5292^;A@ZG^(6KR,1%WYU")N^#5&::O0):F7>:WVU(9;N
MI.OS%2.&Y[Y1<Y1@Y3,CKR*LIXO0=Q-(8\AC[*""%MR)/VX1_RV@HNPE864&
M0M[_PA,98N=$3H5$[D_VX*S:/N0M1>3_B)=0\>5]X+,[TQ'!+I`YT>UM'NEG
MLD2C(334HBYDLS?`LQ:@4BB1+6GYL42++C4;8QS\US;9<DEY1&0<*C7JLM>'
M\,`\(=SZF8X7G!"+L$30<O`:7]S<P$;,RNN_@1R\0`IU3N0W+I!#7HWXR0L3
M<$W)I%@M]8/"&\!],(1G6H")]1TN?TU6)@CDZAI4T1AF\@K#L$TY3Q+R"NY"
MHH3P*)JGL'%*^.U(Y.WGGA/#X36M0KG8#=\R43;V(`[P:AQB3QWMN7'I6G/Q
M?`L*/J'9LA40K$K7$]_CPO5OD\%H+_\@#:@=WV%K#0+MT8+L@-_O@\^0A6_X
MA2_X@*_XT,[X@7_XCL_EAT_X.0X/R$XF$D#D+G'R0UXA*G_GYZZ5T-'T3T$T
M-0M[.7_EDV#N91;>?JL(:.'G63[UH1\B3#_[3[&5V=0B`AD!5$U.1<ZF4C\<
M'-[P/:(+%7SWG>$G3!S9`A+5PY*NY@(*V?(>&/]'!O\HZH,+'Y\0XI`M::P^
M^>$(N5#!'&ID:,\V>/_*W?#VH4+^(1^F1';:8M+M$Y!"0:+M;J3RTP,(?']]
M@G]_!`2&AQ(#C0E_`WT#AGQ]!Y$,DI&3?0V-`P>*B(JDI::GJ*FJJZRMKJ^P
MJ`>%!'P3E9/_"`RIFXI]O[^"E:4$P'V)D0U\F0N'QH2#A8:CA`T1"-"5QK'<
MK`D("*$'H7_BX>'EX`FA"-\(?\WK",WI[:$#X0</#O7CD.0''K4K!\G0`7`&
MV[W[@R#7P8$/"89RA\[?0W_N'C3\PZ^;QX\@0XH<V6T!.9(H7Q7[56S"LU\1
M@-$C!8V0K0/0IB6:9@S9,T&;"#"2-,B8M%$IDRI="I+!P@4#'`S@0XXJJEZ&
M.GT*-8R4T$^/(DE`U!%IM$&[%(V-AN!6-DV-F,I5==#0HU4('"R<R_3N'[]\
M`PL>/'+!!$0["9-T`"RF2Y81)$AX3+1434$1(.0\E-BLH4A2!TB(_P!)$D[-
MG*1Y3:RXM6M7LT398DP.08.KE<^2ZBJ*=>E)JWT)@D#:8!]^T!B_?<V\N?/G
MT*.3!"6=6]O&DU<^BPDXJR!HD3:;]?R;4I_RVE*?(E^]/=.XJWPKPCJH%I_[
M?RK=QT\@PGZJ].DD7&D$/+!`!!.\DY,$;_T''',/&@)5A"D!IUI^$I:20`(7
M*N(/)1FZ)^*([B$``1\-S$1B*HP)]<MAB!'PF$NG7&:(9D=U!B,B"6`U3"\(
MQ,1)!#'VMN*1(\&GBGQV$>!7C*,L`.4?#$"YH9.E,)#6(?0,`,$$$31`#@%=
MD@D/E"JZML":#T!"P%1Z\=$F`G(FP(!&<O_2^8"=$]UI)X<&PM,,'XDXX,`L
MMQU`P`&&4K*,`QLRT.>>#MS&@`,/+(KDIISR91*(G9HBE&22_3)6`Q#(2``$
MI_`QB:L&P2KA3`O\1]4LY'`XCE606&6K-&N&*FPK''YB[+$2F/+KLLPVZ^RS
MT/[J''Z%N`KG`+L4VP@?[5S:D*M`3=5(G";5NFT"E0I#20(/[`G)5/F!^VY4
M\`K3X;#XYNN-(`=L.>P#HY'*8&,S=A=OM`@G#"V%^@[+[@/.GM1P=-12LJVK
M;>KC253LXH=M7...R]$!8EKKJ@.U8IA?CP.$52\#(&];;[P3UVPS*9DVL->P
M*"?0`(-$]O<,DS?_%VWTT4P%2P\#&YHD)T,,N-J`1@YP*R>V]TR]H9X8-L/`
M;7P<&K4AAS9:#LKP8/W7AG:RVLP"AS*,]-SMK6-LO@DX!L'`QHPEU,YT!R[X
MX"EMN(KAA#&0)N&,0P?5?_EJT\<$\/`-C,Z-9Z[YYIQW[CDL)']R&[YY$>")
MAQ#G^?GJK),()S>+-SX+M]2=8G#K$P]@W].X]^[[[R.%[<E!WZQ=CCE_3>/Y
M`,I`%9`Z#!V4K#O$`^^P]=AGK[TJ*$JP@`3W)2+!U!!`\``$4R_`*M&$BWN?
M[@[4\KTGWA,JFI;W;M_>QTKJ[S_AB/N,7QHB,0_APR#`N<16-'07EC5B_R$!
M,2#@JA.V2[PO$;N3&A]\AL'E@<M5B8B`XG92"]U-!0$%^I_K(*?"%LZM`3`!
MQ\"R]9@VE4)(\#`5G8Q""AAVPAG`R,5:<CBY`DH'5E.I50C-5[X'6,,!53K$
M\E8E+@R&30(0R)L2X<0`5KG0/3F;X!?'B*\$]$$CQW%`@N"5*D&5@@\XG,`"
ML$&K"9S$C/JPA")^EA^6&.(6^9$;=.J"CN)IRB+O6$?R.M>0251O((7\"S@F
M0L;J<*@<_FK%`Z+FE%/4RC_YJZ0H1=*6J?4A`7MK0`,>,8'R==)#$7A`9>8Q
M2SF:HE\)^HP>!63&*G4D5+<;I3`=5Q70>1%B#/]90'=VDH`Y#O.9'T%A9":0
M@&(P8#*#N$4K9^<EJ50F`9.Y"P.*4ZM"'$@""QE?<,22B5^ZYR!UL5WK+A',
M;M03FDHQ$8IBQR(*06`6-E0>Q`[@17P:M!6,><>I?#(`__2QFF0Z!H,D@*L_
M8/&/':G2FP2!#7Z8$3"CP,DDV'-$90B2?9E#$99&@M*#HH1.@DP%K+9("Z](
M,9`NS2DJ9(FI6QC&B93[F6@*^B[&'*H3#P!D)+JS@#02Q1;$V$F8DNK.]L`1
MA!\T737-ITK=A9)N8<MB5]&'2@@@8'PH8AX!%,<\^L72&CJ5BZ)05-558*M)
M)"O'Z)0GIC_T-:Z`I83_2S"7B5@RI!@K)44O#M2)=S#F%`R8`"#_T,;@_"4F
MF!L1BB+@U2J"<"IA(A3G5'J`T"XJ=9W=Z$8W.Y42MC2PW=`+J%X1M:K=IE:O
M5)XN^,!/V/I6A:Z:0&>QJKLM2FFT51S`]U"FI6I^UGYA<V)KY92LWT['$]*]
MIW6WRUU0/$`?<3N`\];4$+WT-G"@:%E4&O*VMX'"),J]1%[2.T>S<1<D4_G/
M>9'6$#'BU[^GJ!T#[TO@K)RGA9%X;8%'&2"1F!$6F['L@K?["Q<F>,(BHHXB
M-Z3AB?1H(AY6Q-82B(\&`J='[U#O74`Q8D/T]Q\&6;$F)M@RQ=Y%O@<\($?^
M_XF/'+^COSJ&1H\^@T(%8WB8!ZSP0%R17]YF+BS'6.214Y+(6%PTRB*\<@BO
MR2HL;ZD_+HG`+/HP%A3"9$,3B!HUB5.::B*H#V+N!33Z$X$X3ZZ(BCBK#O/&
MDAU.E$%VM&BMR$QF0%\"SG@F1%--XA@B33FP?$#G+\[ZU3>"<K][I!PJ#JRA
M3&:&9J1@VGR,K!*H'",!FGYTDG@+@4RN`H[@M*,D8#T9D=):U@_J#SC27(E'
MW*3(1'R;)<9YB&NT!69$(40O.=2CXV!#&K9H1X$0$8Y;5`(!/'TV3L:,;6<3
M`C3/KD\?O):@()%:U6.LQ,`85.G=),;,!*#3:$PQOO]QH`\JM9#BJA:0*4.E
M^K")B+19476`"1BJ0']*E79=40P8OAG=(]&+6=M-"C,NPS^4L_@XH:IQC%L6
M$5U!RC"PT8<?&UP"NT`*(N0LB,C"^=#J$="`./.C9/,V635/#<N+,F<2GAOB
M+93E,P+*"LEABU6MM@71&7*+U-U'F>>)NI0@4#7=X2Q5="*4`V)I0CF]Z4TH
MIS@K,M$WH(>$H##;JRLFX#UK>)'M"W#[']O^Z?[JNBWW.7!D#S**!DAV=`TH
M1BCN?@LS[DG9W++XSD%A#6F+)MX%SWMY"$'U/D[>539'B]]Q"0Y'F_V@294)
M+$1[(V&<2#X#8'O4]N/$J`__0G=GA1EKX!C+\"DW`M6<2JI,:!^2^)#,`/[\
M*XS("ABB:]R&,#YCZ*%\Y`?ES13MBIGAW.Q!3T*6U04SF4,Q44*<-3(4W3DA
M2NM'/A]CAY<_I>59+GYN34!,C?ZY\/V':N2//C%)53KI=P-"!Y1/ZZXG":NB
M1J+A%4WV,_,3/SSU=5XE=JT`0^@T?]TP0H@1"Y?`$#IV@2]6#KEP0'87;R16
M<2?6@7=Q'#JQ$2[68[ER%R]&';538_-Q8QV88D/&@1B88@>18_<P$<!18@LG
M@2[$+MR@7(J%1(OS*59S(N@R*/DA7K.`#^[$+U#1*'#32.U2+N+5/R(A6T"(
M+R1%_RP,,B;RUX5D*"R/1WQE2#>*4H'1A"I+1PKQ1`K!T@T`10YSN`J[X&H0
MITR&H(?=@`ZMP(<:8H&`XX=_@6EIF(A'%'RJH&-^-5)H*"L5XH#*\X,3)BMC
M&&!B)XFB$`N<>%.:J(BBN"+*!3-:B(=DUHG_$#:"L`#-93HN=EM[T@"*(T76
MLBJSXE?S\#4<I`]C$XO+P"6GTT$1H#[O0(N6.#@<LD&?\1]HN(4!A8GY,3:;
M)`T<PC3%E3ZZF'R+XHJK9(LM\S6($C;S48RV$8S+0(Y01`^*<AOK*$75>`A5
MTQ`$4"E_08O-4(QFY5>B-HK^&!C2\@J:D6JLT0P81$"2R/\J.M-7'60M6V(;
ME"5%H2,(8&.'S2`FR"`('11P`]`N?M4ZZL9N?80("/*,'Z$<=R&-R7*13?@9
M%@0O\78;!063>@6..M-,3\,:B1`L)3-2NO"1%O.3MY$(%1EO!G)71#EXX.B1
M:O>/3ID4H=,(38D7S*@\Z0`QI`%.PO`@W#*4RL.1\*((_Y1RTP`O_O&-.`5"
MO:)OX(@BP;@Z.-$1M"%]$482LA1H."5%W],F9\F";DF3DB(--,F6:FDQ^N8D
M'!E(L/)U?%!0M]B84M27&4F3)-26RF"(3YF9'M&`O.,1^Y@B9/D(AB*)Z,(/
M^]B0V\)_(\40$,!&,,81;<(T&<G_EAPI%?#`.@GE8L>!"U&1&X5S$IB(#EG$
M*K5C5NXC18;B%S1I(N#(*B\)BL@9F\5R")<T$ZY2G5)$G(H""8^3G>^`FK:)
MB)HYGHJA/EU$4`"#GIY`CFKQ"$X$18>0*:DY']5U*5/#/+IP/A`T;5)$F>!(
M,LDIGG/#&]$@.7U`5')5"^:#0K!W)_OH5Q"SGE($3HJE,_;9)M/6D<VUF%ZQ
M#OS)H5RE".08HHG@H"CD?Q8$CPT`GQP)H)`BH.09HW+%@OD`"3\6(7L%B/DP
M28.8$$0F92)F%]&3/(_P"(3$#B8Y.++40&?4%8R1C"!!0"D8I'!HHY0$E//Q
M#O&TH^G0_Z6`$4&+5!<-1`HH.*:+%&\_=J6`:*1I.J0R^J:O\"`QM13L"721
MT2[SUA4--B+],J?1@9EP&J@B<2"(@:"P,`\NYCPKDB8PRC@$]0O_9'E_<4:!
M081$.'R^!IS$MQ])"A*\\@J?*JBBV@U^^@K5!3$"QASLDR:9"&D!=VZBE1NA
MZ@NH4EU+X9NM@*O8LP49T*N^^JL9L`J\"JS`N@I80*R_2@2C*A=Y@9ZPT%1[
M)6I,HTRZP`^)YS6*H#CQ`)E5HQ&[$!7\H"0I@BGAN4$--2B)!YF[4"N/$'!5
M66"*1`FOFA^F8QL/@)^!%U`(8D8$1YUAY`N-<$KUR"'U6EM?<_^O>Y4IPE"O
MWD@EF0`<#4LH@I`I6>2PDG"?4]D[&9`%&-"Q'NNQ(+`*&_NQ)!NRJE`!3T"R
M'EL%&+"L3"$V8<EP%68(^P".A](N4H$?!=6-]\HJR!1O:V)6K"(I:I$?!ME,
M;-E,NN`ETX"T&`0O@`I8=UD5AT$D9B0:C7D?5"<!6[='DA9IWP$:7$NK*T=F
MD?``7`<FS*.UBF!PXR8)X%,)3G)&E2&W5VL)!A=XAG>Q;(L]&="RJ&"RJ?"W
MJ2"XJ%`!%8`*A*L4#M2I_F@@)0H+U:0B`Q=(M:`,R[A!OS296XE3Q4@E6`J.
M$RI:`:<,&U6)I(M"W+)@*$D)C!!X?Q'_66$S@+;`("*:"`(8MI%%=)V@%Y%0
M&H<@")+!$0,(L"4FNZ+UNW7K$\6`#]?T)E$7%<5K,WP6M:ZPN*=@N*>`O::@
MO::`N(H+N$G1'XC0J(FH3/P6$MJHENC0/)#2B?32N:ZB*+O0+OZ2F`6BD:+;
M([3PLS>5*1.&*;=+KVWA7'G#")&&3/+Z>OFF"3\%L+H$O+70%@F":A+@%[.&
M:LZ5O-&[P)M`%?5H/]%KP5"Z(JV&#9=@OJ7`O:7@O2LLOMV["N"[O3",$OD6
MBRFT>IG99)1X"O'S#B<3%5[C*K9Z"-C"OW]A5LDB)GW%"#:UF)BRG8G`;!(J
MC]^%056XDU,F_UJ$8G&`5&%H"U>4(&:Y^WKO][E9T8/G\6RU)QF"(%FD$"9T
M:POA4PY]\+`+''EX^S.+<L=$`<?4:3.1L(LAP<*DX,*D8,B*@,B*,,.FH,@B
M0;Z)@#Y)54VV])0*=#YGUQ'4`14"=)NB$!<7^!>'@FT,T28(V@R=/`_HH@^J
MW`RC/$?*="AO<RB@C&&66LOWZD9_,%!Y1A54X<FWXF0B"A"%D$0<(3+E`X=/
M`S?W>JGMPBN7.IWBT@S1'`K+W)(38QBE>KTU?,@B^\V++,.)2\-+83IQ012U
M<,/D:;WC&Z?N[+*N@6HJ[!'T7#1)!17L5<CB;`B,;`B0_`?__`>._/_"YRP-
ME$Q-[.R44H((\?P:W4R>^<6HM^P*XME;$!'1L"$W'FF#2>*X2J%13N**_%RX
MX6S2)UO.C]S/(5&+.!R;]2S/,LT480.#G6ADE1F(K!"SJ]8J(8@*GX@*R`#2
M2!+0`VW4Y!R^,XT2%(@8=;74S1&O>9EU[3JZW+++NV#+YVI1\%FM_/<(NS"N
M^S`)VKJ6F^07EZ),=\(0]P$.]P'6/9..\?(.$-.:=J'6<!.[AP*+O)@MS5`U
MS<19U/K6?D72N\6(T8'4JJ#8J5#0B<S24!T2&AW9<C&UE&!2,(-"M-D03*.6
M.VL(I'$R^F!#4"M%.&>0AR!>]]IR6(HE>:C_"^"5V1A4U>PZ1TZAD#WH*F2Y
MD]-Y#?TI)W.T/H$DVQ:EF"T3TX21`2"PW,S=W$?MW-`MP]#=W)!-V=:=+ZV;
M'U*QG;1Y4Y/<,WM5F5BE#"XVP82YFISK5<5Q4_[Q=:K80;_MEJ<K*\>YDV^"
M4Y697[EFN5\92."$W-<=X.0IP(;IW=TM1<K`*)NK/.PK,0",FFP9O_#R),K#
M=]%3F?G]/G]1+[D]F"2#J@:NW\G#D1B.4WGQT`*.3[;!ABD.';*2G,(]R:7)
M$;?AQ%99FT(L(7JQD?AMQ-@X')IME3KS3^2Z#Y`BW'[5+QNT03*I*!VNO_&&
M,AQ*6;OU)V1Y,D=N_Y,;(B:3W>+"]+Y>+AT"9B#O\#;)9$/Z4-&!HLJAX,F*
M`#=M?IN=;,2.Y$A<",K-*B'`0>9X/B'<:1#\!A#I=9L`]1>M:!"0,@F7&AJA
MP.=LGA=S-,IA'E@=.>G8TZJ6GNEGPN*:WNF>WD(E_.FB/NK+8XI=3NJHGNIS
MP\.JWNJNGCFL_NJR/NM'D\F&*JI00`3*2NN\;CTH[I1:0`+"3@5ET.N*000J
M2[*K@.S)[K&K<`3-WK%.\.H-O58RFC<G$B%Q(.S<3@*[;NR!D0%5@*R]>M3C
M3NX#70%(0.Y-4-V=+J<R"D6KERH,<`+=SNU?`.ZH4(4DP=A*';A);<XAC?\8
M`"Y\A(H(M^Z4&4D/J!8`<E``5M#M4*#OI>``6(3ICXW2@\O2Z:[2!JT4Z$P=
MH[P.1#U_IUZ&09YGED-F:5`'5A`%(L8C.F&=9M*'ZXKQ@0H5246O)0WPB\WQ
M`;_2Y[PQ\,!VZ$2^FBDE@CB>^Y`I<"8T1A%X?0`&3#`?O\`/.)$3)&>KHT"@
M80Y.B0"F'^'O`I^]0?_QXQLT?V!8WH.+F8F3$-G.]2=98/)FO]`,$\`%)%#U
MNH2+4I(3T+I+7<]I8>[)NMH-9"_T/M_8'I_Q("\-;"\E/6SPL?'4_XB[,%%G
M=%]$J.8%>V_UD<6/.=$?O20@7M_B236\^^<1B8__]C&<TO\^OL!B]*JKF2:R
M5K\N@8$7$Y-#]Y+U(L4P!9^O2[)46K+$+W>\]L4Q^)H^RF+/^D#_\QI_N(VO
M"`$-$E+MT=G_CV$1ZEV(`',@!F3P(F#R#'I/`L6N2PV54,E!9C*B?LQ/\67_
M^AL__:?@V-;O[IK./R</"'^"@X2%AH>(B8J+C(V.CY"1@U(D4UXO?9F:?6PD
M)%"#`WT##1$1?WU\?Z9\K7T-?P0$?WQ]DK>XN;J[O+V^OX093Q7$Q<4@B\+&
MR\B*%1C+Q4@8P-76U]C9U0.MK=K?X.'989Z>!1P3FU8D4H2B`PZOJ'P)?0R#
M$A.QL[6;XO\``PKLA27:_[)%!0T62Z:0V)&!$"-*G$BQHL5<4<IYHB*&3)\S
MGI@,0O"`SX.2"[@M6&!R@$L')ATX&,"R&Y\#%W/JW,FSI\^?0(,*#9I1HZ<I
M8-B-&>FRJ=.G4*/B'$JUJM6K6+-JW<IU$9$O1C>&Z4JVK-FS:-/NZT-`PBFU
M<'$1T=+%4Q<F2^/JW<NWKU]?*07=^TNXL.'#B!/W?;#@SP%8BB-+GDRYLN5P
M?`@TF'JYL^?/H$,KKJE*M.G3J%.K_KE@ILO5L&/+GDU[UP+.M1,=X(-`T$Q$
MC1<%SW5@0*'BV+CQ,9X<=^[GT`LOF"!K5G1W$1[\02"AM"'KBH;CXE:(?"CO
MN__XS&S`W-KRZ_#C]^T-_4""4`WN/6"@BN5]!@TD,`L#]`F"`'^]Z<<'`PFT
M]IX@"<CTAX/&);"@=Q8B"!,"#1!PP($.#*(*`B'"I-T"__T!X'VT&*>2`_>8
M&.$?,AGG0($P)4`B;RH&6!($[<DGY)!:(0"!+!#4EXYV?W"3)`,E-1C+*KT1
MX(!X+4I)`(>Q<*,=>/<L9]*4L[`T2)E\H,@->0X<<)(@#9"T0$FQ(/#>+!$4
MJ-X`0*KW!YU;LK?9/4D*PIB1:JJ2IY%_L$?DHY!2=5N<@Y5E(3V"[-9-D-;4
MTT>(3?(1)WNJ6#B+=:88DH`$P1%`GIC&@8?``J[>.:7_>;>J\D`#8L8B:FD/
M#$#@>["22<BO]Q%KW'(']($3@94^^">ON;88Z;78[H0BM&;5(H$$J339AP1M
M]<$D-@^`&FIK#'BIRJF"1+"2(23>4VN+M@H"P6YK&HOK+-RTN^:[VTUE)RS*
MV@J>M8(HV^(#$F@'Y;GO)2`PP:]RFNW&'`/$H8#H;=4LJ/$4-XH@Y/[#S0$$
M!*O>`RQ/:>QM<":0`"RS["M!O^#-0FJLC1[`WR"#\@'!K+W.=.4@0R=PM`0T
MG@2OB.U5_+2_4`]BL<5'FVG=OJX.X%S'9)=M6CST(?"I*#,],$'(VB#'6W&S
M1GA`<(T-8"%S)"[06V-W,RCV_X1:IY023HW-^IJ!*8F-(F\W31@DIG_8O5V;
MC8DWN"";VVUSY?<5&@K@CQ/NV)S%C6WVZJQ35@LAJ8BB29X_G7N(JZ*+<W,V
MLV+9^N_`J_9`'RS6$^S)]:A[%0(:@Z,C[RP&+_WTP+!<G5D11`SQ*>\($B[U
MX`_IQ_CDEV_^^>BGK_[Z[)=_'8]H'0!!)ON*R]P$E8+#_.8`%3=`@=;XD(%4
MIS6+((`ST0N?7MK'P`8Z\('7$593A#0``A@-2RC2QJ\\A(T'24E5C5G8+3ZX
M"Q**4(%J>:`*5\C""-J$@J6QSN$T0SBQN:E-C&D/D[1CN<%ECF;66A--_N2W
M!+B(9O__&UUO&..8=)VN79DRSIR&TR&61:@W![C1(%+"HBS>AT3&J6(6<:(X
MXV01@*@S%.!<](`3HA`MZ-/$"SS@!PYH@@,C\,,(2M""%UA@?'*DHQ\L\((6
ME""/'5!!'^9(O@#TP03CX\`?Q[?'%K3@`^B#3QOC!!WN3(!%Y+'0A-*UMRDM
MIX(N21)XD@0/IW''6GAZ`'V(Q1(&R<1I?]@7!$0I.@O=S`$GF8FK8L$RYI`G
M3PSBW+N"&;1*U>H^$C"2TX1F1(+Y3'ZJ&!0A)L`H8*:+&S<[@#[>&)<X4F"0
M+:CC'T?P@A#X(0`J&($)7H#)/IS3`NG\P`M,,`(5!,`/*HC_)P4>Z0<3+-*=
MZB1?"/8Y3T&Z+SJB%!IT9%>:`42``!$P#I!@8JM3JH(\X$G)31(&M(7Q@5PA
MRA?`,MJHEC:L0MOA#WDRIDQ3&A-C]&!/UG(UTPOUQCP6S=7-!B`!3=DTIF+*
M%SE3>#Y[^D$$Z93D^`(0@@X0U`\>2*=3H>J'%@C2H!TH`54[0+X/!,"LD9PD
M5EM@@7-F,CI`A-ML&'"TFB+@5"[AETU[*C/'.`!AR^)97QD&2T',(@&?5-$0
M7RH(EI2$KP\"*<,DNR;VM`=@O2(/K:K)H0KRU++[LZECDPJTI3+5?'T(``<N
M6<<7<"``+1C!0,DWV]2NMIYN]8,]_RNYR#S24P0$E2KY"-F'%N26?-<QDJA\
M-]$8JNB&MK+L1PDF(@75B5E38RQCVW777,KO3W55(X=F\=@1P<)1H3IJ>C'+
MI9[=[7_\V,^?9M(KJ"5I0S@CQ"GR6UXFOH5(FPBP@`=,X`(;^,`(3K""!QS'
M$%"`K'4L`04HT$Z#NI60NG4PA/TXOH&:H`.0[(`?K:K:/KA3N`4EJPE4P(&F
M+OC%,(ZQC&<L5T;P+SX?))"=;B1?F=!#2E+*'Y1\,R:AR3=_&6SL%UMAL\SI
M:*<-NPD\=O7!DB2S<HVY1Y(?(U$I/?9,9OJ3G_8SM\VD:3D9TI6T_M`=[4PY
M0(U1#V0`#/\:<Y9/N%(5JPBR2D>GDH_/(@A`"089@#T;UZP3]F>$)]P!"G@U
MT&I%[F>\\0@&T.IZ*,Q?`)47$#<R`G())(2G-V:+SZ"/`Q`>WP<$^0&$>D`%
M$HYDJCM<`A4X-`0!%8$?2H!0"N#Q`QP(-B9%4`(.(-1\H*'T(]K3O.`%!AMG
MC$BH':%71$R[8Z7V#`NWS>WU);O&P+DHDEJ'JVUXQ].C-NU.LMV9;KO[W7[X
M=B3:`T#X'!!"]RZ>8WY:FN(!,('/@Y``]5VY>R.@N_O.U&#5_1-V7P;>$&_A
MI,&-"".-6SY&`N8J'@"VRBV'`0PHSDU:=JJ_XJ0!88Z%R5<1<I+_4S.7*X/`
M=)H$<C?Q)]T,OXC#+1/QGCM0WI"8U(&$%!A5XBM"I&@2?37.(("U216B<_J4
M+#;?5HI)XSY3>EUQGO.*[%S@AN!/*X2EB!1!PH.\PI2F#W'O7_C\[>P#^B.V
M-73Y_"J$6?JKKSRJ+,Q64-F8K19Y&N"`:BIL[-;A>M<G\O55:6QAUCGX('!R
M@*)V,5/,*X3D*S\5\^SK/E]T#"$0Q\FIA+[9B\^%LAWQ,0L276)';<!Y$=`@
ME31F,ULZB42=29(O.086\Y+]NK0#M3@U*$X(3SU/&H]>43N?)3(Q$L<Y/Z`%
M!,AH'-]B*VY3U)K.]U0W:0#'F6=I2V\&_^5QLJ#\*E@WY:>'XH>XMKU!#K3W
MH+QR-><&AQ:D<DZV0EU6PDG6P1^<!".APB$.<`H6$W*_E%WN9Q%?1UAGT@TQ
MLS,5I'$?<BI4IURE)3/9!529,24P`0\.4%?5I''I,@LLTR8/R`NKUP@2M#C3
MDVZ*UX);$8%K9EC.9X$C6'`:>`\<V%>)UU?F(4RFU#:>U23<@((.,`NT!S$$
M9(.-\((V]D+4PUQ;)(5Q@8,NPAEA(S8#<B6XUT;$5'W7UX$U@7><PQ[69RS%
MM$N[`B/AA'[==5=\PCQ1J(6(0(6,L!M8J(>`.!01*$`"!"%-81\&$CU=A(BB
MEW`))'F5PQ2=$_^)^#9`E6AZH8!Y@>@(?*@(CT$3\+>)HI@3$3B*BM&)B1!7
MIKB*/E&*/A%PC:@(M,<Y'\)IY3$5FO*"S[8;$3&+CI%7J<@<O(A!?5@UW9"%
MAW!CD,"+C66,0+0(J(@(GYARK%B-$`@)KK=PA[!VO6!^7_1?B<``62,FMF,(
MD55C-$0CXR00-[,`]V!949B.#J`/H<9U_Z(J>XAZBS``B;4*Y^884`2-H3AZ
M!^"'UGB0U_@(!+!UIX,X\#!&A+,2P=$@O=%^\Y6'F0(+CT$+X(@(FA%8FB$J
M-B-3'"*.-^61G'0DM+`@%I(?BF(T&'D+F]%,"9"'FM$;*CD+,D$@$0#_DX_A
M#1;C46<B(@&")C=1DCMC0?D!<BO)(*(R-.Z0']/RC[_W:0,Y"$=BA0BYE0/A
MBM^Q.QYR?BPC-94W)1.017/"&TFR+Q+I-_?`C>>A@]I8"*VQ.[`R)E^C<>CU
M=VE2""US&PQ0)EG4"KX'->7F"]:Q'!"P'^4H:HPA-*>RD39CF,Q"5#+3)X/0
MD^1(3+"`@-K!'EM"=H+)4;[G#D;3*'0BEW-9"-%H"/PR05P9FP#AE7[9*'_G
M(B$H6?#"#1:4&;Z9&0+2?(FP@86"<Q#`'WERE\:AF6,W6>B82X6W)1!@$R65
M7M505U>VFE,"`='9):7172I!>%##G/?(6*[2_YLL`9+KI5R;LG!+2`KEN9$"
M.6_U)IOV^0VTZ7P6-R\K$7CP@EEU=1)`>#AER0C[,B;:Z1B%<B7*F4LUZ2%/
M<Y(%I(,=$@LWLW\*8YW`4!+RPQU(DP@^\Y]W)4T`6ASZL$O%1)6P-*+[T:%)
MN5X7FG9`4X@K(R_ZAQ-.N!F%N(=7.0AM=(SW&:38D)]#22/\X`W^Z2_T`'*J
MP`!_59.\$B)P.1*_T5AEUT7!DCJ#0Q):%"$PDRDO-!R-D0`GHG3OA3B$@QS6
M``]8I'&I6#EE"CB%EZ;_`TPVPZ4'U![#X4.G,Y'`=#>_6$.8PZ>[:"-Y*C?J
M@1/*R)H]&D6P*:20^O\+1!JI`*&/N-":VQ@!2T.IG*H+DWH1`>>+;VJE[A"3
M!D)*Y=$->VJJ'8.IA?``HC2EG3JKBO"I%>&-'#=^(%JD5.,(^])9QZ(Q:Y:#
MP,"FVS$GBO`>UE>?452DA-<5KDH(+D,+M%JMCV"K$[&1CS$8Q,JK/K,@=D(3
MY^<-/5D_*$-&N"$M2`D/HL(RH"E+_-$8Y;I<DL"A3](@MD@U;8AE?S,OF3$5
M/I,W>O,G.\2"6=28%Q&MA,``%_6'UOJPWE,5YF$=2>B1W>`A>D,J#<!*Q0$U
ME!D*$"`!G$248Z>71/4_K_F.)U>6>"D)V$EE>2@J;U$2C'*65_(OPD<+;ZG_
M-Y;FEG72&CVAL.?AL!#[L-@J$<2I7,SJK4XC*MQ0H=;G`%`3>*0J(;W*6,QR
M4D)$7<O!#QVHD%$6,9MZ"+_R+JUPGJ'R+[026/[(!Q$0G,:Q*],9M(U:.6PH
MJT5;K4<K$0<:)8S0,U=2>6L"$_O"C]6B+\L",[/4'B[*?BLAE/9Z5#5("#,I
M?I`Q:N\A`:[T)S$S,$-9>>$J,S-1D)H+"ZFY$T)+([.4MZP["'O;B[]!&E$H
MIA-R&UFJNG8J)6IZK)BR.<K1EUY:D!IG)VI*D36$II'0CH3BC@C+6(++I+DB
M/P!K*-,I10LR*>JQ?P!"MY$`,0MB043;NI'ZNK\C_ZH[ZAFIZS]-(7_BRZGD
MV[X4D;KPV[[O.Q"PR+Z%HV2*@+>JDG9P`Q,LN+`1H1SZR#^K2JI;)(SPUTJ&
MD#D:5+?S*[[U&Q#>*#_9IP@-,(Z=4Y$LLB71PQPZ`GJFN8?:\4J-Z,&3AWF6
MJGGY<1NMD+-D&[=SYIH%`AX/(D+RN([;&&<AXX#N`<'\LK01/+Y5H:WL@:.R
M.)UQ1G)_,`$I(7ZJI!Z\@3LL<[:T$I>'D#L<LJP6!!,JXHY.<L&-D$SA%5XQ
M#">:PB!98T$96PI7B\,I>:0,HBE^,V=0BJ3>V2)*"7+\.Y_+*'N[,\1Z*['.
M!9F*$+A)TG=-Y+8>R*5H*_]9G(.>M3D(3)AX3I-*2O6WC+58^?A2MP'`P:28
MO?%?9=N1?VG(G]RNDH,>8F.9>*4*74M^"3J%=>LWJI"OCM"$WK%9`A*^JK+"
MUH"'A-#+XB`*$!R8PTP`OAQEVV>."UD\66D-U5$=^.L.U;P(`C+-REP+P(P(
MF?`6:L,6DB`@X\(D1M('\F)M!%#.!C(_Z5PYX**Y,94.(]L+$_P/Q,DBV?D=
MK5!4[]%T7RP@'K@?:Y*DWO<=$Z@=*6A8\`F*7[L(B1DK0LPP`3*=K?`8<=*U
MJGG#M<F=`L*>(5@P<X9^4DLF&6/0JE>W&+TKN9`.Z\C-QBP)ZRP0,1T*WP,.
MU8;_C>Q6TXVP"2+$`&P1`6<I3A=E#]70!]1!S8X@SKF0S>D@"R+%JH>@"4N4
M"9.;F6\#+C@Q/^)(/(<@U"?E++ED#^!R'Q/P-F>M(J_``!,PP[MPS__0MR9A
M)`04R`ZRF/EE:6X;,[&P'PO`*BC=T%*$'WZ]Q>FG@RVCUP]]R+[W7<GJ(@PR
M*MD$6'7YTLRA@O01HA8JV6F"2^*G(M-GN!H8H2A]J4"<O;@P/.O,)#!]TW:"
M-R$"F2'7)!$0+GQB0?31A%9"ER:A&8^AS([Q'GIU,YIQ'PW`%LQF#QO+)+<-
M/V!*"K:\D"!\)`2R'9D!),']/WTY(2'2W!7IFS-MTP"R_YAB1GF4XQ@G,WE)
M),YLP\VQH,->`@$!$MR[TC*;1$!,30BZ#2H'LI`G@LZ9`]6-U;6[4=_Y&MZA
M4I`FT2%2,Y-V(MV%P!;FHB+K?%C@T@='4Z%_,DR<8]1L@PI)4@]P(PKW\.$8
M7CFQ\RDT,@K9(QAP#=?B`$:-]8PTG(@?0G`Z<G#Z5I".\44X$3W[\QJAED"8
M2(D\/G!GETR<C`C*P=R8HX1-@A.,<<#':Z5D*JB`>BB<,Z<D`JM2DC=_ND:F
MD]*1,%ZR@`O'W2R0T=KHD2IJLQEG30!G?3=/W2Q%G<CV,#_*L\[?D@EN03PQ
M;<P(,`'=D=;@\L[B$M2C8.?KG/\[HI`.HJ+H-1GGX](HDA[3;OX*C'[B\]/G
M.VW5M4T3?9!E8MWA@1D<W"SBW@,!\],P7NWJU#$!>?+H<H[4C>[-S!EGXP(N
M.)/5Q`/4^+,`NZ[BZYP.LH-1KRYJV=;:L6[K)W[<R)Y`;$$`]E(+>/(V0'V<
M$SX_S!H/*?$]^7T(WE[3;.'>QDSH+M[-C`#C@HP9=3NGNC`!20(NO<'F"^LL
MPKX?)T/BL6`+:6[IYZPF";3.O5'IP[,<MIT*]>`J1L0\-RTNL$#B_W[<!2(*
M6Z+FZ,T?)].$HJ"1]A#30'TWYC+QSL+4M>T.\D#B:C/O4";LV6/;4@;NLE!J
M[NWJNN[_$D9="\07@0&&)N@]"[(.JX,CSJFR"E,[X1TO+G"#X*T=)A.NU?+0
M+/E3[E`S"NQM,ZI=#[`@[X<@[-%$[J/F]0Y?&N6^[ZEPW/F1">J^".S>[M^0
MN@/0O(X@[!:TSC?/T^C]5Z>`X.(\T^N\"7I3VT@M'N'-WBG^4>$"U%8]]BA/
M]C,/^#:-^#Z-X(FN":X2+B/CQG^O";400Y_N^(UREBJNWJ,,WS(?WC5/"V:/
M\+!\,I0/.R*T*D@MSM/QS?<AS@+6[QV.^$N_[*,0T^Z]SK)C^;`_/,.#"@/B
MY^+L%J+0F-[R4S*_A^,"_8YO[JG`(80^/]>\U%81E*.C"+TY_V13>%D+*\6.
MH&DJL?W4QAD8F61]O(U=7QIX^Y;6!BU2?7:-JLU7C94!!@@0?WQ]`P-]?'^*
MBA(0$PQ_#7T'?P=]#7\$?9%]"(L(`PD)#A,3BYF;?WT$?X=\KJV(!P,'#Q!]
M#K"+AY"6#)*>BL&QB;Z?MYX#?`E]D,*ZC8^<PY:8?Q*IBKR5S7\/?<BG#XG7
MIJ>7W'R$E)*GA`]_"WT+L(0#J*?GK*<1$0FJ!$#-8@`.X)\($C[A(\8PGZ9%
M]NH50F5,F#X$JQ*NL@3!TZH_#E:9<X=N44%FY/(1LJ;H)*)##D`62G`OTLA\
M.'/BS*:SI\^?0(&R>A`3@824.?=EJO^T@)(A/I0..(#W"@$]I0L6*()J]5^M
M7)6FQ@MK2!DM;_""]ER@;@$""`,Z]GRE:!\"3P@.)/#D]=\?OTMQ\HE`R2[>
M`X=9$3A`25'C!@X6-!BF5JVZRHJT9L8LK$]"1ITB(LH7LL^_0T>QW=/T"AR?
M"1'*/7C0[]1#@ZXP1N"#C<^W!@,(TEM5,]8$/IH>'(+P.O:NT9F.W\JZJGET
M/M-UE3[M&C:J7WUX'CJ>7-&$@J="0B"(R=Z?6\A-,R-`2!!$SX,[25R]Z;;)
M"00$2,`"_02W"D82#"`/)GU$P%8S["T$BRZV92-:(NX]1(!T\^AS4#<;@1/7
M1QB5M(@EJP3_J-4M#&!#$W3<I#C@>\VX^$<IKYG"'D&0N,=9/CS]*.20NY##
M"@3C^+1/`@T<T&23?#"`@&)6.?`*!`D@MXA]6Q[@VP`!07!`1U=-B4`#KZ@3
MG"'.#+D/`0E`P@!@@M7$"EL.Y"+!`P'19Y0W,=65$Q\+"')G6P,D^`":IDP@
MV0!G2G9F9),1Z=-EE1$H8)N5@:E9/`0H"&<",YYR``$L/8#-GMH$.$@$J_SS
M5GA8GL+`FY"0JE5(C\Q(8(/D-%#J7P0P`*LS^<%YBJZ*)'#+<5N=IZRS?4#+
M;"6H0@3KM-B@JA2QQG:CB"2?+L+`>94NH.R4U6JV@+24K52*5LRJ__O/K7^<
MZY"`*K[[2`.")(#-!)4Z4.R9Z'J"+['T#FLN5J/ZJBR^U$)K6X^A9B)GM7P`
MK,@MQ37+[XSL.OC748N0RJ]6)6N6`*P2R-I`*<[8:ZDJ-^?,F3)UY<)S3_1A
M9^4]RM`U%,!JOKF(4@>P51?/K]SJP)0\FY6TH$2^.>5@E*F$YF#7&!(JAF".
MZV1C@:FD#)^!C1U80JPH(Q91K_RLLTI(!87VW7SW[???@.OD[`1=\^UC4&\%
MKOCB`]0V)%V+6QIDY#DG'B=;PN[MT-)9Q</6:DQZ<_64BXCUW@"8.`FU@H,8
M[*3H19>=MI!OSAWHH':&/4`N9.]#U+??0O\$J:MO\BR78JWP87O=>1O>/.70
M1R_]]!5RZO?A0#F@.?7<_Q1>N9AEV7UEDX^?Z2_!V)W4(@FI0W8F9T:)Y@`/
M,+"P(@PHKQ5;4JZN#@.G`DG'TO2*.,W)4@Q@TP)ZE!;<"8H!E%J=4AQUB@2%
MXBR#N,<WXH&H1*".%$M11J0FP[S`8<I\*$RA"H$BBL7-HG`KC.%/0B'#OY6O
MAC@<TJX:V+?._<4!=,()8IHE#%E%!0&`"<@IRI*`(58B?<(XC##T\I<_Y,4Q
MCKG+]NYV0KT!QQ`LR:$8QTC&,IKQC&JY(1K7*+K;L9&#;P1*%X$")O?Q,(YX
MS*,>]\C'G*BQCX#_#*08YQ@4FNQ.D(A,I"(72;D_,O*1D/P;(7_"I&*%,9*8
MS*0F%SDY+REOBS\"WR9'&<=)7NH]@R"E*E?)RC).CF<!S%GP6DE+')JR)\ZB
M5"UWR<M>+NZ51@+3`Q"0OZM<QH!-M!\\&I"_3!Q`F6/QI32E=\N>4`*(T\RF
M-K?IDU?2)W_!B00[%I@O4O4,*DT,!=RL1,4@<O.=-ZLF/.=)SWD"LTB!<5\&
ME58H+$$&;O&``)?J25#.R+.@"$TH*^^IC42,8TQ@>ET"@[.`J4%@*@>(S8`L
M6D6%>G10S_/)`]SRT9*:-(^=+,XLFN66X&A/$;.!J?:L\@!1:(4HE!#E_TD1
M>M!\6$6@=]RI4(>J0D?F1'U$3>I<0DK)!D2``$%5JE2G:L,?79&J6-T*4W6B
MK@-&,ZM@#:N0C"K6L@YBJSBA7UE"9M:VNO4<;XTK1-"*-_?15:YX)>H-@\@6
M??81@WP#[-]6RD;"5@8!;ER$3HG4T[G:-:^0!6LGH5HIVP@2<FI1"E*S"#BK
M36^6.[NK.Z(*6L:*5AMK96MD5SO4R2W@'YC%FE\KP4RM%(L!]#C*9`B@/?X%
M,$YQPJPZ2,C,E-2O`32A#W.P1,P\'00[B&%F@NC#3/MQ$"H=RU]&-8,<3Z8D
M3<4%B0.D%(&8*`\2QTVF\EK7)N2H"SM6A.#MTO\;OP0M\%;";&Y,\L<<)^%V
MN\$MSF[$9+3G,J<!N77`9`(L3,=FPAK/7.^`&5/;@YAWO`($X%)#.UO6>GBG
M-Y2=93OG0UJ438FA0J_!\I(Z@!'3G*C,C.I\DS:W#`T2`5%&D_)U@(3(;9E@
M`@6.7Q<_>""OH23F[MJ<B8DF)J1S([6Q\M`)9<V8I4>HHX2&XX%8Y<$C@:R@
M&B1VS(#ZP6X6R-L'EWRLIJ6TS\CA_-W'PIF9_7U.$>S\!YM-S(HGWW0!";HJ
M2#DS"_H-],.(]FCYT(<35M#E9Y)15]NJIJ6?#:A0S\746SIFEK393TV)B!MR
MW!?`V.TS>9FH(Z$*K-G_-O\L3:NQFZ._%IS\)4(R!VYS\B1(:OS9FBZO*%ZH
MW><T940:>;LYH:A9G<%4>W`P[K/;HW4=#X^)^MA+&>`KO)2@#0_)>HD.-T%?
M>3LG+N5L.WX/`M@&528%64QJ]M(P>?N>)BY)2F-;S=+RE:80MN4MI89*1Z:+
MZCZM&YQ+:36Z&P-K^(6IU)@H,RN*:5'4Y2LMGDV36\3T0(%3#;E\@MK&3T5,
M[*P;>5B*I;_SE`!3.#K6#T^YVQSS)"_5I**)$W5'V-V*B//)*HL]*V?4%2!P
MB_OH[P2F.F:!-LTT#6U22<"\6>?2G`KCM3*V(E&&,=):G.53HWCZ/;2R4F58
M_WVEHWA`TRHQ=J9HY>M_^93VGKX+IH\EZM$<Q3W"?M.7ZCT]AFB%4Z"2LMZ&
MY8#T$%--S&[%R&@/B,-,@%NVKEBV>VY_@H_'5RBQ[JD9EBE.01M.[TX+R%NE
M66"12E3GBIG`(_WUX_Y;J]WJ)+:5N0&KA\MB-MG8CSU50+`/_C;)RAG`"-JL
M2$P9#'=!RMYK0_C0'W[T=^I\_)4WZ-//?B:)CQ/$RA#[0E3M$D%YHN*X_JCD
MC]SG!=,8U@7E+(BE24Z8+OZ.5@)M(3-WT0AES?IKE3,UE0A&IWT$&$G<IQ*K
M9T+^5UIIU6_6M'SXQ`@^86[4LUFG,`&!(BR6,3Q[L?]%9M<\I[(H5O%O"%8I
M1E$<L:43>6&!0H<9RH$A!1B#FG2`^I0M^&,E9S5LU85CV65=_(,`V9425@)`
MJ%)RNS)>I)-`-(=;_N9>RO47]I-<X_`4$#`9\I4O#,`<VA`!"A(E0(A<6[$[
M45(+ZC"%V=8Q7]A,>2(E`;9O11->]L,<^F5A2R,(9\(*X45=RO&$OJ$L;]A,
M<<@5XT!C\0!;LG-IGC,(P"$\*<-,&K5KZD``2*)NK,<9QN(P,IB)BL1]208Y
M569G.89C\!-.B]%B-*84@69S.P8<378JD%%W)P:)X11L3X-E5B0!9Z)E9N8T
M=?$Z3D*(&92*2()$!=84P''_BJ]C;Q_CAF68"7'"06368Q?3-'PR"P(#/ZF&
M98/AA\T()Y#`B\-()[&8"=,V4L)%:W(!4%:C#'&2.)58&>ZDB?*(2-PW;9!S
MCT13::'F;\Y6%P7F&+QA%OLP6[>E6`B&/.O8.T_S/G!!CFWQ;$MC:<)%"P&)
M6+QE-)MVC+&6$LF6$LNVD<D3-%`!/%F""7!R40#5CVE24VQF-)0F#`9S.XQ6
M._!`%+MA@\V&-0@):Z'F0__7>A/E?_,XE&_$?0L'.:@S)0LG:@E7<.\A;_\(
M/UGQ"@_5$0]W)#6Q<WT6/QFW)FM"-KQ(*``7$&BR;P1FAF$8$%F!7$["<A/0
MCOGF_W``)W/L$S^L9I<C!SP/E@D8Y7(+F4'`1D#Z1I;!TD36<$CXPR8+%X:,
MF!G:8PJX.#_]UB+Q<EH-U6%$F9EQ=(!T!UAA!WJD-Q9DUW9=D7F?HGI6E`B2
MYPEX1W9I$77#9'/WX#.9%U-EUS1MD3Q109N;49J`10NH"72>D!5_YG5GATV=
M1PUU`W=2$7B,5RXW]0]NL0`U)7DR1C1V-PB&=)RN)YR727@^Y"7XAW_$U@J2
M)ILKI3T6YPZ6B6?#I9GPN9GQJ4D,2$QL57TCA20#.)_\*4,'V)]X%(]3)!CM
M.37M`:`(BD/_F:"/5'TAV`"7Q*`2RCT'N)\^<2]-%25?!O\4%FIJ`-D8X4EX
MNS`U=?:A.8%UKU=]5M0*$#BA+OI+F,$*301U)](LC%$)$J`7>_%$E;!$1A(8
M-;$7=!(0?,&:P7!)"S=1`%1S,"5P^:*83.H8E%`WRO=$>!$,R?=6#BH(Y/2B
M7AH]!\@*CO)%N#4GN(<)8TH+.<I;1G8FMI`^/]HGMD"..&@>"D84MK4(D"%W
M-6DP/=.G'Z,P,,:F@+(54XD=<XHD!"8F>)(+MY<O;55]3;$57UJID1.F_B87
M8Z(<R,64BH%N0^-<K?!-;6J3;;-O3/8Z>+9NY#!M;S)MLG6(L(J%5*%O(Q67
M%@15$$!2;K6E]!.AEAJL.H.IHK;_)*&B(`'7E+R5);F@'`UE&_5C3DHC*#EG
M.EFZ#TGV)DEF-N*DK7;6+"5I-!#5<!:D/9+W&9':GI6@/"TJK.[*&<2:/(MB
M)8ORIIX:0("&+7'A%^HS((1"&--Z(PLTF\Y1%_7Z0B4X@F*9L+3`).345VZ1
ML%L1&6VV&$CBK_<`08]RIE\E5BKZKB#+-P?X#T9D1?A'1%?$&+("&#LZH"EC
MI5G*LDY$9U7J?:UP(B?K#2N+L\QG*D=412GK1%F:I>IJ4A\;LD@K.8%T-CI!
M@1?*/0)*52JJ+BB:M%8;%`MZM6=4?9+'!V>BM6#;$UD;MF,DJ5X"$F2;MB:A
MMH!4?6]1_Y!L2[;E,U*4X26_D(*X!*E$T7UZ`7XG&K48^A/[F1?6>:%!]UJY
MLBQ>)B2)Z[24Y`R$BWW,`4'PJ%//^#'-6+4JF'XJN&4_V2FM(']Q&[:34T`1
M:C=WL2QX(2LQLQ>M2T35-@XMF[I+5*/-1KL]VF-4U*-_D:5UD;I^X1>2(;M8
MVC4-\!E#%+P%9!1^\1:>`#F<IQ=:]$3WD+S,^XJ\F[VVB[W#NPS%:UGEA$7/
M![1_H3Z/<3O[$!F((2O:FU.5TA@[ZKOB*RGLB1F:$B"'-KI).SDD>[KD`+&+
MX"BHLT#,&Q`Q(PB(.;Q[0B96$BAO$1?$M"AF45'L>K&Z2Y:20O\?=7HC=XK`
M@:+`;TK!M_,63"BNN\J%!BR\/.2P";0GNJ4,2.(@!A<SD'$Y/K>(5I2PW(M[
M"UPEZX4U'<'"4S*G?K*K]"$,.HR^6Q)L7GM[;#)>DN$DDB+`CXH_DB%YE?6Y
M:B&4^ANRY5-K#:B3^T:&:;844[%E77FL^W`JYOI%S`$F8B,6_Z`8MA.P-(G&
M_19L8J-8KR4(1D,78)8VL247$+2/IO9RR',E8/0H<8%G?8J4>0S'(I9L8D+(
M].,`C\@S20(2CUP<2D$?9>-N<2$7-+&X<F8+O/J,#YPW*FHE'=/%6NM:6..C
M8OQ`:E?&K.`D+)'&AJ`92*0J$DP_>JS_(&`QQWS9IW9L16("H44B0;V\-.J`
MBT8C%K2H%'L;#PY`R#CXD=D6BXJL(*AC"&FQ/(L7R<?Z*?L`PPJC#M(*A:C&
MR8""64MR-:(\I^5KRG[:MY^ARG#!RNV9GV8&RU8[.;CUL+1\7>@<";_S%NW\
M'FW")$D2-9'ARZ%BE;(KT5GQH,Z$P;LURXZBA.O1B!'M4CX4.M@\KX0#52A<
M;WH:&4&,8`EDR!5[:EB2)_4::K*+Q)(".1!--AK[*1:$7"S,%H`62Q=+#B,$
MA,6A*!U!BYD@N_,*1$^2P3VW*.9RQ4A5?0::2@*]OSG1LG0B:+C;45YA12WD
M%Y[[%S<Z1,=W_[.<Q=8T>G]^`;^PJ];!D-8SRJ."=J-F+=<VFGSR>WS1"[2,
MP1=/M+-!>B)=TQCFEM=PO43GQ[N(<1<L*]B<A5IS[;M"&PP[2M=];2HN^XYJ
M\:#`.KI]]5+[=YJ1@1=TD26(Q5T89U=6)J)]=8\,QQC-PW_)4YZB,]?N0Z*.
M!3DYO:[J`-R8-+9#0K,XI-SPZ:#-`H$#L`<;,-W47=W6?=W8G=W:O=W<W=W>
M_=W@[=UV$$@!@AR$`VVO<6O_\I:9$!N-,`B=\`W\BAR[H1DL4A??U`?P,!&J
M8`A!P@R=$)+U;13T$0&8X`J\\2V7H"8$/A@'C@@)/H-=_49<FX"[</\"!I#A
M&K[A'-[A'O[A(![B(C[B)%[B)D[B*$#>Y%`(6C((`=$AD9`0EK`AG#=@E]3B
MW.!4_L@(B<#?A7`(^0`P%+05^V`LCJ'?0!X+YU`<1LX-RI$*27[<$\Y&DLHO
M/3$`&'[B6K[E7-[E7N[E*0Y(J+([H6%!1Q'E24X(M_,KFH/CI,`,<_Q4$D`X
M_=T2_IT/&"A0$/&JT'P(8*3@7W,J'MD:?R[AEH$F2N@.(2-Y*[58_',B'0/*
M0<&`[RS(:()[A:13+#CI/N&W+&4J7`R^2B(\%GHSM*"Y\X<DGGXB!*:NAI18
M2Y3E7S[KM%[KMB[B8=Y'!/![5`$@&S(<P;#_0:CP+08N&*@8*M(PY@]`03Y^
MYXOP#0L4X"Y>%VURYBE2["81Z,7"/JT1(-@NY1NXC*5)%[:I#`/"A:6Y):1S
MT&AA>6<14Z%"HG3WK+,,.4P#%M[)=D^QFTYCFT3A%_Z.[U<!FO0P-8US<S,Z
MJ5:!K)"2%4"X&'3W6HB!HK?*Q_``=U!5JRQ3M4#G&)-*=Q$O8T2Q&L#1-+O#
M%QA%Y&LE>;LC%6@S[HO!M<+R"U<NZ[=^\SB?\R>>ZWQTQ'M.Y#=B)%PZ#S!.
MCL9^Y-ZN4>2`,A1D";/`$TX5(##>XJ20#*:1Y%%>YWA&YX?P(MJ`W$59&?@X
M&13KE3'-,WCXVHK%_]X'K:2K@UQY`E5G(R7I)FN,:-+P@UQ-(A67B6]SR<YK
M$IGLN"8QYR6+0?<A&#J?K':(CR7JHF.,P3O/E(M0%0FO_279\)9]I6^:?S5A
MXA?(55%C8A2CGZ,U5SP/!VOMQHHGV%!%@V.SL1A*<990TYZ)X,<UK_.ZO_N\
MK^$\OT<^#_33_C(2\%1W(0TS$PS!__,@80YPONL$,.?7)!(/+B`M%RAZ/NWX
M`R`4A/4\P=_;_^M*/O[@'A3W.&JC=HB>%2I!LR07E84'+6RGII,#5):5KA0#
M9-R+$BI=!0@'?W\#?'P#?P2%A'P1AA&+A8Z-BX<$@P1\#9I\EXF?F'^<F_^>
MBGP+!`P'A:.=A)F=I8.@F8B7I9:+LW\)#!"&B*+!AXREE87(N(C$C*RVC*"Z
MIJ)\N];7@PD0#@L-V(,#)P;CY.7FY^CIZNOL[>[O\.XHW_3U]O?X]0F"LP<)
M@ZMF[0,X`,$?!`/X#;3F+]L_</X&2+16<!!"B0DK_@FX\:'%8`>#(30(CN0L
MA"=%:LS'LJ7+EX/ZL&0&X0"#D)8P(:M&P&;(0<0@W)PE36<U!@,@;!Q0:L$#
M7OQT@1)FK9>P!824,B+6T]L#/EH?#+BY8$'88Y<0$'`*59:G3VSWI36%-6FA
MN`<N^4380)"$67\/;$+T-_#@GC<3AKK[M&SCLG__RLX]=BAG(LA(P57F"LV3
MX(T-*E5S*<B!QVOAXJE>S;JUZ]?S8,J>3;NV[=NX<^O>?4UF/DZ9&3C@@^!0
M+P8)"AVH"6'L<)*"#1'PJ.MX`@2_)`Q8P(!/7DP(&CAP0!36@$D+F)T4+_Q!
M]Z=;GQGZE9Y/\DQD#26O=L@]`P+AC4?+'\V%$B!Y8W52B'M\/+!<`N*1YXEP
MQ`G&0`2S.***-A?^H>$!.0DWU!\4-G#@@=14T\U_QSQP6"C=*:*9,Y\L\E9Z
M#"#$WV@L84>`C-^D]MJ01!9I9#NQ\:;DDDPVZ>234/[A6Y145KF+5$UBY1-N
M;UEY3T`FWF:(2PL\-")J_^(<J>::;*Z6I)=PQBGGG'1*6>>=N"6`U9,)&&*2
M;6?B.<MP\-DV9DO;'<0CFFTVZNBCY+PIZ*245FII3)=FJNFF>![*$BH__A@H
M.&E":NJI0TK*Z:JLMBK;E/<LA,!I]1Q`4D'\6(-`KKO20RM#!^2JSY*[VFK/
M*B#!U*NK=7J*J+",HBKMM/"HRNRUV&(+JST$>$-BE_40T\`"'%'$HP30[H+5
MJ+Q`D!P^X.:&3+K6\.&`<[)A28\AWF)WC2$YAL<`5MR9V&>#V0*U*#X^?D6/
MD-1&++$YUB9L\<65;EL/`5I!<,E7*O+!P%.;Y'C(N+R4)?)3_HUVW@!]DI>>
MF?\'1."4GT`1\$"9^B$P\Q\.C#S530<X@,!PMHK\CW@"C>?SRG^T7*:(_PR'
M'%#!F'BT=Y$YP#(W?Y3,77+;D+>U/T)OA-4A@H%K52%7,\>++P9YFZVS^"Q0
M'(D/ESKQW]16S&QR!JW"#T+\<-10`@\-5!'B#2E&"`(7K;3+=1215/E#R":+
MTD<2G?9NY1-I]/E2`/V*L<;T$&!:`@Y<<E-E6%V"X0/#22"!0:S4_IFG`"K5
M^RRW?-)0,V`9]%5!JD@X]`%.:=V`6)]@:)$W!_ONC2&6V`K!`N052)4PTB\2
M&GGW8G@*=DD!W0WEH=D-E/5361.:)]QC$N9?">,=JY__["(5X`8X+<&YB@!]
M6%<?1K.`/FB%#WUXBBL(,`%!9$)*!=%=<2[1!_[U02)]^%$"U34!"@YE`26<
M0&)":$)1E#`"%211"NO"0A5FJ`^,(X`$6(A!&5)P;1$41;Q6QQ+$J.(2FC#%
M,R[!"J]Y@T;3D,HT$J&>XCV`8U&IC#84\18$,*`!&'H+[KPQ"7=]L7C@@$5W
M;!$)8"AC?,Q`3AF9`1Q44"6*C9B/OMP7BJJL!13Y2X1-^,"_NRT,'U=T5]\(
MR$A3&;!5.KR)[D:CPSX8!(+JNT4?O''!"&I0B%(:X0<'X)L'3,`D$R!/`A*X
M2D0@()6D',0#9.**/TC`7J<D_P0.8QDUWY!2`D/A)08=D$M2]JD/F<18;XI(
M(*5,`RF<82(P""26:08/:#RZ)HU"(;NHD0=YQ,$.<HI#C+]T"0+>@(!!8G<0
M-!Y$*0=87B+\-1S+3",T6#M(.M>).Q+UTT%(9./VDK).J4`&,O4;A#H'X;5/
M?,QKS+.8_^QQM.44*EJ-S"B;'LFJ;OTE`A<\P`='&(OAW((!$TA`)R=@R9Q)
MJ1$(&.64/@B.;1%R%BSRC0.2B0";I0(PA]"I]1J0">L)\X,_'<0M2UI+9<Z"
M==\@R[I$P8VR_.,F-]%3F=ZYG:W>!&1[XEO,(N,1J8*,)'I*:\_L%2Q[F>9,
M*(,=<?_N0IPSX4YF5XV:(:PZE/R(CSN&$(1<UWDOH#64+%?MQ2EX\1P][<*M
M..7%:"`T3:7-K1I'RY%$#VD/!]ADCT3QFT9'2R2.KBH3$TC*!8G93"$.0(6W
MD$XG=S@45R`5@B!\:C"$Z=*<D;(/P.4/<$.HEFP&=;BC2>4J_W%4IAA70;!U
MZBZ@*MU\:(5)1?,7GLI577M,M!X[ZV:01$O:\K+&M)S*Q(\Z48T=#G>#!"HA
M%7LZ@6I\T`$TM2W,6)K;J.7R(#15RP!FR8\((*64M.Q2AS8205[.LI?#7:%N
M%RS2KUP"`O+M+G6[6P^8/6D`GN4PL[Y;CS*Q9;SF37%KT+O_*5C<5J2N3*`K
M1!K;R"RPAQ2$+TT;(%.1V1"G*OPD&#NQ.U[&LJD'D4!1G^A+F1!U$!UJ+@*4
MW(CMZ26$'-ZPB+?,9=Z0F#804[&8Y:',!<!,16>>A5,2%1F"#6,9@@"16-86
M9^^`R!`7S49A!8*PC8P&1`@)ZRR^PKD_$V?/@`;1++BFUX>P&:'5U7*7)TUI
MV7QY-F$>LZ;3P>)*>[K2H\2(J$=-ZE*;^M2H3K6J5\WJ5KOZU;".M:QG3>M:
MCWH3,)$<BC?-:W1T^M/`WG*HADWL8AO[V,A.MK*7S>QF._O9T(ZVM*=-[6I;
M&]F"9IC''+;K7GM['+\.MKC'3>YR_YO;&GH[RB*__>UPKXH!`42@!!?XV^"&
M$IEK\T1,C=H'!,EDN,`%R14=^)!&3"!,$%RA)N<=U)J*`H>@O.#`%:G4/JP"
MX".5Y0X5"<%_N.(!.Y2`ZLY-\I)KZF!>7#>[>^WN)Z5@"=;H`0[J,2O`(")8
MUB"`(Q+A"-[VD)0@\L0"(@!Q4IZRN;L0*58:<,H+>>\OC4`B2'G.DYXW^>%(
MC*W2PY9+D4;@FT:6R2R744$(9OT/]14%_4S.]K97*I$C)P1Y5R[FECL)""FX
M1A!<\`VF1R`P$^#YU(GG,;37(M0&H:DMI:-4!@!3E[]`^J#X-Y()[$FD?:)@
M(@K/L4N4L/_ANA2%!"`Q07M1OB*.=[S#0X_.#.6.]+;['KW<3OO:6ZFB$,CS
ME>9.]Q3;G4DW\`$V:A`#;(@T:4<;5P0H%X%"90*'ZR5EJ/ZA>%A<V3T8`GH"
M9YHL)/<P)H7XT6M+#_W#.[P30R^]]STT,HN'/O07Q(1TTG\);0#WNK;/O_Z=
MY%EHJKSW8_9[2I(#%S`(*<`"%U`$,#`(,?`#J`$K$F!A\D<\G4`*H*=;@V!Y
MKH!?E90<,G$AW*<NU@-H.Z=+09=$I=<M[!5VH#1ZL35T`$$<JZ1D_?9^L?1D
M!Z&!E^""D]-+R;)_0!B$MA%>?--M`%AWE`($+#`(.W`!3KB$?Q#_!#9P#:^$
M2R+%8./A?O*'4E<45!A!??>"82T8&N=Q8#D8@B<Q`<VA.Y%A>2!G9:84(U3$
MA9GP2DC!,:`D??.EA@/`AHXG$1#P%RR8`/65%+OC"GK(,87P7T+8B([X$B:F
M>Z%UA)HF@+QQ`2LP"`CHA`7X!S&@`3-7%1#@+F,!#@V`3SCE%``R,"H5*C<1
M*@WP#]PA8`P5BY[`3IA`*R"R#;?2`-\S"-R1%]N!5:KH177Q'\01&4/1`,3H
M9[P8-F`'("J5#9[Q'T:CC(/`C(K2+7'WB-[XC8/"+_]'B>9EB;OAA#GP!T#`
MB47P!RZ@`1H@`^`XC_18CTVR,[D70')'_XY(."E/^`<PL`).R`-_,`3P*(_V
MF)`*N9`N833;,X[\.%KFJ!LZ@(Y_D`(Y,`-_4`,"H`$"P)`@&9(BV0\Z<XH0
M&9$9-9&Y00-.V(Z[\(D:$`0C.9,TF9"88X0HJ5$JB1LSP(DW,`L_`(\:4`/8
M\!\<4RA'DPKI`BK=0A)F@4^Q8Q#;L`NXHQ!;!0[!4#226)-<V95/<B%@\PUW
MQCUD699F>99HF99JN99LV99N^99OF6UWPI(6R9'P*)/8T"V%X'Y3UAQ\D%+U
MHAU]J!0-$($H1"[U]9<F\9<8AA#UE5HVD7:DA%)RZ966>9FX\0!]4H28R2DI
M()`)F`)*`(\"P/]W>3D:-(5")-$M]>()HPAC\^-"J;0+S!A3%D(B?9%'88,4
M-]F9OOF;+U%-H@"<F\(#G$@'0NF`W[!>8@A*O;5H`-=?[S<!:Z=+Q'5!M71!
M%"1OQ-F=WDD/%_)'WVDIZW@%0EE\K0,+_+!3L^"+K:E0[J*%*`0TP/5-&6@T
M7X>=N)`(6#5$X_F?ETEJ`$HI*5`$-D":IKF</+(/!R"9$70ZM32*MJ1.-9,C
MB<F(J=13X',+W[1:2B$4`QJBF&F6(BHH:R"4<,`MQM4N'?04P@1!P"5R^D2=
MU0`!R_=*UW4>?7`3V!$!"T5%[^1`?U*B1"J2(%*910HG=JD!2G`!"YC_I%`:
MI5'2'&$II7`"DV;@!A>@`U;:I5Z:&Z/!65_*)$)`FG@`FC0PIFJZIK\!%&SJ
M)"[0D1H@!']@G)BHD6^:IWI:;'K*&TEPE[-`ET!`#]V`BKS@.L`(BTE9-_*C
M4H@PC83@"]D&/H)0'^O#/5EY>7UV$F5!$E4)#N22#?;1IZ1:JN>&`_"H!`GZ
M!YN8CO\R`;@31#)D/80D$1+0%PD$FT2!3*%'2E[S8V$#3!97'Q+0').P#%,G
M4HXG/SY:>(6)4L4!3*>$0@R@>*9ZK=@Z:4;@D:$X"Y^YI=A@,\"X)_4%<;7D
M"HWP'Q3106;F9-XB1?\0?Z^%``_0'/P0"]@H_TR\9'$TM1;-9TME80MBFJT$
M6[#9<J#*:0UVB@W6*DL69V!J9PBPFH.IM:ZO]6#QAPUC-X%F)ZM-I19O(5)9
M>![34ZX"BPDQ9+`JN[+78@13^`TZP*77,+&\L#3U-7H12TA]54B[F@@(1"!#
MP5W5^DVK5#B"X`N]E0!_=W$?5*_5"C.^>$O]ZC*LR;)62R5F,:176P\R@)[8
MP`($>0V%Z0^S>7`B@T/GBC^>H!&Q)%(R@4(9=%THY1%@P5`WT7J@U*#RDXNF
M1"*(J0W$D5(2BK=;6[A*@D+=:+B[(`1$>0TS\)/8$!Y_5PT$-@@&=J[\4TN*
MQTL\!A2C%R8Q@5Q`NO\1$""D+@6CP"6"VL$+HZ=*.I=5"%03BCN[N-%`]Q(Z
MM#LIC):[O%MI.S1L^MB[5?*#PEN\W35ENV.\RKN\(HF\6LN\T!N]CC@2TEN]
MUGN]V)N]VKN]W-N]WON]X!N^XCN^Y%N^YGN^Z)N^ZKN^'(9`&/>^[\L'?C"_
M]%N_]GN_^)N_^KN__-N__ON_`!S``CS`!%S`_0MMP<N^Z\MC%M#`#OS`$-S`
M%&#`%%S!%GS!&)S!&HS!'-#!'OS!(,P!+>"?"LR^$+3!*)S"*KS"+-S"*LP!
M)%S"ZGO"+ES#-GS#.)S#%@S#,MS#0-$'.AS$0CS$1.S"/.S#,DS#1;S$3-S_
MQ$ZLOT>,Q`JLQ$]<Q59\Q3<<Q5*\OE2,Q5[\Q6!,P5J\Q>G;Q6%\QFB<QO8[
MQF1\OF:LQG`<QU?,QFU<OF\LQWB<QT-,QW4\OG>LQX`<R"W,QWT<OG\LR(B<
MR!=,R(7\O8>LR)`<R0#,R(W<O8\LR9B<R6L<PY7,O9>LR:`LR93<R=K[R:%\
MRH@\RJ2,O0O``:C\RJ"LRJM\O;!<RY@LR[-<O;:\RXKL`1Z0R^++R\*,R,`<
MOL-\S'I<S."+S,P<Q\K\O<T<S6C\S-XKS=;\Q=2,+:-V';KF8=O,"R#!.(0P
M:K/'=M=\SE:<S=>"<9[G":M$'NR<""/DL_<FNM/5_U.)^VGHO,]-K,[,<F.T
MV5(0)`@`33Q]D$L_`IW&%WB2IL_\_-!#[,^N4M`.^Q1L^%(Y)P$VE-`_?`T)
MH-$(Q,D.#=$DC<,2W2H8EUPF4H/U?&,_TD"MJ-`,88TR6G(E?=,V?-*LLDD8
MP0]@U$#\P-,284&W$"HR396A$H$FA]-,S<(ZO2H4[;`7C=&[D-"KA&4=C6X1
M0%1`0G)-_=4H_-2<$D)D.0LL99]DG3\<7:UO`4%YR11;.6Y@/=<8+-8M1FR+
MUA/$@]?P9A%)%1E#M(KY/-)T7=@$++W[^\R&O=@#C-CZJ]B,'=G^Z]CY"]F2
M?=F5';V)K<R8W=GW2]GX:__9GNW9H/W9G#W:HUW:]BO:J'W9JEV_K-W:D5V[
M\ZPNKSBPS]DZHX$=!RTAN)US@\TM`-=4Z\<2`_-]N7'<$T@/FUW,LMW9\@R_
M\4P/-BH\;J9S3+%&P,@U3C%G8]E6\+&AH^$`?Z%2T(,(X&-FVQ&6Z0%"N4D(
MY,(V<B9+(?8-^>4Z=8$5?2(ZHWHTWP0B"0%2(%*IW"U/,5B5=E8-B;+?-:/7
M_$D,_KT+S4T/TAV_Z?O<F!W=%0Y<)!Q3I`1?F3"VD61QJ5=!)M0)05=!6VTS
M*/27+D/6\7H**K1`+FYY.X5;_79DBM!!2OO3OFA*S]M#-9X>_OHRP`@)D,#5
MN/K_EV_HX26>%\(:%3M:0C:JXT-W'DV."5&NY+>QX<-]X1@NV1J^X20,MSI(
M1:6'017K.C_E"H2HF0O4>3S!(T53NL[U"V@>6\5AYS+E6I:T2IVP#2$45O\1
M5O>=YZ]U2[<R`8I^<$S'3G)A7Z]E"[$CZ0YW>#J>Z,21L=KYEZ<8>+;AY?9\
MOF$NYN[KY21LHSJ7'8N7YA\D`?C9A4+T2EH20=S@GK?$4,MG2Y5.-Y,06^@$
M8S+E13O.8+CC%&4!<>"<*X=N?;#S`%^G9]!^X^D!@]/327T8Z]A^Z5YH2?_Q
M[/F933EB,XZ0'ETNZE%-OJ4^VZ=.YM\04_^P7!$P[PWB_U.2KK0["J3L-5Q[
M&0'[,.\E&#;W5UPU0Z.EAT),=T7FQ.C%_G#^KE*W2N'+$%N=X",.;O'Q-`&6
MIQ;$U0BMA.^W_7VQ9'X4I&08[_%:+E^F9'GG+NJ_7<WKOMAC7N$B?2<@IJ'$
MB>[I/KXQ+_/M3O.K0NSV^9LZ__+=V_.&/?/27?/%6_1@CO1SK?3PR_3"Z_3H
M"_5T+?7O2_4LX7/<\0U--7Z\D;%%B:1^Y)R?$D#%7;MJS_4M7>%&S[U8'_4_
MO_3T<#1[@@SP#5%&(V=&T[8(@]T1S@CJB@F0<*1^IAA[4S0'X32BT%;"$`QF
MYO<&P>`"?@C*H6AX_W!FIB6+1?_YDN41V!T9N]L)[)V,%B$@Q9$<,I.,FY\H
M9B;X`D+X;F_UI#[W7ZWUTQVNA=D@C_D5,UZ8H;&CMQI+*]X-Z*+DRJID[:D=
M079@-=U\#N`-Q1J(&!1+^"9_DWFK5]Y\M[IO#91;6WU+,(WBS[_]RF?DP6H3
MTGJOCUD6*]Z>/^(-_]%\0P=&'M+[I3>VR@\(?0P2!'^&AXB)AGV,C8Z.?(J2
MDY25EI>8B`L0$`X(AGP#B`=\!W]\J*@+?P-\"8:MIZFHHH@#"`F?F;N\O;Z9
M?L'"P\3%QL?(R<K+S,W.S]#1TM/4U<5_!(_:C(62"7U_!PD0D7SDA7VM!`/@
M[.S??`3_YW\3#0T3\:?=^@Z%`Q/L=/UAP`#"@V^+O@U@]Z?/@T,$0H&+]T\"
M'P01&SY,]PZ<.(;Q^K$".''=!(NZ\@'$Y@!4H7@0(O9Y1<_>A#\((D#X$Y-/
MGP4>$^2+J-)FOGR\MFV+]*NI4U\-^MCK(V$14UCI&D8@P)7!J3[=?&(C$`$L
M@56(P$TP];2MV[?6XLJ=2[>NW;MXGV%3^FA?H@-]#CC@4Y`G@WSI*/9!X"`"
M.\`/'"S(%X'/Y`41$##8%^]!9@<2&!Y*$.$F@IG?3C]X`"ZKH8@@"21PX+E?
MI*P.60,6+%&?9\:A2\ZN[?*/!$\1'IZJ"L&>P5*&*D\>.0%!_X/GCP?SJ6J1
MLF7+F3<CJ(6)[Z.K;].[_=;R#]"-Z-TU1/_UY]=#8A61;JB^O_]+>04HX(`$
M%FA@,^[-HN`L:$G"0!\1Y)(-`0@@I@X[$B0'$H0)>+;``Q-,L`H!)W%6R(,1
MBG9(!`T8LD"(J_B434/DP582`C$10$J$6<D(#HH)'!#!82=R&!N.7+'E(6F"
MX!?!DP<(V:0A((J8TR802.D5D$(^R8>'58Y8HHJ7+&AF*/^EV8L#BRG21WRX
M-;#0`*;XQ$!U^=V7"&N-W*3FG_X=*.B@A!9J:#*`2D(FH$(JE^BCD$8JZ:2*
MY)D6G**<]Q4"$QP&#BB?)N)``P_X1?_IJ90<JNJJK+8:%Z4)F/KG`BVB:NNM
MN.8Z"9NZC&?*F[;@1I]80$$0JJ6@//ED>[K>ZNJST$8;;;/45FOMM=A.PAZH
MF6(Z7R+Y97-LJ*,=UQQ;V48J[;KLMEM@NO#&*^^\_64SU4Y:<766?!#J^]*G
MWXPK26CKT)NHNP@GK#`U!C?L\,,/.]!<@PK2"=V"K%PU'2ST@>(>NA"KM_#(
M))=,3,@HIZSRRBP[:_++,+?;\LPTUVSSS:G&K//.K.+L\\]`!PTOST07+:C0
M2">M]-)J&NWTTW@Q+?745%<M"=189UV-(5IW[?715N/\]=AD#\-UV6BGS7#8
M-ZOM-M1GORW_]]PGLVTSW7C#''?>?*-M]]U]!X[PWH(7CO7?-1NN.+2$+^ZX
MSHC3_/CDAC9.^>4*1SXSYIP3:'GGH#.N.<NAEU[7YZ:G7NCHI*ONNC2HORZ[
M@*RO//OMR\2.^^YRU:XR[\";_8<U%!1O_/'()Z_\\LPW[_SST$<O??(F'-C!
M]-AGKWWVQ_B><O#@ZP[^^`AZ'S+YO(OOJ@<66$!!!QTX(X(%(?A!`3(>!)/_
MXAU\8$'^^V-&^RPP@F'<KQ@6T)^!S'<^].%.?:U*H!_<1X'YC6`$(1"!'T)0
M/PL&XP-^Z(`)*#""__F!?06<8#`(:`$->J""!,Q;\51H@0[4\(3U_^-@"&^H
MPA+BT`0<,($.@]$!#FBP!`3$X/M,8((.>+!W:1J/6^C$0$4X\('#4UC[/O!"
M#Y1`!!]XGPIL6+PO@M`/(B@!""T`PA+XH00^]`,'!OB!-)K@`R8PHPR1N$85
M4$`%(Z2?^TS@1Q6L<(6!I,#_.+B_#XS`C6[TGQ(Y2`$]0K$_L6I$`S[!#D>T
MXA%C<=$$&!$A5F@*$0G8I*R8=L7;09!5$K1?""@8@DJ.@`)<I&`([R<"129P
MC2H,)ALK6$(R'I!N,UQA"2HH`A%D$)<=6*8&>]A"9RKRF?$;@0HLH((1K#&!
M(NC?!XPYE_]$(#3NJ8<I'3"G"G%D(:%DQ_\F!_"D=<X)9'\HU0!6N;16SNZ5
MJPH@_-HW`O;5\`..).@*Z7?"_G'@A!"-J`?ZY\()QA!O\!.&!]@'OP^$P`,(
M+2@/!SB"_F4P!"8-QOOL5\EQVK"#&E3H)=/#&D<]:#RN`54BN#(0/V4,I^1)
MQ#X)T(`(-&AJ_I0=0'G&O@`F55K^L90[,-25K^AK1(7@J5"IHB^:4(D07'$4
M4I^JNJ62-7A1)==4I:**KZ1"%#S5:K`:D`J0)>`X!&``/EEY5M.9M:^[\T]-
M#W%3^>"'7*&\TR'Z<0##*F)")_'J6`$+NK]2]I_^.:<H7M0BQ^H)(OZ0RG@F
M$%IV+D2R_%E+V"[_6]DLLC:I_\DD(S9IRJ`B2ZL^X88I.MD(O^P'L9-]+>4L
M*]S4J4F*;;E%%1-1W,L1M[FA6Z[#H#NYYU*7<](U&`/.>%W!P<^ZW1UN=N=%
M@(>&-W`<Z,9YPS=>>95WO7U++WCAJ[CVNM>\]*6;?%V;7\S:-UWO[>_<]BM@
M5_X7P/@ML-H(K.#7'1C!#78;@R-LW`=C*\`4+MN$I[&]#GOXPR">7O4,=+T0
MF_C$S.N>A:^%X0R/;<,N[MR*69S@&'<-QNTRZ/OBUXSYU>^8Q=B?4PO7/Q,.
M.1DD-:`Q)'CDO,S86BVVL=9PS"X)4M""&-2@#I\(0A&2T,@7M7()70C#_Q0B
M\WX)K.$-/9##^MF0QPGT(9N!*,3Z$=&(;TQB+478Q">^ZLG4BK*4L4;E=6VQ
MBV84HS$MF<8UMO&-<9SC%NV(1TLBDX\3+&0@9TD!0O[QD!-,Y"(_^L%'OM$/
MDJPE)2UM#4`'NL:#AEJAI15+"G#:UK;$)?MF>#TT^A+5-`3U,$503%WB+9D3
ME&8SGSE.:1YRS-:D7R^SN<UN?A.-XB3G3%U]*T''VFFSCI9`;4A`@XJSA&%F
MZ$0_\%``*K"A=82H3.F64?UQU*0@=21'%TI`DSHSI?:+7QE=RM!F6M3,K>9V
MKKS][:*%&VI-;3CL%(XKADM\9P^_>-XH7G%8:R@<X^K]^.(XWFWS;$/D@[*`
:R;<1<I07CN2V*LB9SN3R`U%@YC-?12```#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
